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Sporadic Creutzfeldt-Jakob Disease (sCJD) is a rare but devastating 
neurodegenerative disorder characterised by misfolding, propagation and deposition 
of the prion protein in the brain, leading to neuronal death and rapid cognitive and 
functional decline. As there is no obvious genetic cause of sCJD, the epigenetic 
status of sCJD patients may clarify spontaneous prion disease aetiology or reveal 
biomarkers of the disease. Blood from patients was profiled to document genome-
wide differential DNA methylation. 
38 loci were identified as being differentially methylated in sCJD blood, including 
two which associated with disease severity as measured by the MRC Scale score. 
Of 7 loci considered for replication, 5 showed similar effects in a second cohort of 
patients, but not in patients of Alzheimer’s disease, iatrogenic CJD, or inherited 
prion disease, suggesting these effects are specific to the sporadic form of CJD. 
Notably hypomethylation at a site in the promoter of AIM2, an inflammasome 
component, retained its association with disease severity. 
Hypomethylation of FKBP5, a gene known to regulate the cellular response to 
cortisol, prompted further investigation which revealed that circulating cortisol is 
indeed elevated in sCJD patients. Profiling of frontal cortex-derived DNA showed 
that differential methylation observed in blood is absent from the brain methylome. 
Machine learning classification of sCJD based on genome-wide methylation data 
was able to classify sCJD and healthy control status with an accuracy of 87.04%. 
This is an appreciable level of accuracy but importantly sets precedence for further 
classification of prion patients in more complex clinical and research settings, as 











Sporadic prion disease is a rare but devastating neurodegenerative disease, with 
136 mortalities in the UK during 2018. This study of DNA methylation in the blood of 
these patients has identified one gene (AIM2) which appears to become 
progressively demethylated as the disease progresses, making it a promising 
biomarker for patient monitoring, particularly during therapeutic intervention. 
Another gene (FKBP5) is also demethylated in sporadic prion disease and has 
established connections to psychiatric disorders and a system which communicated 
between the brain and the periphery, namely the hypothalamic-pituitary-adrenal 
axis. It possible that this system is dysregulated early in the disease process as 
there is no correlation with clinically presentations of disease severity. FKBP5 has 
also been implicated in a number of other dementias and psychiatric disorders yet 
its involvement in neurodegeneration remains unclear. Further work showed that 
cortisol, an anti-inflammatory agent, is elevated in sporadic prion disease patient 
serum. This finding strengthens the case for deeper investigation into the role of 
FKBP5, a known suppressant of cortisol action, and peripheral inflammation in 
neurodegenerative diseases. 
Machine learning classification models using our DNA methylation dataset was 
shown to have promising accuracy (87.04%) and could be further employed in 
analysis of prion disease subgroups, particularly in subclinical carriers. 
At a Departmental scale, this work establishes an analytical pipeline for analysis of 
methylation data at the Genetics, Epigenetics and Bioinformatics group of the MRC 
Prion Unit at UCL, affiliated with the National Prion Clinic at UCLH NHS Foundation 
Trust. A blood-derived DNA extraction protocol was also optimised to complement 
the current Neurogenetics extraction protocol, using 1/40th of the volume yet yielding 
sufficient blood-derived DNA for methylation analysis. This work represents the 
foreground of a more detailed examination of prion and rapid dementia patients in 
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Prion diseases are transmissible neurodegenerative disorders with unique 
aetiologies and pathologies, which affect a broad range of mammalian species. The 
first prion disease to be identified was scrapie, which has been endemic in parts of 
Europe since the 18th century (Plummer, 1946). Scrapie was known to be an 
infectious disease, and early experiments by Cuillé and Chelle not only 
demonstrated that healthy sheep could be infected through contaminants present in 
the paddocks previously occupied by scrapie sheep, but that the disease could also 
be experimentally transmitted into goats (Cuillé and Chelle, 1936). This lead to the 
hypothesis that scrapie was caused by a slow-acting virus, as sheep developed 
symptoms relatively slowly as per several other slow-acting viruses which affect the 
nervous system (Ter Meulen and Hall, 1978). However unlike other viruses a 
“scrapie agent” could not be isolated, nor cultured, nor inactivated by heat or 
treatment with formalin in the same way viruses could be (Parry, 1962). 
In 1957 it was reported that tribespeople in the Fore region of Papua New Guinea 
were weathering an epidemic of a neurodegenerative disease they called Kuru, 
meaning “to shiver” or “to be afraid” (Gajdusek and Zigas, 1957). The disease was 
observed to present with ataxia and a mild tremor, followed by progressive loss of 
motor and cognitive functions. Brain homogenate extracted from those who died 
from Kuru was shown to induce similar pathology in chimpanzees if inoculated 
intracerebrally (Beck et al., 1966), prompting a separate experiment where 
inoculation of homogenate from a Creutzfeldt-Jakob Disease (CJD) patient was also 
shown to induce neuropathology. CJD had been first described in the 1920s 
(Creutzfeldt, 1920) yet was still acknowledged as “an ill-defined term for a group of 
subacute presenile encephalopathies characterized clinically by dementia, 
involuntary movements (myoclonic jerks), and other less constant findings that often 
include ataxia” (Gibbs Jr. et al., 1968). Indeed, the condition’s second namesake, 
Alfons Jakob, is thought by some to have identified bona fide CJD as Hans 
Creutzfeldt’s descriptions do not overlap with current understanding of prion disease 
pathology (Katscher, 1998). Transmission of prion disease pathology into 
chimpanzees using CJD patient brain homogenate by Gajdusek established the 
cause of CJD as transmissible and thus analogous to the scrapie agent. 
In 1981 Prusiner et al. reported the purification of a hydrophobic protein component 
from the scrapie agent (Prusiner et al., 1981). The following year Prusiner published 
a manuscript which considered the agent in detail and employed for the first time 
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the descriptor “prion”, a contraction of “proteinaceous infectious particle”, to 
distinguish the agent from viruses and other infectious nucleotide-based particles 
(Prusiner, 1982). Prions were subsequently purified from CJD patient brains and 
shown to contain epitopes present in the scrapie prion preparations being used in 
laboratories (Bockman, JM. , Kingsbury, DT., McKinley, MP., Bendheim, PE., 
Prusiner, 1985). To this day definitive diagnosis of CJD is only possible through 
detection of prion protein aggregates in brain tissue by post-mortem histological 
examination. 
Creutzfeldt-Jakob disease is now understood to result from template-driven 
misfolding of the human prion protein (Griffith, 1967; Prusiner, 1991), from which 
follows a rapidly progressive dementia with co-existent signs such as myoclonus.  
1.1 The Prion gene and its protein  
Human PRNP is located on chromosome 20 and encodes a 253-residue protein 
(PrP) in two exons, of which only the second is translated. The product’s primary 
sequence is highly conserved across mammals (Prusiner and Scott, 1997). The 
mature protein is 209 amino acids long, contains an internal disulphide bond and 
two sites that can be variably glycosylated, and is membrane anchored (Prusiner 
and Stahl, 1991). PrP has a modular structure which is displayed in Figure 1. 
Normal genotype at codon 129 of PrP can be homozygous or heterozygous for 
methionine or valine and is a major disease modifying factor. Its effects on disease 
will be discussed in later sections of this thesis. 
The relationship between PrP function and dysfunction remains unclear. While there 
is evidence to suggest it has multiple neurotrophic roles, Prnp-/- mice are 
phenotypically quite normal with some minor alterations to neuronal and immune 
function emerging with age (Zomosa-Signoret et al., 2008). It is thought this is due 
to PrP’s role in maintaining axonal myelin, and decreased proteolysis or loss of 
glycolipid membrane anchoring produces similar effects (Bremer et al., 2010). PrP 
has been shown to increase neurogenesis in the dentate gyrus of the hippocampus 
in a dose-dependent manner, yet as of itself this increased neural proliferation does 
not result in a greater final volume of mature neurons (Steele et al., 2006). 
Recombinant PrP has been shown to induce synaptogenesis in vitro, while native 
PrP has been identified as a receptor for amyloid-β through which synaptic function 
and long-term potentiation are inhibited (Laurén et al., 2009). PrP coordinates 
common divalent metal cations in various regions of the brain (Pushie et al., 2011), 
in particular Cu2+ which induces morphological changes in full length PrP structure 
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towards a more beta-sheet based conformation (Thakur et al., 2011) and promotes 
its own clathrin-mediated internalisation (Zomosa-Signoret et al., 2008).  The normal 





Figure 1: Tertiary structure of PrP. Histidine residues (magenta) in the N-terminal octarepeat domain 
coordinate Zn2+ and Cu2+ cations. N-teminal and C-terminal fragments can be produced through α or 
β-cleavage. Figure from McDonald and Millhauser, 2014. 
 
The native structure of PrP is commonly termed PrPC to distinguish it from the 
misfolded, aggregated form associated with CJD (Prusiner, 1991), which is termed 
PrPSc  (from PrP-Scrapie). Thinking beyond the supposedly necessary 
characteristics of an infectious agent, this being a nucleic acid component, Griffith 
hypothesised that the scrapie agent could derive its infectious characteristic through 
molecular templating (Griffith, 1967). This proposal was vindicated through studies 
of Prnp-/- mice which demonstrated that native PrPC is necessary for infection by 
PrPSc-containing inocula, which has led strength to an early model of prion disease 
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whereby PrPSc, arising stochastically, self-templates using PrPC as a substrate. 
Further work has provided evidence that the label PrPSc is reductionist and perhaps 
unhelpful, due in part to the existence of various strains of prion particles with 
distinct conformations (Safar et al., 1998) and phenotypic effects (Prusiner, 1991). 
But most strikingly recent findings suggest that the presence of PrPSc aggregates 
does not necessarily correlate with clinical presentation, nor spatially with neuronal 
loss (Sandberg et al., 2014; Alibhai et al., 2016). As such expansion of the “protein 
only” model to account for concepts such as prion strains is ongoing, with labels 
such as PrPI and PrPL becoming more common when referring to infectious and 
toxic (lethal) moieties. Current models of PrPI suggest its structure is fibrillar in 
nature, and fragmentation of infectious prion fibrils into smaller assemblies through 
sonication has been shown to almost double a sample’s infectious titre (Terry et al., 
2016; Vázquez-Fernández et al., 2016). An alternative hypothesis, the “virino” 
model, postulates that PrPSc is in fact associated with a nucleotide species and that 
the two are necessary to infect cells and cause pathology (Kimberlin, 1982). This 
model also accounts for strain variation which may be influenced by specific 
sequences of oligonucleotides but does not explain subclinical prion infection. To 
date no nucleotide fraction has been successfully purified from infectious prion 
isolates and the model has been largely disregarded. 
1.2 Creutzfeldt-Jakob Disease 
CJD is the most common human prion disease and can be separated into three 
varieties based on aetiology: sporadic, familial and acquired. Sporadic CJD (sCJD) 
accounts for 85-90% of cases (Zanusso et al., 2016) whilst a number of dominant 
alleles of the prion protein gene (PRNP) are known to cause inherited prion disease 
(IPD). Other cases can be acquired, for example through consumption of prion-
contaminated food which can cause variant CJD (vCJD).   
A second form of acquired prion disease, iatrogenic CJD (iCJD), mostly arises from 
contaminated cadaveric pituitary-derived human growth hormone inocula and 
contaminated dura mater transplants. The former was recognised in the UK in 1985 
(Powell-Jackson, Kennedy and Whitcombe, 1985) and in total 77 British growth 
hormone recipients (out of 1849 total) who had all received the same preparation of 
growth hormone have developed iCJD. Subsequent genotyping has revealed that a 
polymorphism at codon 129 in the prion protein modifies the incubation period 
before disease onset, where possession of the valine allele has been associated 
with earlier disease onset (Collinge, Palmer and Dryden, 1991; Rudge et al., 2015). 
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196 dura mater transplant recipients have developed iCJD, with the majority (123) 
of cases occurring in Japan where dura mater repair after neurosurgery was a 
common practice (Brown et al., 2006). A specific brand of dura mater – LyoDura – 
was used in all instances where infection has been observed (Yamada et al., 2009). 
Cases of iCJD have also been linked to neurosurgery, corneal transplant and blood 
transfusion from a donor carrying vCJD prions, although improved patient screening 
and instrument decontamination has since been effective in reducing exposure of 
patients to prion contaminants. 
Variant CJD (vCJD) emerged in the United Kingdom in 1996 (Will et al., 1996) and 
was recognised as distinct from “classical”, sporadic CJD on account of a much 
younger age of onset, longer disease duration and neuropathology involving 
deposition of kuru-like “florid” plaques of prion protein (PrP). The first 10 victims of 
vCJD were identified by the CJD Surveillance Unit which was instituted in 1990 to 
monitor the effects of a bovine spongiform encephalopathy (BSE) epidemic in the 
UK and potential transmission of BSE to humans. vCJD was subsequently 
characterised through molecular strain analysis of PrP and murine bioassays as a 
strain of BSE that had indeed infected humans through the food supply (Collinge et 
al., 1996; Bruce et al., 1997; Hill et al., 1997). To date, 228 cases of vCJD have 
been documented, 175 of which occurred in the UK (The University of Edinburgh, 
2017). With one exception (Mok et al., 2017), all individuals were homozygous for 
methionine at codon 129 of PRNP. 
Inherited Prion Disease (IPD) was first documented in the Backer family in 1920s 
Germany: 70 years later a D178N mutation in PRNP (Kretzschmar, Neumann and 
Stavrou, 1995) was identified in DNA extracted from the preserved brain tissue of 
one of the family members.  This mutation and several others (see Figure 2), as well 
as octapeptide repeat insertions, are now known to clinicians and used to diagnose 
IPD. As with iCJD, codon 129 genotype of the PRNP allele which encodes the 
mutation is known to modify some forms of inherited prion disease (Gambetti et al., 
2003), notably D178N which causes Fatal Familial Insomnia if the mutant PRNP 
allele encodes 129M. 
Sporadic CJD (sCJD) can be distinguished from other rapidly progressive 
dementias by observing increased signal on T2 weighted and diffusion weighted 
MRI sequences in the striatum, thalamus or cortex, increased 14-3-3 protein in 
cerebrospinal fluid, and periodic sharp wave complexes in electroencephalograms 
(Zanusso et al., 2016). However, a definite diagnosis according to WHO criteria can 
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only be made through neuropathological observation of aggregated PrPSc 
deposition in the brain. Subsequently there are cases where diseases such as 
rapidly progressive Alzheimer’s Disease, Lewy Body Dementia, and viral 
encephalitis have been mistaken for CJD. It is also highly likely that cases of sCJD 
have been masked in patients with existing dementia diagnoses. As shown in 
Figure 3, deaths per million per year in the UK have risen from 0.5 in 1988 to 1.8 in 
2017 (The National CJD Research and Surveillance Unit, 2017), possibly due to 
improved diagnostics and awareness but perhaps also due to a shift in median 
population age or other unknown factors. 
 
 
Figure 2: Known genotypes associated with familial cases of CJD (Mead, 2006). Some of the 
pathogenic mutations listed above have been reported in simplex cases of CJD and could reflect the 




Figure 3: Deaths per million per year from sCJD between 1986 and 2017 in the UK (The National CJD 
Research and Surveillance Unit, 2017). 
Prion diseases have a heterogeneous clinical presentation both between and within 
subtype. To better delineate patient progression and outcome, a scale of disease 
severity was published in 2013 after monitoring patients enrolled in the UK National 
Prion Monitoring Cohort over the course of 373 patient-years (Thompson et al., 
2013). The MRC Prion Disease Rating Scale (henceforth referred to as the MRC 
Scale) was designed such that patients could be scored retroactively based on 
commonly documented clinical parameters, and allows cross-sectional analysis of 
biomarkers and disease features across disease progression. Despite the scale 
proving useful for patient monitoring and triage, both important aspects of patient 
management, prion disease remains incurable. To facilitate rational drug design and 
improve patient treatment and management, deeper knowledge of the disease 
aetiology and pathology is needed. 
  
1.3 Epigenetics 
Epigenetics can be summarised as the study of how the action of genes can be 
temporally and spatially regulated, a process which has been known to direct 
physiological development since Conrad Waddington’s coining of the term 
“Epigenotype” in 1942 (Waddington, 1942). Outside the original context of 
developmental biology epigenetics has also been studied in the context of disease, 
most notably cancer of which epigenetic dysregulation has become a hallmark 
(Brown and Strathdee, 2015), and recently such dysregulation has been 
convincingly linked to neurodegenerative diseases such as Alzheimer’s Disease (De 
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Jager et al., 2014; Lunnon et al., 2014), Amyotrophic Lateral Sclerosis (Xi et al., 
2013) and Parkinson’s Disease (Masliah et al., 2013).  
There are three canonical branches of epigenetics: the action of non-coding RNAs, 
modifications to histone proteins which coordinate chromatin structure, and 
modification of DNA, principally methylation of cytosine residues. Partly due to the 
chemical stability of the latter epigenetic mark and the comparative molecular 
fragility of protein and RNA, DNA methylation has been enthusiastically researched 
in many biological contexts. DNA methylation predominantly occurs at the 5’-carbon 
of cytosine in cytosine-guanine dinucleotides (CpGs) which are both relatively 
depleted and unevenly distributed across the human genome. CpGs cluster into 
genomic features known as CpG islands, defined as regions of >200bp containing 
>50% GC composition and an observed to expected CpG ratio of >60% (Bird, 
1986). CpG islands are frequently located upstream, on, or downstream of gene 
transcription start sites and often extend into the gene body (Gardiner-Garden and 
Frommer, 1987). Although around 70% of all CpGs in the human genome are 
methylated, these islands are characterised in part by the absence of methylation.  
This is notable as compared to a fixed random rate of mutation of cytosine residues, 
methylcytosine is 42 times more likely to mutate via deamination to thymine (Cooper 
and Youssoufian, 1988). This suggests that CpG islands are conserved during 
evolution in part due to their lack of methylation (Sved and Bird, 1990; Serge 
Saxonov, Berg and Brutlag, 2006). As early as 1986 Adrian Bird suggested these 
regions may serve as binding platforms for protein factors, and in doing so prevent 
the binding of enzymes that introduce DNA methylation as well as providing an 
accessible substrate for transcription factors, chromatin modifiers or repressors. 
Thanks to genome-wide sequencing, we now know that 72% of all annotated 









1.4 DNA Methylation Machinery 
 
1.4.1 DNA Methylation Writers 
DNA methylation is introduced by DNA methyltransferases (DNMTs), a family of 
enzymes of which three have been identified in humans: DNMT1, DNMT3A and 
DMNT3B. These enzymes were originally identified in bacteria and are highly 
conserved, sharing the same 10 motifs between prokarya and eukarya (Kumar et 
al., 1994). DNMT1, DNMT3A and DMNT3B take cytosine and S-adenosyl-L-
methionine (SAM) as their substrates, the latter of which is the methyl-donor. In 
brief, the methylation reaction begins with a nucleophilic attack on the 6’-carbon of 
cytosine by a conserved cysteine-thiolate residue of the DNMT, after which the 
cytosine is everted from the double helix into the catalytic pocket of the DNMT. The 
now-anionic 5’-carbon of cytosine attacks the donor methyl group of SAM and S-
adenosyl-L-homocysteine (SAH) is expelled. Beta-elimination separates the DNMT 
from the cytosine moiety and loss of a proton resolves the stabilised purine ring 
structure to 5-methyl-cytosine (5mC) (Bestor and Verdine, 1994). This process is 
allosterically stabilised by proton transfer between the 3’-nitrogen of cytosine and a 
proximal carboxylic amino acid and, importantly, can be competitively inhibited by 
the reaction’s by-product SAH. A summary of the reaction is presented in Figure 4. 
 
Figure 4: Chemical structures of DNMT substrates and reaction products during methylation of 




The first eukaryotic protein to be identified as having methyltransferase activity was 
purified from murine cell culture, after which the peptide sequence was determined 
by Edman sequencing and used to generate nucleotide probes to investigate a 
cDNA library. One cDNA product was found to encode a transcript of a gene 
homologous to bacterial DMNTs (Bestor et al., 1988). This methyltransferase was 
able to symmetrically methylate hemi-methylated DNA in vitro, as well as restore 
symmetrical methylation at CpG sites in murine cells transfected with hemi-
methylated DNA, while de novo methylation of similarly transfected unmethylated 
DNA was not observed. This confirmed the existence of a hypothesised 
maintenance DMNT which ensures symmetrical DNA methylation is restored after 
semi-conservative DNA replication (Stein et al., 1982). In humans this is encoded by 
DNMT1. DNMT1 has been found to colocalise with replication forks during S phase 
of the cell cycle, as has UHRF1. Studies have shown that Uhrf1-/- mouse embryonic 
stem (ES) cells exhibit significant global hypomethylation and that UHRF1 has a 
seven times higher binding affinity for symmetrical CpG-containing sequences when 
hemi-methylated rather than fully methylated (Bostick et al., 2007). This suggests 
that UHRF1 binds to hemi-methylated CpG dyads post-replication and recruits 
DNMT1, which restores methylation on the nascent strand. Intriguingly, further work 
revealed that DNA-bound UHRF1 everts 5mC out of the helix in a similar fashion to 
DNMT1 (Arita et al., 2008; Avvakumov et al., 2008; Hashimoto et al., 2008). 
DNMT3A and DNMT3B were identified in human and murine genomes by a 
methyltransferase motif homology search (Okano, Xie and Li, 1998) which was 
prompted after low levels of de novo DNA methylation were observed in Dnmt1 
knockdown recombinant murine stem cells (Lei et al., 1996). DNMT3A and 
DNMT3B were found to have equal methyltransferase activity for unmethylated and 
hemi-methylated substrate DNA. Further research revealed that they have relaxed 
substrate specificity and can methylate symmetrical CpApG and GpTpC triads, 
though it binds preferentially to CpG dyads. The rarity of non-CpG methylation in the 
human genome, taken with the above, suggests that DNMT3A and DNMT3B hemi-
methylate cytosines in these three contexts, before DNMT1 introduces symmetrical 
methylation on the unmethylated strand at CpG loci only (Ramsahoye et al., 2000).   
A fourth gene lacking methyltransferase activity was identified as having a cysteine-
rich region homologous to similar regions in the de novo DNMT3s (Aapola et al., 
2000).This gene was named DNMT3-Like (DNMT3L) and was found to only be 
significantly expressed in germline cells. Dnmt3Lnull mice are sterile and Dnmt3L+/- 
offspring of maternal Dnmt3L-/- mice are nonviable. It emerged that this was 
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because loss of Dnmt3L function lead to a failure to methylate maternally imprinted 
genes during oogenesis (Bourc’his et al., 2001). Further work revealed that 
[Dnmt3a-/-, Dnmt3b+/-] oocytes were also unable to establish imprinting, suggesting 
that DNMT3A and DNMT3L in combination are responsible for initiating imprinting 
during development (Hata et al., 2002). Immunoprecipitation studies of DNMT3L 
revealed that it binds specifically to histone protein H3 and that successive 
methylation of H3K4 prevented this interaction (Ooi et al., 2007). It is thus clear that 
post-meiotic de novo DNA methylation depends at least in part on the underlying 
chromatin landscape being amenable to DNMT3L binding. 
1.4.2 DNA Methylation Erasers 
DNA methylation is removed through passive and active mechanisms. The former 
can rely on exclusion of DNMT1 or UHRF1 from the nucleus, leading to a dilution of 
5mC across successive generations. Another form of passive removal also relies on 
replication-based dilution of 5mC, but in this instance 5mC is oxidised by TET1, 
TET2 or TET3 to 5-hydroxymethylcytosine (5hmC). DNMT1 has a considerably 
weaker substrate affinity for 5hmC and so DNA methylation is not maintained over 
successive generations and is diluted out in a similar fashion (Hashimoto et al., 
2012). 
Suggested active mechanisms of DNA demethylation also involve TET enzymes. 
One proposed mechanism is that 5mC is oxidised to 5hmC which is then 
deaminated to 5-hydroxyuracil (5hU) by activation-induced deaminase (AID). 5hU 
would then be replaced by cytosine through base excision repair as several DNA 
glycosylases have high affinity for 5hU:G pairs. However in vitro work has 
demonstrated that bulkier adducts to the cytosine ring increasingly block AID 
activity, thus this mechanism is unlikely (Nabel et al., 2012; Rangam et al., 2012). 
TET enzymes are also capable of successively oxidising 5hmC to 5-formylcytosine 
and 5-carboxylcytosine (5caC). These moieties are substrates for the thymine DNA 
glycosylase TDG, and depletion of TDG in murine ES cells leads to detectable 
increases in 5caC (He et al., 2011). Modular structures and catalytic pathways of 
enzymes involved in DNA methylation and demethylation are summarised in 





Figure 5: Writers, maintainers, and erasers of DNA methylation. Catalytic domains responsible for DNA 
methylation, 5mC oxidation and 5fC/5caC excision are shown in light blue, green and magenta 
respectively. Domain abbreviations are as follows: ADD, ATRX-DNMT3-DNMT3L; BAH, bromo-
adjacent homology; CXXC, zinc-finger Cysteine-X-X-Cysteine; DSBH, Double-Stranded β-Helix; 
MTase, DNA methyltransferase domain; PHD, Plant homeodomain; PWWP, proline-tryptophan-
tryptophan-proline motif; SRA, SET and RING associated; RING, Really interesting new gene; UBL, 
ubiquitin-like domain; UDG, Uracil DNA Glycosylase. Figure adapted from Wu and Zhang, 2014a 
 
 
Figure 6: Catalytic pathways of passive demethylation (TET only) and active demethylation (TET & 
Base Excision Repair) mechanisms. Figure adapted from Wu and Zhang, 2014b 
 
1.4.3 DNA Methylation actors  
DNA methylation has a range of functions exquisitely dependent on local genomic 
and epigenomic context (Jones, 2012). Typically, methylation at promoters 
correlates with gene silencing, while active promoters are unmethylated. This 
means of regulation is tightly linked with chromatin structure and modifications: in an 
active promoter the transcription start site (TSS) is depleted of nucleosomes. 
Nucleosomes which flank an active TSS bear H3K4me3 marks which prevent 
DNMT3L binding, or may contain H2A.Z, a histone protein which also blocks de 
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novo methylation. The relationship between H2A.Z and methylation is bidirectional, 
as depletion of H2A.Z deposition results in global hypermethylation, while disruptive 
mutation of DNMTs increases H2A.Z presence (Zilberman et al., 2008). 
Furthermore, chromatin immunoprecipitation sequencing (ChIP-Seq) analyses of 
TET1 distribution revealed that TET1 localises to active promoters which overlap 
CpG islands (Wu and Zhang, 2011), as TET1’s CXXC motif binds strongly to 
unmethylated CpG dyads (Zhang et al., 2010). TET presence at these sites 
therefore maintains demethylated regions by oxidising local 5mC as part of its 
previously described role in removal of methylation.  
Conversely, silenced promoters tend to contain nucleosomes and methylated CpGs. 
A well-studied example is the DNA mismatch repair protein MLH1, which is 
frequently silenced in cancer. Methylation of MLH1’s promoter directly correlates 
with nucleosome occupancy and in turn with decreased expression. Treatment of 
MLH1-silenced cells with 5-aza-2’-deoxycytidine, a cytosine analogue resistant to 
methylation, is sufficient to demethylate the promoter, remove nucleosomes and 
restore expression (Lin et al., 2007). It is thus clear that DNA methylation emerges 
from and can remodel the underlying chromatin landscape. 
An essential function of DNA methylation in humans is repression of transposon 
activity in somatic cells (Walsh, Chaillet and Bestor, 1998). Transposons are 
parasitic DNA sequences that can copy and paste themselves across the genome. 
In humans transposons are thought to comprise almost 60% of the total genome (de 
Koning et al., 2011), with copies of one sequence (Alu) comprising up to 10% of the 
human genome. As well as impairing overall genomic stability in somatic cells which 
can contribute towards progression of cancer (Roman-Gomez et al., 2008), in some 
instances disease can be caused by gene-specific insertions in the germline 
(Dombroski et al., 1991). Transposons and indeed all repeat elements are enriched 
with CpG dinucleotides compared to the rest of the genome, albeit less so than CpG 
Islands, with Alu sequences alone containing 23% of all genomic CpGs (Luo, Lu 
and Xie, 2014). These sequences are highly methylated in somatic cells, and 
demethylation is associated with increased activity and subsequently is reflected in 
the global demethylation observed in many types of cancer.  
Study of the difference in methylation landscapes of the active and inactive X 
chromosome has greatly informed our understanding of consequences of DNA 
methylation based on genomic context. Contrary to expectations, a ground-breaking 
study discovered that the active chromosome is 2.4 times more methylated than the 
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inactive chromosome (Hellman and Chess, 2007). Subsequent experiments 
confirmed that the inactive chromosome was mostly methylated at promoter 
regions, while the active chromosome exhibited extensive gene-body methylation, 
particularly in exons. As well as correlating with active transcription, gene-body DNA 
methylation has been linked to alternative splicing by preventing interactions 
between CTCF and DNA. CTCF is a scaffolding protein which binds to DNA with 
relatively low specificity and in doing so coordinates chromatin loops. This is thought 
to affect the kinetics of RNA Polymerase II during transcription, affecting the 
incorporation of additional exons (Shukla et al., 2011; Racko et al., 2018). An 
important example of this is to be found in activation of CD4+ T-Cells, where in 
naïve cells CD45 is unmethylated at exon 5, allowing CTCF to bind. Subsequently 
an isoform of CD45 containing exon 5 is expressed. However, exon 5 is methylated 
in activated CD4+ T-Cells, preventing CTCF binding and excluding exon 5 from the 
transcript (Marina et al., 2015). CTCF frequently colocalises with TET1 and reporter 
constructs with a CTCF binding site are hypomethylated compared to analogous 
constructs lacking a binding site, suggesting that CTCF may be able to establish 
demethylation (Stadler et al., 2011).  
Canonically, DNA methylation has been assumed to block binding of proteins such 
as CTCF and transcription factors such as those which bind to cAMP-Response 
Elements (CREs). This model stems from early work describing how methylation of 
CREs in the proenkephalin promoter inhibit expression in cell culture, and a reporter 
gene study of promoter CRE methylation which showed similar effects on β-globin 
expression (Iguchi-Ariga and Schaffner, 1989; Comb and Goodman, 1990). Yet 
recently evidence has emerged that CpG methylation of motifs may increase the 
binding affinity of some transcription factors, such as CEBPβ  (Zhu, Wang and Qian, 
2016). This is perhaps surprising as until recently this property was associated only 
with proteins containing a Methyl-Binding Domain (MBD), members of a family 
known as MBD proteins. 
The first two MBDs to be identified were Methyl-CpG Binding Proteins 1 and 2 
(MeCP1 and MeCP2 respectively), although MeCP1 was later discovered to be a 
protein complex containing MBD1 (Meehan et al., 1989; Lewis et al., 1992; Cross et 
al., 1997). Identification of the MBD allowed cDNA screening for new family 
members, leading to the identification of MBD2, MBD3 and MBD4, of which MDB1, 
MDB2 and MBD4 were found to specifically bind methylated DNA in vitro and in 
murine cell culture (Hendrich and Bird, 2015).  
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Perhaps unsurprisingly, although their shared function is to bind methylated DNA, 
different MBDs play different roles. MBD1 interacts with chromatin assembly factor 
1, and the two proteins localise to heterochromatin in the nucleus (Reese et al., 
2003). This suggests that MBD1 may play a role in establishing heterochromatin, or 
at least in its maintenance. As well as an MBD, MBD1 contains a transcriptional 
repression domain at its C-terminus which can silence genes without the assistance 
of chromatin assembly factor 1 (Ng, Jeppesen and Bird, 2002). Yet MBD1 is also 
alternatively spliced into at least five isoforms which can contain either zero, two or 
three CXXC motifs, motifs which as described previously have high binding affinity 
to unmethylated CpG dyads (Saya et al., 2002). Because of this, transcriptional 
repression and chromatin remodelling promoted by MBD1 is likely to depend on 
expression levels of the splice isoforms, particularly the balance between the 0/2 
and 3 CXXC motif containing isoforms, as well as local density of DNA methylation 
in the sequences it binds to. While these four MBD1 isoforms are promiscuous, the 
fifth isoform lacks a CXXC domain and so only binds to methylated DNA. It has 
been shown to block TET1 binding and therefore prevent oxidation of 5mC (P. 
Zhang et al., 2017). In this sense it can be considered to have a more defined and 
perhaps distinct role from the other isoforms, which are less competitive and thus 
poorer inhibitors of TET1 but as a result allow fine tuning of TET1 activity depending 
on the local genomic landscape. 
MBD2 has been shown to recruit the MeCP1 complex, and in doing so associates 
with histone deacetylases which facilitate gene silencing (Ng et al., 1999). However, 
MBD2 also has two isoforms, of which MBD2a has an N-terminal domain which 
allows it to interact with RNA helicase a, a factor in CRE-binding (CREB) 
complexes. In doing so, MBD2a can actually activate expression of genes governed 
by CREB through binding to methylated, and thus canonically silenced, CREs 
(Fujita et al., 2003). 
MeCP1 is now also known as the NuRD complex. NuRD on its own cannot bind to 
methylated DNA, relying instead on MBD2 to recruit it. Interestingly, alongside 
MBD1, the closely-related MBD3 was also identified as part of the NuRD complex 
(Zhang et al., 1999). This prompted knockout experiments in mice where Mbd3-/- 
was found to be embryonically lethal, while Mbd2-/- mice were viable and could 
produce offspring (Hendrich et al., 2001). This suggested both differences in 
function and potential redundancy between the two genes and so NuRD complexes 
containing tagged MBD2 and MBD3 were purified and analysed. Strikingly the two 
MBD-NuRD complexes did not copurify and tagged complexes were found to 
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contain different subunits (Le Guezennec et al., 2005). Le Guezennec et al. 
hypothesise that MBD2/NuRD complexes bind to demethylated DNA and establish 
histone deacetylation, which favours binding of MBD3/NuRD complexes to 
deacetylated nucleosomes rather than to DNA. Thus deacetylation and 
transcriptional suppression can be established by MBD2 and maintained by MBD3.   
To further complicate matters, two paralogues of MBD3 have been identified with 
mutually opposing functions. MBD3L1 replaces MBD3 in the NuRD complex and 
can interact directly with MBD2, enhancing silencing of methylated genes without 
the need to bind to deacetylated nucleosomes (Jiang, Jin and Pfeifer, 2004). 
Conversely, MBD3L2 can compete with MBD2 for binding of the NuRD complex but 
lacks an MBD domain. In doing so, it can displace the NuRD complex, potentially 
clearing the way for transcriptional reactivation (Jiang et al., 2005). 
Less complex are the known roles of MBD4-6. MBD4 is a thymine glycolase with 
high affinity for symmetrically methylated CpGs where one methylated cytosine has 
undergone deamination to thymine (rather than uracil, the deamination product of 
unmethylated cytosine). In doing so it excises the thymine and plays a role in 
mismatch repair (Hendrich et al., 1999). The recently discovered proteins MBD5 
and MBD6, despite containing MBDs, do not show any ability to bind methylated 
DNA in vitro. However, they do localise to heterochromatin, suggesting a potential 
role in remodelling or maintenance (Sasai et al., 2010). 
It is clear from the above that MBD1-3 and MBD3L1-2 play complex functions 
depending on their splice isoform ratio, their relative stoichiometries, their 
subcellular localisation, and their interactions with underlying the chromatin and 
methylation landscape.  
Unlike MeCP1, MeCP2 is a single protein. Situated on the X chromosome, MeCP2 
is notorious for developing germline mutations which can cause the 
neurodevelopmental disorder known as Rett’s Syndrome, almost exclusively in 
females. Rett’s syndrome is characterised by early loss of speech, coordination, 
microcephaly, ataxia and autism, although it is typically non-lethal (Amir et al., 
1999). Like MBD1, MeCP2 contains both an MBD and a transcriptional repression 
domain which coordinates histone deacetylases. In fitting with the post-natal 
emergence of Rett’s Syndrome, MeCP2 is most highly expressed in mature neurons 
rather than developing precursors or other brain cell types such as astrocytes or glia 
(Kishi and Macklis, 2004). Here, incredibly, the absolute level of MeCP2 seems to 
correlate tightly with the level of CpG methylation, with high throughput ChIP-
Page 39 
 
sequencing revealing that ~70% of CpGs (the proportion of genome-wide CpGs that 
are typically methylated in human brain (Ehrlich et al., 1982)) associate with MeCP2 
(Skene et al., 2010). This blanketing of neuronal DNA suggests a generic epigenetic 
control of transcriptional regulation, and indeed its role is more complex than simple 
transcription repression. Counter-intuitively, while disruption or upregulation of 
MeCP2 dysregulates thousands of genes 85% of those genes are upregulated in 
both cases (Chahrour et al., 2008). Like MBP2, MeCP2 associates with CREB1 at 
CREs near actively transcribed genes, as well as covering regions of methylated 
DNA and preventing TET-induced demethylation. 
As discussed above, DNA methylation has a complex bidirectional relationship with 
both underlying chromatin modifications and associated proteins which in turn are 
differentially enriched across genomic features. It is also clear that this relationship 
is extremely dynamic but also partitioned into several stages between DNA 
methylation and demethylation, and chromatin condensation and relaxation, 
allowing for subtle and adaptive control of gene expression. It is therefore not 
surprising that DNA methylation can be influenced by a cell’s environment, be this 
during differentiation in response to intercellular signalling, over the course of a 
disease or even as a lasting response after tobacco smoke exposure (Joehanes et 
al., 2016). With the recent development of new high-throughput technologies to 
measure changes in DNA methylation, epigenetic research has become 
increasingly useful in uncovering novel biological mechanisms and providing new 
insight into disease processes. 
1.5 Measuring DNA Methylation 
There are two approaches to measuring DNA methylation (global and specific) and 
methodology varies between them. Early research focused on global levels of DNA 
methylation, and so techniques such as high-performance liquid chromatography 
UV (HPLC-UV) (Kuo et al., 1980) or liquid chromatography mass spectrometry 
(LCMS) (Song et al., 2005) were developed to hydrolyse DNA, separate cytosine 
and 5mC through chromatography and then calculate the global 5mC/C ratio. 
Antibodies against 5mC can be used in ELISAs to measure global methylation with 
greater ease but a trade off in accuracy. These methods are useful when large 
changes in methylation are expected, such as in analysis of tumour-derived DNA. 
Due to their genomic abundance and enrichment of CpG sites, methylation levels at 
transposons such as LINE-1 are also studied as a surrogate marker of global DNA 
methylation levels (Yang et al., 2004).  
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A subsequent quantitative development in the study of global DNA methylation is 
the luminometric methylation assay (LUMA) (Karimi et al., 2006), which incorporates 
the restriction endonucleases HpaII and MspI. HpaII only cuts DNA at unmethylated 
CCGG sequences, while MspI recognises the same sequence but is insensitive to 
methylation. Each DNA sample is digested in two separate reactions using EcoRI 
and each respective enzyme, after which the EcoRI 5’-AATT and HpaII/MspI 5’-CG 
overhangs are filled in using a DNA Polymerase extension assay. This is done in a 
pyrosequencer, which uses predefined stepwise addition of nucleotides, 
incorporation of which is coupled with a luciferase reaction that produces light, to 
sequence DNA. The ratio between the light signal during the incorporation of 
guanosine and cytosine in paired MspI and HpaII-digested samples is equivalent to 
the global proportion of 5mC.   
The second approach to studying DNA methylation is site-specific and early 
methods also made use of restriction enzymes. DNA can be fragmented and then 
digested with the methylation-sensitive HpaII enzyme which only cuts at 
unmethylated sites, before PCR using primers which anneal around the CpG of 
interest. The amount of product generated from intact fragments, normalised to a 
separate control amplicon from the same sample which does not contain CCGG, 
can be used to quantitate differences in methylation between samples within the 
amplicon, albeit with low resolution. Another approach using next generation 
sequencing is to digest DNA using HpaII, sequence the fragmented products and 
align them to a reference genome: the number of sequencing reads at each intact 
HpaII site corresponds to the methylation level at that site (Kurdyukov and Bullock, 
2016).  
The current gold standard approach to detecting DNA methylation is to begin with 
bisulphite conversion (Frommer et al., 1992). This chemical process results in the 
deamination of unlabelled cytosine to uracil, which is typically followed by PCR 
resulting in a conversion to thymine. Methylated cytosines are highly resistant to 
conversion and so remain unaffected.  After this treatment CpG sites can be 
assayed for cytosine or thymine using standard genotyping techniques, allowing for 
a ratio of C:T and thus a ratio of methylated:unmethylated cytosine at the site to be 
calculated. However, the product of bisulphite conversion is fragmented, single 
stranded DNA with increased sequence redundancy, which has consequences for 
long-term storage and assay design. After conversion a simple melt curve qPCR or 
the difference in Ct between two qPCR reactions with primers specific to the 
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methylated and unmethylated site can be used to calculate relative methylation 
levels. 
In the absence of a prior hypothesis, measuring DNA methylation at hundreds of 
thousands of loci is required. Whole Genome Bisulphite Sequencing (WGBS) is the 
most expensive means of detecting methylation on this scale in terms of sample 
input, cost and analysis. Because most of the data collected does not relate to 
cytosine methylation, Reduced Representation Bisulphite Sequencing (RRBS) is a 
more cost-effective approach which involves digesting genomic DNA using MspI to 
enrich the sample for fragments terminating in a digested CpG before bisulphite 
treatment and sequencing.  
Illumina Infinium arrays are cheaper per sample than the previous two techniques 
but are limited to measuring methylation at approximately 27,000, 450,000 or 
850,000 sites, and the distribution of probes on the former two arrays is mostly 
restricted to CpG islands and shores.  Moreover, the arrays can currently only be 
used to investigate human DNA preventing study of methylation in mouse models of 
disease. Yet the cost-efficiency of the array has permitted the analysis of sufficient 
numbers of samples to power studies of genome-wide DNA methylation, and as a 
result the array has become widely used. The technology underpinning the Infinium 
array is described in more detail in the next section. 
1.5.1 The 450K Array 
The 450K Infinium beadchip array contains probes targeting 485,764 CpG sites 
genome-wide, covering 99% of RefSeq genes with an average of 7 probes per gene 
(Illumina, 2012). Each probe contains over 100 nucleotides, of which two at the 
centre correspond to the CpG site. There are two types of probe chemistries and 
the first (Type I) is inherited from the 450K’s 27K precursor array. These consist of a 
pair of probes at each site, one of which recognises unmethylated CpGs and 
contains a CA corresponding to GT sequences where unmethylated cystosines are 
converted to thymines, and one which recognises methylated CpGs and contains a 
CG corresponding to an unconverted guanine-cytosine pair. Because DNA 
methylation is thought to generally correlate across short sections of DNA (~50bp), 
CpGs underlying the probe hybridisation site are assumed to be methylated or 
unmethylated per probe type and the probe sequence is designed to reflect this 
(Bibikova et al., 2006; Eckhardt et al., 2011). The second type (Type II) uses one 
probe per site and at the 3’ end is a cytosine to complement the guanine of a CpG 
pair, allowing either adenine or guanine to be incorporated upon hybridisation to 
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unmethylated or methylated DNA. In doing so probes per site decreases from 2 to 
1, and underlying CpG sites are accommodated for by including variable “R” 
nucleotides, preventing bias towards different hybridisation efficiencies of 
methylated or unmethylated DNA amplicons. Probes lose binding efficiency after 
inclusion of more than 3 R nucleotides, and so while allowing greater target 
capacity, Type II probes can only reliably target sites in regions of low CpG density 
(Bibikova, Barnes, et al., 2011). 
Once DNA is hybridised to probes, labelled nucleotides are incorporated in a single-
nucleotide extension step. With methylated DNA cytosine or guanine are 
incorporated and if DNA is unmethylated adenine or thymine are incorporated. The 
former nucleotides are labelled with biotin and the latter with 2,4-dinitrophenol. 
Immunochemistry can then be used to identify methylated and unmethylated loci 
based on green or red fluorescence respectively. Site-specific signal intensity is 
recorded and output per sample in intensity data (iDAT) files. The process of 





Figure 7: Type I (A) and II (B) 450K probe chemistries. Type I probes are complementary to either 
methylated or unmethylated DNA, hybridisation of DNA to either probe is linked to a single nucleotide 
extension at the site immediately adjacent to the CpG target which is identified by 
immunofluorescence. Type II probes allow incorporation of either adenine or guanine at the site 
complementary to the target cytosine, meaning the same probe can report either a methylated (red) or 
unmethylated (green) signal (Figure from Bibikova, Le, et al. 2011). 
 
1.5.2 Addressing technical limitations of the 450K Array 
The technical limitations of the 450K array have been extensively discussed in the 
research community and reviewed in the literature. The intensities in iDAT files are 
used to calculate a ratio called “β” (𝛽𝛽 = 𝑀𝑀𝑀𝑀𝑀𝑀ℎ𝑦𝑦𝑦𝑦𝑦𝑦𝑀𝑀𝑀𝑀𝑦𝑦 𝑓𝑓𝑓𝑓𝑦𝑦𝑓𝑓𝑀𝑀𝑓𝑓𝑓𝑓𝑓𝑓
𝑀𝑀𝑀𝑀𝑀𝑀ℎ𝑦𝑦𝑦𝑦𝑦𝑦𝑀𝑀𝑀𝑀𝑦𝑦 𝑓𝑓𝑓𝑓𝑦𝑦𝑓𝑓𝑀𝑀𝑓𝑓𝑓𝑓𝑓𝑓+𝑈𝑈𝑓𝑓𝑈𝑈𝑀𝑀𝑀𝑀ℎ𝑦𝑦𝑦𝑦𝑦𝑦𝑀𝑀𝑀𝑀𝑦𝑦 𝑓𝑓𝑓𝑓𝑦𝑦𝑓𝑓𝑀𝑀𝑓𝑓𝑓𝑓𝑓𝑓+𝛼𝛼
), 
where α is a corrective factor.  β varies from 0 (totally unmethylated) to 1 (totally 
methylated) and so is an intuitive measure of DNA methylation, but in 2010 Du et al. 
showed that a logit-transformed variant of  β, “M”, leads to less bias during statistical 
manipulation of extreme β values (Du et al., 2010).  
In 2013 Chen et al. published a list of cross-reactive probes included on the array 
(Y. A. Chen et al., 2013), suggesting these probes could not be considered reliable. 
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In the same year Triche et al. devised a pipeline (normal-exponential out-of-band, or 
“noob”) for correcting background fluorescence (Triche et al., 2013). By that time it 
was also known that the two different probe chemistries present on the array lead to 
heteroscedastic bias between type I and II probes, possibly because Type II probes 
had higher background signal and so β values are compressed away from 0 and 1, 
and towards the median of β = 0.5 (Dedeurwaerder et al., 2011; Pidsley et al., 
2013). A number of normalisation strategies were subsequently published to correct 
this bias and thus increase Type II assay sensitivity (Maksimovic, Gordon and 
Oshlack, 2012; Pidsley et al., 2013; Teschendorff et al., 2013).  
Illumina’s GenomeStudio software allows basic manipulation of 450K data, but not 
the adjustments detailed above. Researchers began to develop and expand upon 
multiple diverse packages using the statistical platform R for data processing, 
quality control and complex analysis. Wrappers such as RnBeads and ChAMP 
began to gather these functions into relatively user-friendly programming steps in 
2014 (Assenov et al., 2014; Morris et al., 2014). Interest also surrounded the issue 
of cellular heterogeneity and how imbalances of cell composition between and 
within sample groups could contaminate data. Houseman et al. published a 
reference-based method for blood and later a reference-free method for other 
tissues to gauge cell composition from methylation data, which researchers adopted 
as a tool to regress out the effects of such changes from EWAS (Houseman et al., 
2012; Houseman, Molitor and Marsit, 2014). Such corrections are now regarded as 
“critical” for epigenetic analysis of heterogeneous tissues (Jaffe and Irizarry, 2014). 
In 2016 a list of probes overlapping single nucleotide polymorphisms with mean 
allele frequencies of 5% and above was published and while these may have utility, 
for example in imputing ethnic background of the sample donor, many studies 
routinely exclude these probes from analysis (Zhou, Laird and Shen, 2016). Various 
permutations of these corrections are regularly applied in any study which 
incorporates 450K array data, and discussions of the technical constraints of the 






1.6 DNA Methylation in Neurodegeneration 
Many studies of altered DNA methylation in disease have a major limitation in that it 
is difficult to establish whether the observed effects are causal or a consequence of 
pathogenesis. This is particularly difficult to resolve in studies of central nervous 
diseases, where the affected tissue can only be sampled post mortem and therefore 
pathology is usually advanced. Study of blood-derived DNA as a proxy tissue is a 
useful means of identifying methylation sites which may become increasingly 
altered across the course of the disease, and in some instances such changes have 
been found to reflect similar changes in the brain (Masliah et al., 2013). Although 
familial neurodegenerative diseases have been studied, it is perhaps sporadic 
disease where study of DNA methylation might prove most useful, as these forms of 
disease are the most prevalent and lack Mendelian genetic determinants. Instead, 
alongside disease modifying polymorphisms, risk has been linked to lifestyle factors 
such as exercise (Sofi et al., 2011), diet and Body Mass Index (Luchsinger and 
Gustafson, 2009), years of education (Larsson et al., 2017), smoking history (Wang 
et al., 2011), sleep disturbance (Clark and Warren, 2013) and late-life depression 
(Singh-Manoux et al., 2017). Study of differential methylation in disease may reveal 
how these factors modify disease risk and pathogenesis, as well expand upon 
understanding of the disease mechanism itself. Yet dementia and other forms of 
neurodegeneration are frequently heterogeneous in clinical presentation, age of 
onset, disease duration and neuropathological profile, confounding dissection of 
nuanced pathological mechanisms.  
1.6.1 DNA Methylation and Amyotrophic Lateral Sclerosis  
Amyotrophic Lateral Sclerosis (ALS) is a complex and variable neurodegenerative 
disorder characterised by the progressive death of motor neurons (Zarei et al., 
2015). As with many neurodegenerative diseases, almost 95% of cases are 
sporadic and median age of onset is 64. ALS is incurable and disease duration is 
typically 2-3 years, although some individuals such as the late Stephen Hawking 
have been known to survive for much longer after initial diagnosis.  
Several genes are associated with both familial and sporadic ALS and of these 
C9orf72 is the most common (Dejesus-hernandez et al., 2011; Renton et al., 2011). 
A hexanucleotide expansion (GGGGCC) in this region is associated with disease 
development, and profiling of blood-derived DNA revealed an association with 
expansion length, shorter disease duration, and hypermethylation of a CpG island 
adjacent to the expansion (Xi et al., 2013). This is remarkably similar to 
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observations that in peripheral blood mononuclear cell-derived DNA the length of a 
GAA expansion in FXN, the most common cause of Friedreich’s Ataxia (FA), 
positively correlates with upstream hypermethylation and downstream 
hypomethylation. Upstream hypermethylation in turn inversely correlated with age of 
onset and FXN expression, while downstream hypomethylation correlated positively 
with earlier age of onset (Evans-Galea et al., 2012). Because of the difficulty of 
accurately sequencing the length of such repeat expansions, altered DNA 
methylation at the expansion boundary was thus a useful prognostic marker in FA 
and is potentially useful in ALS. Similarly, Nuclear Magnetic Resonance Imaging of 
ALS patient brains identified an association with increased C9orf72 promoter 
methylation in blood and reduced grey matter loss over time (McMillan et al., 2015).  
As DNA methylation varies between cell types, studies of leukocyte-specific 
methylation in whole blood have also been used as a proxy measure of leukocyte 
proportions in monozygotic twins discordant for ALS. Researchers found that over 
the disease course regulatory T-cells are gradually depleted and macrophage 
populations increase, which in combination leads to increased production of the 
inflammatory cytokines IL-1, IL-6 and TNF-α (Lam et al., 2016). This reduction of 
regulatory T-cells mirrors findings from ALS model mouse research, and further 
investigation showed that the demethylated region specific to regulatory T-cells in 
the first intron of FOXP3 was hypermethylated in this cell population in rapidly 
progressive ALS patients (Beers et al., 2017). This dysregulation of cytokine 
production in the periphery is particularly notable as motor neuron axons are outside 
the blood-brain barrier, and thus particularly vulnerable to aberrant and cytotoxic 
leukocyte activity. Findings such as these raise the possibility of epigenetic therapy, 
and follow-up work by Beers et al. showed that in vitro expansion of regulatory T-
cell populations could restore normal inhibition of effector T-cells, suggesting 
extraction, expansion and re-transfusion of ALS patient regulatory T-cells may have 
a therapeutically effect (Beers et al., 2017). 
1.6.2 DNA Methylation and Parkinson’s Disease 
Parkinson’s Disease (PD) is the second most common neurodegenerative disease 
and is clinically characterised by rigidity and tremor, followed by psychological 
symptoms and cognitive decline. The median age of onset is 60 and risk increases 
with age, while median disease duration is 15 years (Lee and Gilbert, 2016). Males 
are between 1.5 and 4 times more likely to develop PD, potentially in part due to the 
neuroprotective role of oestrogen in dopaminergic neurons which are particularly 
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vulnerable in PD (Gillies et al., 2014). There are multiple subtypes of PD, each with 
a wide range of clinical presentations and trajectories, making management of the 
disease difficult. 
PD is also associated with several genes, although mutations in these genes are 
not completely penetrant and so a complex array of factors are thought to underlie 
pathogenesis. SNCA, also known as alpha-synuclein, is heavily deposited in post-
mortem PD brain and so has been a primary focus of research in molecular and 
genetic studies of PD. Aggregated deposits such as these “Lewy Bodies” are 
observed in many dementias and proteopathic seeding and protein dysmetabolism 
are thought to underlie many neurodegenerative diseases. SNCA expression was 
found to be elevated in the substantia nigra of PD patient brains (Gründemann et 
al., 2008), and a CpG island overlapping the promoter was found to be 
hypomethylated in PD patient substantia nigra, putamen and cortex-derived DNA 
(Jowaed et al., 2010). It is possible that increased expression of a protein prone to 
aggregation and deposition could over time be sufficient to initiate pathogenesis, in 
which case demethylation of the promoter region may be a necessary step during 
the early stage of disease. Demethylation and upregulation of SNCA in HEK 293 
cells was shown to be induced by dopamine (Matsumoto et al., 2010). While there 
are obvious differences between HEK 293 cells and neurons, these data do suggest 
an explanation for how dopaminergic neurons in the substantia nigra may be 
particularly vulnerable during PD pathogenesis. Increased expression of SCNA 
initiates a positive feedback loop: SCNA sequesters DNMT1 in the cytoplasm, 
excluding it from the nucleus and resulting in a 30% global reduction of DNA 
methylation in PD frontal cortex-derived DNA (Desplats et al., 2011). Given that 
neurons are post-mitotic, it is likely that this decrease in methylation is specific to a 
non-neuronal cell type which loses DNA methylation over successive mitotic 
generation.  
Methylation potential has been proposed as a prognostic and diagnostic marker in 
PD. The plasma SAM/SAH ratio is a measure of the physiological capacity to 
regulate DNA methylation, with higher values indicating greater capacity. This ratio 
correlates positively with DemTect score, a measure of cognitive function (Kalbe et 
al., 2004), and negatively with platelet SCNA levels (Obeid et al., 2009). This is 
particularly relevant within the context of PD as a common prodrug therapeutic, L-
Dopa, must be methylated to become active. This process depletes cerebral SAM 
by between 36-76% in PD patients receiving L-Dopa. Consequently, these has been 
speculation that supplementing PD patient diets with folate and vitamin B12 may 
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prevent hyperhomocysteinaemia and potentially delay disease progression (Müller, 
Woitalla and Kuhn, 2003). Whether there is a connection between SAM/SAH 
dysmetabolism and disease severity or rate of progression remains uninvestigated 
and altered DNA methylation profiles in patients being treated with L-Dopa may be 
worth studying. 
1.6.3 DNA Methylation and Alzheimer’s Disease 
Alzheimer’s Disease (AD) is the most common form of dementia. Risk increases 
with age, and while a number of dominant causative mutations can cause familial 
forms of the disease, over 95% of cases are late onset Alzheimer’s Disease (LOAD) 
(Lu et al., 2013). Some cases of LOAD may not be sporadic in the purest sense as 
a common and potent genetic risk factor has been identified, namely the 
apolipoprotein 4 allele APOE4 which is enriched more than two-fold in LOAD 
patients compared to the general population (Saunders et al., 1993; van der Flier et 
al., 2011). Study of familial AD has revealed mutations in genes which handle 
metabolism of the amyloid precursor protein (APP). Neuropathological hallmarks of 
Alzheimer’s disease include deposition of aggregated forms of amyloid-β, a 
metabolite of APP, and deposition of hyperphosphorylated tau, a microtubule 
associated protein, into structures respectively named plaques and tangles. These 
two proteins have been studied extensively and while multiple biological processes 
are known to be involved in AD pathology, pathogenesis remains incompletely 
understood as non-demented individuals can exhibit AD-like pathology without 
developing clinical symptoms (Lue et al., 1996).  
Early studies of DNA methylation in AD showed decreased immunoreactivity of 
5mC in neurons and glia of the post-mortem entorhinal cortex, an area of the brain 
affected at the start of AD pathogenesis, while neuronal DNMT1 immunoreactivity 
was also found to be reduced (Mastrianni et al., 2003). Interestingly this decrease in 
5mC correlates with the abundance of neurofibrillary tangles, deposition of which 
correlates well with the development of clinical symptoms. Hyperphosphorylation of 
tau was also shown to be dependent on the availability of SAM, as the tau 
phosphotase PP2A is activated by methylation at L309, thus a decreased SAM/SAH 
ratio leads to tau hyperphosphorylation in N2A cells and mouse brain (Sontag et al., 
2007). A decreased SAM/SAH ratio has also been found to result in PSEN1 and 
BACE1 promoter demethylation and upregulation, which in turn shifts APP 
metabolism towards producing greater fractions of amyloid-β (Fuso et al., 2005). 
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SAM is a methyl donor in many biological reactions, so to what extent dysregulation 
of DNA methylation contributes to this imbalance is unclear. 
DNA derived from frontal cortex and hippocampal tissue is not differentially 
methylated at genes known to harbour causative mutations in AD, such as APP and 
PSEN1 (Barrachina and Ferrer, 2009). However, a DNMT3B haplotype (rs998382, 
rs2424913) was found to increase risk of developing AD to an odds ratio of 3.03 
(Pezzi et al., 2014), and subsequently shown to interact with the APOE4 allele to 
synergistically increase risk to an odds ratio of 11.13, almost double the expected 
ratio of both haplotypes combined (de Bem et al., 2016). The precise relationship 
between the two haplotypes and potential of increased AD risk is unclear. 
As well as differential methylation at genes known to cause or predispose towards 
AD, with the advent of genome-wide methylome profiling dozens of genes have also 
been shown to exhibit differential methylation in AD in various tissues, as reviewed 
by Qazi et al. (Qazi et al., 2018). Reflective of the broad range of cellular 
dysfunction associated with AD, these genes relate to pathways such as 
inflammation and oxidative stress (COX-2, NGB, NF-κB, UQCRC1), cytoskeletal 
and cellular morphology (SYP, SORBS3, SPTBN4, ANK1, CDH23), and 
neurotrophic activity (BDNF, CREB, CREB5, TBXAR2). Of these, ANK1 has been 
reproducibly identified as becoming hypermethylated and indeed dysregulated as 
Braak stage increases in AD cortex across multiple cohorts of patients and in 
several studies, the latest of which implicate this gene in other neurodegenerative 
diseases such as Huntington’s Disease and Parkinson’s Disease (De Jager et al., 
2014; Lunnon et al., 2014; Mastroeni et al., 2017; Smith et al., 2019). However, 
while the biological functions of these genes make them good candidates for further 
research in the absence of functional studies their roles in disease pathogenesis 
and progression remain incompletely understood.  
1.7 Clinical aspects of DNA methylation 
It is important to note that the changes in DNA methylation observed in the 
neurodegenerative diseases discussed above are relatively modest, and rarely 
exceed 10%. However, due in part to the large changes in DNA methylation 
characteristic of the diseases, DNA methylation has been most successfully 
connected to clinical research in the context of cancer. While genome-wide 
alterations in DNA methylation are a hallmark of cancer, specific changes such as 
hypermethylation of the MLH1 promoter is almost diagnostic of sporadic 
endometrial cancer (Simpkins et al., 2002). Furthermore, measuring methylation at 
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the MLH1 promoter can triage patients who may have developed endometrial 
cancer as a consequence of Lynch syndrome, where MLH1 hypermethylation is not 
involved, rather than sporadic cancer more efficiently than genetic sequencing, with 
obvious benefits to counselling and disease management (Bruegl et al., 2014).  
Site-specific altered methylation was considered as a diagnostic tool in the context 
of breast cancer as early as 1997 and then considered as a prognostic tool in 2003 
(Huang et al., 1997; Chen et al., 2003). With the advent of genome-wide 
technologies, profiling DNA methylation in different tissues from various types of 
cancer patients has become easier and more rewarding. Oncologists have recently 
used the 450K array to establish a reference dataset of 9 control neurological 
tissues and 82 brain tumour classes, which were able to classify sample type using 
a simple random forest machine learning tool (Capper et al., 2018). Sensitivity and 
specificity of the machine learning model was 0.989 and 0.999 respectively, and in a 
replication cohort 977/1,104 patient samples could be matched to a tumour class, of 
which 838/977 classifications matched decisions made by histopathologists. The 
remaining 139 patient samples were further profiled in terms of DNA copy number 
and targeted sequencing, leading to diagnostic revisions in 129 of 139 cases. 
Because of the genetic heterogeneity of brain tumours, methylation analysis 
provides a cost-effective way to not only inform diagnosis but also potentially 
identify rare novel subclasses of cancer. 
The extent of lymphocyte invasion into a tumour is recognised to be prognostic of 
patient outcome, with greater infiltration associating with improved survival (Fridman 
et al., 2017). Using a support vector regression model, tumour-derived DNA 
methylation data can be deconvoluted to infer the proportions of immune cells 
present in a tumour biopsy, thus potentially improving patient stratification 
(Chakravarthy et al., 2018). Given the above, it is likely that DNA methylation data 
will increasingly inform cancer diagnosis and prognosis, with translational potential 
for studies of neurodegenerative disease. 
While brain biopsies are invasive and technically complex, liquid biopsies such as 
cerebral-spinal fluid and peripheral blood are more comfortable for the patient and 
easier to perform. A recent study found that, due to the large changes in DNA 
methylation found in cancer, methylation-dependent immunoprecipitation (MeDIP) 
of circulating tumour DNA from plasma has potential for cancer diagnosis (Shen et 
al., 2018). Because of the low abundance of normal cell-free DNA, let alone that 
derived from tumours, bisulphite conversion is likely to destroy extracted material 
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and thus be refractory to analysis.  MeDIP-sequencing bypasses this problem as 
sequences are enriched for by differences in regional methylation between case 
and control. Shen et al. found 14,716 DMRs between 24 pancreatic cancer patients 
and 24 matched controls, the majority of which (9,931) were hypermethylated in 
patients. Further work shows that this technique can be used to classify cancer type 
(pancreatic, breast, lung, renal, bladder, AML). Because of the uniquely dramatic 
changes to the methylome observed in cancer it may be that this technique is not 
tractable for profiling neurodegenerative diseases, but nevertheless this work is 
illustrative of the huge translational potential of studying DNA methylation. 
The prodrug 5-azacytidine, a cytosine analogue which cannot be methylated by 
DNMTs, was approved by the American Food and Drug Administration in 2004 for 
the treatment of myelodysplastic syndromes (MDS) , a group of blood cancers, and 
acute myeloid leukaemia (AML) (KAMINSKAS, FARRELL and WANG, YONG-
CHENG SRIDHARA, RAJESHWARI PAZDUR, 2005). Like many 
chemotherapeutics, 5-azacytidine interferes with DNA replication and does so by 
irreversibly inhibiting the action of DNMT1 (Friedman, 1981). As with any treatment 
which non-specifically disrupts DNA replication and thus cell division, there are 
many side effects from treatment with 5-azacytidine, including fever, gastrointestinal 
effects, headaches, dizziness, weakness and insomnia. Another analogue, 5-aza-2’-
deoxycytidine, was subsequently approved in 2006 by the FDA and by the 
European Commission for treatment of AML in 2012 (Agency, 2013). This analogue 
differs from 5-azacytidine in that it specifically inhibits DNMT1, whereas 5-
azacytidine can also be incorporated into RNA and inhibit RNA methyltransferases. 
Curiously there are to date no trials directly comparing the clinical efficacy of these 
drugs in AML, and a meta-analysis of both treatments revealed no significant 
difference between the two (Almasri et al., 2015). A comparative study in AML cell 
lines revealed disparate effects on cell function and viability, possibly as 5-
azacytidine also affects RNA processing and in fact is preferentially incorporated 
into RNA (Hollenbach et al., 2010). The effect of these drugs on genome-wide DNA 
methylation is relatively unknown as studies of DNA methylation in response to drug 
application in vitro has focused on genes previously associated with AML, and 
changes where observed did not tend to correlate with altered gene expression 
(Estey, 2013). Cultured bone marrow samples from MDS and AML patients which 
were profiled on the 450K array after 5-azacytidine treatment showed widespread 
differential methylation at 65, 769 probes, of which 65,664 were demethylated, 
albeit at a modest level (median Δβ = -0.028) after 24 hours. However, these effects 
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were found to cluster strongly with patient identity rather than treatment status, 
suggesting the data may be confounded by non-experimental factors (Tobiasson et 
al., 2017). 
1.8 Study Rationale and Aims 
As described above, study of DNA methylation in neurodegenerative disorders can 
not only uncover new associations between the disease and candidate genes, but 
also reveal new biomarkers, prognostic markers and targets for therapeutic 
intervention. Nuanced studies of specific genes have also correlated DNA 
methylation with known risk factors for the disease, such as an association with 
BDNF promoter methylation with blood C-Reactive Protein and homocysteine 
levels, and with APOE4 status in AD patients, suggesting a use of BDNF 
methylation as a proxy for disease risk (Chang et al., 2014). In the tauopathy 
Peripheral Supranuclear Palsy, a known risk haplotype at 17q21.31 acts as a 
methylation quantitative trait locus, with increased dosage of the risk allele 
correlating with degree of hypomethylation at the MAPT locus in both blood and 
brain (Li et al., 2014). In addition, association of magnitude of differential 
methylation with disease severity has been established in AD, where Braak staging 
was found to correlate with degree of hypermethylation at the ANK1 locus in the 
entorhinal cortex (De Jager et al., 2014; Lunnon et al., 2014). Methylation as a 
proxy measure of anticipated disease severity and risk is thus also potentially useful 
for patient counselling and monitoring. 
Except for codon 129 genotype, there are few routinely employed prognostic or risk 
markers for sCJD. PrP is the main candidate protein for targeted intervention, and 
treatments address general disease symptoms rather than specific biological 
pathways. Prion disease research and prion patient treatment could therefore 
potentially benefit from a study of the sCJD methylome. For example, changes to 
DNA methylation which associate with disease severity or rate of progression could 
serve as biomarkers for study of novel therapeutics, while changes which seem to 
be established before clinical decline may reflect pathogenic events.   
Study of DNA methylation in sCJD blood is a more practical and useful approach 
than study of brain tissue for several reasons: blood is much more accessible from a 
clinical perspective and so has promise as a source of disease biomarkers. 
Moverover, sCJD is a rare disease and not all patients have post mortem 
examination, whereas nearly all patients donate research blood when blood is taken 
for genetic testing to exclude mutations in PRNP, resulting in a larger sample 
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resource for study and greater statistical power. Blood can be sampled 
longitudinally, allowing correlation of the methylome at various stages of disease 
with clinical phenotype such as disease severity and rate of decline. Additionally, 
while prion-infected brain tissue is an Advisory Committee for Dangerous 
Pathogens (ACDP) category level 3 biohazard, blood from patients diagnosed with 
prion disease can be handled at ACDP containment level 2 meaning it can be 
processed in laboratories and hospitals without the need for specialised facilities or 
training. Finally, blood subtypes have been extensively studied and phenotyped for 
decades, and bioinformatic tools to deconvolute the effects of cellular heterogeneity 
in blood are significantly more advanced than the equivalent for brain tissue. 
There is a dearth of non-PRNP risk factors in sCJD and so a genome-wide 
approach is necessary to identify novel targets. Of the genome-wide methods 
considered earlier, the most cost-effective technology which permits study of 
enough samples to power a genome-wide study is the Illumina Infinium 450K array. 
This platform also benefits from extensive use in the literature, an abundance of 
open-access software to process and manipulate data, and good correlation with 
other validated technologies such as pyrosequencing (Pearson’s R2=0.967, 
(Dedeurwaerder et al., 2011)).  
The initial aim of the study was to profile genome wide methylation using 450K 
arrays in a control and sCJD cohort and investigate differential methylation between 
both groups, correlate methylation values in the sCJD group with clinical metadata, 
and use an array of bioinformatic tools to infer whether differential methylation might 
affect particular biological pathways, originate from specific leukocyte classes, 
overlap functional genomic features or prove useful as a diagnostic or prognostic 
tool as described above in the context of cancer. 
In the results and discussion chapters I will describe the results of this initial stage of 
the research, how findings were validated and replicated using pyrosequencing and 
how replicated findings were tested for specificity in DNA derived from other prion 
disease and patients with different neurodegenerative dementias. I will then explore 
the tissue specificity of observed epigenetic dysregulation and its effects on 
physiological function. Finally the the utility of 450K data as a diagnostic tool in 





2.1 Discovery Study using Illumina Infinium 450K Beadchip 
2.1.1 Sample Selection 
Sporadic CJD samples were obtained from patients referred to the National Prion 
Clinic (London, UK) or the National CJD Research and Surveillance Unit 
(Edinburgh, UK) under a national referral system. Patients were enrolled into the 
National Prion Monitoring Cohort Study which entailed a visit to hospitals, hospices 
or patient homes by National Prion Clinic staff followed by a review of diagnosis of 
probable sCJD according to published World Health Organisation criteria (World 
Health Organisation, 2003) by senior clinicians (J. Collinge, S. Mead and/or P. 
Rudge). The Cohort Study allowed longitudinal monitoring of patients via further 
visits and telephone assessments, and the connection of each patient’s genetic, 
clinical, and neuropathological data over the course of the disease. This eventually 
lead to the development of the Medical Research Council Prion Disease Scale, a 
measure of disease severity between 20 (healthy) and 0 (moribund) based on 
clinical and care milestones, which in many cases could be retrospectively applied 
to patient samples taken before the development of the Scale based on clinical 
records (Thompson et al., 2013). Diagnosis of definite sCJD was confirmed 
postmortem by the Neuropathology Division of the National Hospital for Neurology 
and Neurosurgery (University College London Hospitals NHS Foundation Trust), 
according to the World Health Organisation criteria.  
For the discovery study 114 patients enrolled in the Cohort Study with pathologically 
confirmed definite sCJD were selected. 112 control samples were from healthy, 
non-cognitively impaired elderly volunteers recruited by the Medical Research 
Council Prion Unit from the National Blood Service (31 samples), or from healthy 
non-cognitively impaired elderly volunteers recruited by Cardiff and Vale NHS 
Hospital (75 samples). All donors were from the UK and of white British ethnic 
origin. Sample demographics for this section of the work and all subsequent 





















sCJD 114 68.0 (49-85) 50.9 46:22:32 6 (0-20) 
Control 106 69.0 (41-83) 55.7 Unknown 20 
Replication 
sCJD 72 59.9 (26-86) 58.3 54:23:23 4.5 (0-20) 
Control 114 78.2(61-93) 64.9 Unknown 20 
Specificity 
Control 114 78.2(61-93) 64.9 Unknown 20 
AD 59 71.8 (58-87) 47.5 Unknown NA 
iCJD 18 46.4 (41-53) 11.1 27:73:00 11.7 (1-18) 
IPD 11 48.5 (38-68) 72.7 44:44:12 18.6 (13-20) 
Brain 
sCJD 58 68.8 (40-87) 42.9 65:25:10 0 
Control 33 74.0 (41-89) 54.2 Unknown 0 
 
Table 1: Demographics of patient and control samples used in experiments. 
  
The clinical and laboratory studies were approved by the local research ethics 
committee of the National Hospital for Neurology and Neurosurgery (University 
College London Hospitals NHS Foundation Trust) and Cardiff and Value Hospital 
(Cardiff and Vale University Health Board), and the Institute of Neurology 
(Department of Brain Sciences, University College London) respectively. All patient 
samples were obtained with written consent from patients, next of kin, carers or 
Independent Mental Capacity, with ethical approval provided from the Scotland A 
Research Ethics Committee. 
Samples were selected from these two groups based on age and sex matching 
between control and sCJD groups. As control samples were less plentiful than sCJD 
samples, 56 male and 56 female donors within the typical age range of sCJD age of 
onset (55-85 years of age) were selected and matched with sCJD patients of 
equivalent age and sex.  Inclusion preference was given to patients enrolled in the 
Cohort Study from whom multiple tissue samples had been taken (specifically brain 
tissue, and RNA-stabilisation tube-stored blood for study of RNA). Where available 
clinical data such as PRNP codon 129 genotype, MRC Scale score, MRC Scale 
slope, and age of onset were linked to patient samples for associative analysis of 
these data with DNA methylation. In total 114 sCJD and 106 control samples were 





Figure 8: Violin plots of age density per sample group in the 450K array discovery study. Numbers per 
group are displayed above each plot. 
 
2.1.2 Extraction of genomic DNA from blood 
Extraction of genomic DNA from blood took place in a Class II MSC hood, with all 
used/unneeded materials being discarded into a container of 2 M NaOH and left to 
sterilise overnight. In order to optimise DNA extraction from whole blood, several 
kits and conditions were tested. These are listed below: 
Zymo Quick gDNA MiniPrep Kit 
Several conditions were trialled using this kit: the manufacturer’s protocol (a), the 
manufacturer’s protocol with proteinase K digestion steps (b, c), and the protocol 
with a proteinase digestion step and a subsequent leukocyte pelleting and wash 
step. 
a) 200 µl blood was mixed with 800 µl genomic lysis buffer, mixed by vortexing 
and left to stand for 5 minutes at room temperature. This was then 
transferred to a purification column which was centrifuged in a benchtop 
microfuge for 30 seconds at 10,000 g before the column was washed with 
200 µl DNA pre-wash buffer, centrifuged again under the same settings and 
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then washed with 500 µl DNA wash buffer. After another centrifugation step 
50 µl DNA elution buffer (preheated to 65oC) was incubated on the column 
for 5 minutes at room temperature before DNA was eluted by centrifugation 
at top speed for 30 seconds. 
b) As (a) with additional protease K (200 µl of 2x Digestion Buffer, 20 µl 
protease K) treatment for 10 min at 65oC before mixing with lysis buffer. 
c) As (a) with additional protease K treatment overnight. 
d) As (b) with centrifugation at maximum speed for 30 seconds, discarding of 
supernatant and resuspension of the pellet in 200 µl dH20 before mixing with 
lysis buffer. 
ZymoBeads 
a) 50 µl blood was mixed with 200 µl genomic lysis buffer, before mixing with 
10 µl ZymoBeads. After a 5 minute incubation at room temperature the tube 
was centrifuged at 1,500 g for 1 minute and the supernatant aspirated. The 
pellet was resuspended in 200 µl genomic lysis buffer before another 
centrifugation and aspiration. The pellet was resuspended in 200 µl DNA 
pre-wash buffer and transferred to a fresh tube before centrifugation and 
aspiration of the supernatant. The pellet was then resuspended in 500 µl g-
DNA wash buffer before a final centrifugation and aspiration. Elution buffer 
was preheated to 65 oC, 50 µl were mixed with the pellet and incubated for 5 
min before centrifugation at 10,000 g for 1 minute. The supernatant 
containing purified DNA was collected. 
b) As (a) but volume of blood increased to 200 µl and genomic lysis buffer to 
800 µl. 
PAXgene Blood DNA Kit 
Samples were processed according to Qiagen protocol but all volumes 
reduced by 1/5 to conserve sample volume. 1 ml buffer BG was mixed with 
10 µl PreAnalytiX protease. 1.7 ml blood was added to 5 ml buffer BG1 and 
mixed by inversion. Samples were centrifuged for 5 minutes at 2,500 g, after 
which the supernatant was discarded and 1 ml buffer BG2 was added and 
mixed by vortexing for 5 seconds. After centrifugation at 2,500 g for 2 
minutes the supernatant was discarded and 1 ml buffer BG3/PreAnalytiX 
protease was mixed with the pellet by vortexing for 20 seconds. Samples 
were incubated at 65oC for 10 minutes before a brief vortex and addition of 1 
ml 100% isopropanol. Samples were inverted 20 times before centrifugation 
at 2,500 g for 3 minutes. The supernatant was discarded and residual 
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isopropanol was mopped up using a cotton bud. The pellet was washed with 
1 ml 70% ethanol before centrifugation at 2,500 g for 3 minutes. The 
supernatant was discarded and tubes were left inverted for 10 minutes at 
room temperature, before precipitated DNA was dissolved in 200 µl buffer 
BG4 at 65oC for one hour, followed by overnight incubation at room 
temperature. 
Illustra Nucleon BACC3 Genomic DNA Extraction Kit  
8 ml of blood was poured into a 50 ml falcon tube containing solution A (30 
ml dH20, 10 ml reagent A) and mixed for 4 minutes. The tube was 
centrifuged at 1300 g for 5 minutes and supernatant discarded. The pellet 
was resuspended in 2 ml reagent B and transferred to a 15 ml falcon tube to 
which 500 µl Sodium perchlorate was added and mixed by shaking, followed 
by addition of 2 ml chloroform and more mixing by shaking. 300 µl resin 
beads were added to the suspension without shaking which was the 
centrifuged at 1300 g for 3 minutes. The supernatant was decanted into a 
fresh 15 ml falcon tube and DNA precipitated by addition of 2 ml ethanol. 
DNA was spooled onto the tip of a heat-sealed glass Pasteur pipette and left 
to air dry before resuspension in 500 µl Tris-EDTA buffer. 
 
2.1.3 DNA Quality Control 
Concentration and integrity of extracted genomic DNA was measured by 
TapeStation (Agilent), or a QuBit 2.0 fluorometer (Thermo Fisher) and agarose gel 
electrophoresis. A Clean and Concentrator kit (Zymo) was used to clean and/or 
concentrate fragmented (TapeStation DIN value <0.7) or dilute samples ([DNA] < 25 
ngµl-1).  Sample concentrations were adjusted to 25 ngµl-1. 
2.1.4 Bisulphite Conversion 
500 ng of DNA in 20 µl was bisulphite converted in a Veriti thermocycler (Thermo 
Fisher) overnight using an EZ DNA Methylation-Gold kit (Zymo) according to the 
manufacturer’s protocol. Briefly, 130 µl CT conversion reagent was mixed with 20 µl 
DNA and incubated in a thermal cycler for 10 min at 98oC, 150 min at 64 oC, then 
maintained overnight at 4oC.The following day converted samples were loaded into 
spin columns, washed and then desulphonated. After two more washes column-




2.1.5 Infinium Beadchip Hybridisation 
Bisulphite DNA was sent to UCL genomics for array hybridisation in accordance 
with the Infinium HD Assay 15019519_B, 2011 (Illumina, 2015). Briefly, bisulphite 
DNA was amplified, enzymatically fragmented, precipitated and resuspended before 
hybridisation. Samples were hybridised to Illumina Infinium 450K beadchips in two 
batches of 12 (July 2015, August 2015) and three batches of 96 (August 2015, 
December 2015, February 2016). Each batch of samples was spatially randomised 
across a 96-well plate to prevent segregation of CJD and control samples between 
separate beadchips, which might predispose the data to batch effects. A total of 112 
controls, 116 sCJD samples and 20 vCJD samples were hybridised, with each 
batch of 12 or 96 samples containing a methylated, unmethylated and commercial 
leukocyte DNA standard (Zymo, Zymo, AMSBIO). Beadchips were then washed, 
stained and dried before imaging using an iScan (Illumina). IDAT files were 
generated and delivered from UCL Genomics via dropbox. 
 
2.2 Data Analysis of Illumina Infinium 450K Beadchip Study 
2.2.1 Case-Control Study Using RnBeads 
RnBeads version 1.6.1 (Assenov et al., 2014) and dependent packages 
(RnBeads.hg38, biomaRt, GenomicRanges, GEOquery, ggbio, GOstats, Gviz, 
IlluminaHumanMethylation450kmanifest, methylumi, rtracklayer, sva, 
RefFreeEWAS, MCLUST, hexbin) were downloaded from 
https://bioconductor.org/biocLite.R and loaded into R version 3.2.4 (Team, 2016). 
IDAT files were deposited into a working directory subfolder named “data” and a 
second empty subfolder was created titled “analysis”: these were assigned to the 
variables “idat.dir” and “report.dir” respectively. The manifest .csv file containing 
sample IDs, technical data and patient metadata was placed in the working directory 
and assigned to the variable “sample annotation”. Case-control analysis settings 
were configured by Dr. Holger Hummerich and performed using the hg38 build of 
the human genome, default preprocessing, QC, normalisation and exploratory 
functions, and RefFreeEWAS to correct for cellular heterogeneity (Houseman, 
Molitor and Marsit, 2014), as well as inclusion of age and sex as covariates. Multiple 
testing was compensated for using Benjamini-Hochberg correction. The code used 
to define these parameters is displayed below in Box 1. The pipeline was run on an 
independent server using 20 core parallel-processing and completed analysis after 











rnb.options(assembly = "hg38", 
filtering.sex.chromosomes.removal=TRUE, 
identifiers.column = "Sample_ID", import = TRUE, 
preprocessing = TRUE, qc = TRUE, exploratory = TRUE, 
export.to.bed = FALSE, export.to.trackhub = NULL, 
exploratory.region.profiles = character(0), 
differential = TRUE,  
differential.comparison.columns = "Sample_Group", 
differential.site.test.method="refFreeEWAS", 
differential.adjustment.sva = TRUE, 
covariate.adjustment.columns = c("Gender","Age"), 
filtering.cross.reactive = TRUE, 
inference.sva.num.method = "leek", 
differential.adjustment.celltype = TRUE, inference = 
TRUE, inference.targets.sva = c("Sample_Group"), 
differential.enrichment = TRUE, logging.disk = TRUE, 
enforce.memory.management=TRUE) 
 
rnb.run.analysis(dir.reports = report.dir, 
sample.sheet = sample.annotation, data.dir = 
idat.dir, data.type = "infinium.idat.dir", 
save.rdata = TRUE) 
 
Box 1: rnb.options used to define parameters for the rnb.run.analysis function. Report 
and data directories were defined as “report.dir” and “idat.dir”, while sample sheet 




2.2.2 Case-Control Study Using ChAMP 
ChAMP version 2.10.2 (Morris et al., 2014) and limma version 3.36.5 (Ritchie et al., 
2015) were downloaded from https://bioconductor.org/biocLite.R and loaded into R 
version 3.3.4. IDAT files and manifest .csv file were placed directly into the working 
directory. These were processed and corrected as per documentation (Data import, 
QC, BMIQ normalisation, SVD, batch correction using ComBat (Johnson, Li and 
Rabinovic, 2007), Houseman or EpiDISH (version 1.2.0) reference-based celltype 
correction (Houseman, Molitor and Marsit, 2014; Teschendorff and Zheng, 2017)) 
on a local dual-core processor machine with 32Gb RAM. Limma was then used to fit 
the corrected data to the following linear regression model:  

























ref.m <- centDHSbloodDMC.m[,1:6] 
out.l <- epidish(myCombat, ref.m, method = "RPC") 
message("Mean value for each estimated Cell Proportion:") 
print(colMeans(out.l$estF))cellFrac<-as.matrix(out.l$estF) 
message(names(which.min(colMeans(cellFrac))), 
        " has the smallest cell proportion, all other cell 
proportions will be corrected by linear regression.") 
lm.o <- lm(t(myCombat) ~ cellFrac[,-
1*which.min(colMeans(cellFrac))]) 
EpiBeta <- t(lm.o$res)+rowMeans(beta) 
CorrectedBeta<-EpiBeta*100; 
message("Correction for cellular heterogeneity between 
samples is complete.\n") 
 
#CorrectedBeta used in final linear model 
Mod <- model.matrix(~0 + Sample_Group + Age + Sex,  
data = myLoad$pd) 
colnames(Mod)[1:2] <- 
levels(factor(myLoad$pd$Sample_Group)) 
Contrast.matrix <- makeContrasts(sCJD - CTRL,  
levels = Mod) 
Fit <- lmFit(CorrectedBeta, Mod) 
Fit <- contrasts.fit(Fit, Contrast.matrix) 
Fit <- eBayes(Fit) 
BonferroniLimmaLong <- topTable(Fit,  
number = nrow(CorrectedBeta), coef = 1, 
adjust.method="bonferroni",p.value = 1.00 ) 
 
Box 2: ChAMP pipeline run in the working directory containing sample manifest.csv and .idat files. 
Either Houseman or EpiDISH correction is used depending on the analysis 
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Differential methylation (Δβ) values at CpG sites, p values and Bonferroni adjusted 
p values were extracted, and association between corrected beta values at these 
sites with MRC Scale Score and Slope (Thompson et al., 2013; Mead et al., 2016) 
and PRNP codon 129 genotype was tested for using bivariate Pearson’s correlation 
in SPSS version 25 (Corp., 2017).  
Bumphunter (Jaffe et al., 2012) was used within ChAMP to identify Differentially 
Methylated Regions (DMRs) from corrected data using default configuration. 
2.2.3 Inference of Signal Origin Using eFORGE 
To infer possible cell or tissue type specificity of results, the list of cg codes (eg. 
cg10636246) corresponding to significantly Differentially Methylated Positions 
(DMPs) were uploaded to eFORGE version 1.2 (Breeze et al., 2016). Site-specific 
associations with functional elements and modifications were investigated by 
associating the list with DNAse1 hypersensitive sites (DHSs) and Histone 3 (H3) 
marks using default parameters. 
2.2.4 Study of Differentially Variable Methylation Sites Using iEVORA 
To assess differential variability of methylation at CpG sites between sCJD and 
control samples, the iEVORA algorithm (Teschendorff et al., 2012, 2016) was 
downloaded from Teschendorff et al. 2016 (Supplementary Software 1) and applied 
to 450K corrected beta data in R version 3.3.4.  
2.2.5 Study of Genomic and CpG Feature Distribution Using GOLDMINE 
ChIP-Seq data from T-Cells, B-Cells, Monocytes, Neurotrophils and Natural Killer 
Cells (E04_15, E031_15, E062_15, E030_15, E046_15 respectively) were 
downloaded from the Roadmap resource (Roadmap Epigenomics Consortium et al., 
2015) 
(http://egg2.wustl.edu/roadmap/data/byFileType/chromhmmSegmentations/ChmmM
odels/coreMarks/jointModel/final/). These were aligned to the hg19 build of the 
human genome, which was labelled with coding gene regions, Dnase 
Hypersensitive Sites, Transcription Factor Binding Sites and Enhancer Sites. DMRs 
and DMPs were aligned to the genome and genomic and CpG feature distribution of 
each group was called.  
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2.2.6 Study of Common Motifs Amongst Differentially Methylated Regions 
and Positions 
DMR sequences were input to MEME-Suite in FASTA format (Bailey et al., 2009). 
Identified motifs were probed for common transcription factor binding using MEME-
Suite’s TOMTOM tool under default settings. 
2.2.7 Enrichment Analysis of Differentially Methylated Transcription Factor 
binding sites and Differentially Methylated Genes 
Transcription factors found to be associated with DMRs (TOMTOM) and DMPs 
(Goldmine), and genes overlapping DMRS and DMPs respectively were uploaded 
separately to Enrichr (E. Y. Chen et al., 2013; Kuleshov et al., 2016) which 
associated uploaded genes with gene ontology and biological pathways using 
publicly available repositories. 
2.2.8 Machine Learning Classification of 450K Dataset  
CaRET version 6.0-81 (Kuhn, 2008) was used as a wrapper for machine 
classification of disease phenotype in a blinded subset of 450K array data. The 500 
and 5000 most significantly altered probes were screened for pairwise correlation 
and redundant probes were discarded. Beta values at remaining loci from 105 sCJD 
patient and 105 controls were united, randomised and partitioned into a training set 
(75% of samples) and a test set (25% of samples). 10-fold 10-repeat Recursive 
Feature Elimination (RFE) was used to select features for model training from the 
top 500 probes (ranked by significance of difference between sCJD and control 
groups) with iterative removal of one probe at a time.  
RFE-selected probes, probes corresponding to the 38 DMPs and the top 5000 
probes as ranked by significance were all used to train stochastic gradient boosting 
machine (gbm) models and averaged neural network models (avNNet) using 10-fold 
10-repeat crossvalidation in all instances. gbm models were tuned by adjusting the 
number of boosting iterations and tree depth, while avNNet models were tuned by 
adjusting number of hidden neuronal layers and weight decay value. 
Finally a stack of random forest (ranger), gradient boosting machine (gbm), 
multivariate adaptive regression splines (earth), support vector machine 
(svmRadial), and averaged neural network (avNNet) models were generated, 
compared for accuracy and then combined using generalise linear regression to 
form a meta-model using the caretStack function. 
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2.3 Validation and Replication Using Pyrosequencing 
2.3.1 Sample Selection 
A second age and sex-matched cohort of 72 sCJD and 114 control samples was 
assembled according to the same methods and criteria as described in Section 
2.1.1. Sample demographics are displayed below in Figure 9. 
 
 
Figure 9: Violin plots of age density per sample group involved in replication and test for disease 
specificity. Numbers per group are displayed above each plot 
 
2.3.2 Bisulphite PCR for Pyrosequencing 
Sites for validation and replication were selected based on statistical significance, 
effect size and biological function. Pyrosequencing assays overlapping cg03546163 
(FKBP5), cg00052684 (FKBP5), cg25114611 (FKBP5), cg17714703 (UHRF1), 
cg02481950 (METTL9), cg02448796 (KCNAB2), cg04286737 (PRNP), cg05001044 
(MIR1977), cg11823178 (ANK1), cg14008593 (TTLL10), cg10636246 (AIM2), and 
cg17515347 (AIM2) were automatically designed using PyroMark Assay Design 
version 2.0 (Qiagen), and manually adjusted to fit the following criteria: 
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i) Primers do not overlap CpG sites 
ii) Forward and Reverse primer length does not exceed 25 nucleotides 
iii) Sequencing primer’s annealing temperature is 40oC 
Primers were then checked for specificity using BiSearch (Arányi et al., 2006). 
Forward, reverse and sequencing primers were ordered through EuroFins.  
Samples were bisulphite converted using an EZ-96 DNA Methylation-Gold kit 
(Zymo) according to manufacturer’s instructions. Assay PCR reactions were 
optimised using bisulphite converted DNA and a thermocycler configuration with a 
variable extension step temperature (Table 2, Table 3). Temperatures which 
produced the greatest amount of specific product were used in subsequent 




Bisulphite PCR  
Mastermix Per 2 µl DNA 
10x Buffer B1 2 µl 
10 mM dNTPs 0.2 µl 
25 mM MgCL2 1.32 µl 
H2O 13.28 µl 
10 µM Primers  1 µl 
HOT FIRE pol 0.2 µl 








Stage Temperature Duration Number of 
cycles 
Stage I 95oC 15 min X 1 
    
Stage II 95oC 45 s  
 52-62oC 45 s X 35  
 72oC 3 min  
    
Stage III 72 oC 10 min X 1 
    
Total  3h 3 min  
Table 3: Thermocycler settings for bisulphite PCR featuring a 52-62oC variable extension step in 
increments of 2 oC across 6 sets of 2 columns of a 96 well plate.  
 
Optimum PCR elongation conditions of 56oC were determined for cg03546163, 
cg00052684, cg25114611, cg17714703, cg17515347, cg11823178, 58 oC for 
cg02481950, cg02448796, cg04286737 and 62oC determined for cg10636246, 


















A PyroMark Q24 was used for result validation and a PyroMark Q96 was used for 
replication (Qiagen). 20 µl of each PCR reaction product was added to 60 µl 
sepharose bead solution (2 µl sepharose beads, 40 µl pyrosequencing binding 
buffer, 18 µl H2O) in a 96 well plate. The plate was sealed and vortexed at 1500 rpm 
using an IKA MS 3 vortexer with a 96-well plate adaptor (IKA, UK) for at least 5 
minutes and no more than 10 minutes. 25 µl 0.3 µM sequencing primer was added 
to each well of a PyroMark Q24 or Q96 plate and placed on the vacuum 
workstation.  Bead-immobilised DNA was then passaged through a vacuum 
workstation (Qiagen) before mixing with sequencing primer in the PyroMark plate for 
10 seconds.  The plate was heated at 80oC for 2 minutes, allowed to cool for 5 
minutes and then inserted into the pyrosequencer. A PyroMark cartridge was loaded 
with PyroMark reagents (Qiagen) according to volumes computed by PyroMark 
assay design and inserted into the pyrosequencer. Nucleotide dispensation order 
was generated by inputting the target sequence before and after bisulphite 
conversion. Where possible a non-CpG cytosine was selected as a bisulphite 
conversion control. 93 samples were assayed per pyrosequencing run as well as 
methylated and unmethylated standards and a zero-template control.  
2.4 Testing Disease Specificity of Replicated Differentially Methylated 
Sites Using Pyrosequencing 
A third cohort of 59 Alzheimer’s Disease (AD), 18 Iatrogenic CJD (iCJD) and 11 
Inherited Prion Disease (IPD) patients was assembled from the National Prion Clinic 
and Dementia Research Centre’s register of samples according to the same criteria 
as described in Section 2.1.1. AD patient samples were collected with consent by 
the Dementia Research Centre in compliance with the local research ethics 
committee of the National Hospital for Neurology and Neurosurgery (University 
College London Hospitals NHS Foundation Trust). 
Due to differences in age of onset, disease duration and prevalence per sex in iCJD 
and IPD, in this instance age and sex matching was less exact between disease 
and control groups. Sample demographics are displayed above in Figure 9. 
Samples were assayed for methylation at cg03546163 (FKBP5), cg17515347 




2.5 Testing Tissue Specificity of Replicated Differentially Methylated 
Sites Using Pyrosequencing 
A fourth cohort of frontal-cortex derived DNA samples from 33 non-prion and 58 
sCJD patients was assembled from the National Prion Clinic’s register of samples 
as described in Section 2.2.1. Non-sCJD patient frontal cortex tissue was obtained 
from Cambridge Brain Bank (Cambridge, UK), while sCJD patient frontal cortex 
tissue was obtained from the Neuropathology Division of the National Hospital for 
Neurology and Neurosurgery (University College London Hospitals NHS Foundation 
Trust). Samples were assayed for methylation at cg03546163 (FKBP5), 
cg17515347 (AIM2), cg10636246 (AIM2), cg04286737 (PRNP), cg17714703 
(UHRF1), cg02481950 (METTL9), and cg11823178 (ANK1). 
2.6 Testing Leukocyte Specificity of Replicated Differentially 
Methylated Sites Using Magnet Assisted Cell Sorting and 
Pyrosequencing 
2.6.1 Sample Selection 
Fresh whole blood was collected prospectively from 7 sCJD patients and 13 healthy 
relatives/spouses of patients during home visits to patients by National Prion Clinic 
staff (T. H. Mok, A. Nihat, H. Odd, P. Rudge,), with research and ethical consent 
being obtained as described in Section 2.1.1. Sample demographics are shown in 




Figure 10: Violin plots of age density per sample group from the Magnet-Assisted Cell Sorting 
experiment cohort. Numbers per group are displayed above each plot. 
 
2.6.2 Magnet Assisted Cell Sorting 
MACS was used to enrich cell fractions for T-Cells, B-Cells, Neutrophils and 
Monocytes using antibodies raised against CD4+, CD15+, CD19+ and CD14+ 
respectively. The MACS (Miltenyi) protocol was optimized using blood samples 
donated from non-MRC staff and students at UCL’s Institute of Neurology, with 
consent provided according to the criteria of the research ethics committee of the 
National Hospital for Neurology and Neurosurgery (University College London 
Hospitals NHS Foundation Trust). This allowed comparison of the effects of filtering 
blood prior to MACS and washing micro-bead conjugated cell pellet prior to column 
loading on final DNA yield.  
Sorting took place in a Class II MSC hood, with all used/unneeded materials being 
discarded into a container of 2 M NaOH and left to sterilise overnight. According to 
the manufacturer’s protocol, Whole Blood Column Elution Buffer was warmed to 
ambient temperature before starting MACS. Depending on blood sample volume, 1 
to 1.5 ml aliquots of blood were passed through 30 µm filters into 15 ml falcon 
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tubes. 75 µL antibody-conjugated Microbeads per 1.5ml whole blood was added to 
the tube, mixed gently and incubated for 15 min on ice. The sealed tubes containing 
cell mixtures were then removed from the MSC hood and centrifuged at 445 g for 10 
minutes at room temperature. Tubes were returned to the MSC hood and after 
aspiration of the supernatant the cell pellet was resuspended in 1 ml ice-cold 
separation buffer (PBS, 0.5% BSA, 2mM EDTA, pH 7.2). Labelled cell mixtures 
were loaded onto Whole Blood Columns set in a QuadroMACS magnetic separator 
and flowthrough was collected in a 15 ml falcon tube. Each column was washed 
three times with 3 ml separation buffer before the column was removed from the 
QuadroMACS separator and eluted with 5 ml Whole Blood Column Elution Buffer. 
Sealed tubes containing eluted cells were removed from the MSC hood and 
centrifuged at 445 g for 10 minutes at room temperature. Tubes were returned to 
the MSC hood and 4.7 ml supernatant was aspirated. The pellet was resuspended 
in the residual supernatant and 100 µl of cell suspension was added to 300 µl TriZol 
reagent (Zymo) and stored at -20oC for downstream RNA analysis. DNA was 
immediately extracted from the remaining 200 µl of suspension using a Quick gDNA 
MiniPrep Kit (Zymo) with a 10 min proteinase K incubation step as described in 
Section 2.1.2. 
2.7 Statistics and Graphics 
Pyrosequencing data were analysed in SPSS version 25 (Corp., 2017), which was 
also used to correlate corrected beta values with patient metadata. All other 
analyses were performed in R (Team, 2016). Genome-wide inflation values (λ) were 
calculated by dividing the median chi-squared statistic of probe p values by the 
expected median (Devlin and Roeder, 1999; Hinrichs et al., 2012). Plots were 
generated using ggplot2 version 3.0.0 (Wickham, 2016), or qqman version 0.1.4 
(Turner, 2018) and edited in Inkscape version 0.91 (Harrington, 2005). Where 
shown, box plots adhere to Tukey representation (Mcgill, Tukey and Larsen, 1978), 
where upper and lower hinges of the box correspond to the interquartile range, the 
median line divides the box and two whiskers protrude to the largest value up to 1.5 
times the interquartile range. Outlying points are plotted individually. Where there 
are significant differences between experimental groups, a black bar with asterisks 






3 Using Illumina’s 450K Infinium Beadchip to investigate 
genome-wide DNA methylation in whole blood from sporadic 
prion disease patients 
The principle aim of this project was to investigate differences in DNA methylation in 
blood both between sCJD patients and control volunteers, as well as within the 
sCJD patient group, to uncover molecular markers of the disease. In order to 
accomplish this, a new blood-derived DNA extraction protocol and bisulphite 
conversion protocol had to be established, as routinely used blood-derived DNA 
extraction protocols were high yield but low throughput. Moreover, an analysis 
pipeline for 450K Beadchip data would have to be selected and different settings 
tested to remove unreliable data and improve quality control metrics such as 
technical or batch variability and genome-wide significance inflation. Finally, I aimed 
to perform exploratory analysis and linear modelling of the data to examine the 
genomic distribution and potential biological consequences of differential 
methylation, as well as test for associations with disease traits.  
3.1 Relevant Methods and Sample Demographics 
2.1.1 Sample Selection (page 54)  
2.1.2 Extraction of genomic DNA from blood (page 56)  
2.1.3 DNA Quality Control (page 58)  
2.1.4 Bisulphite Conversion (page 58)  
2.1.5 Infinium Beadchip Hybridisation (page 59)  
2.2 Data Analysis of Illumina Infinium 450K Beadchip Study (page 59)  
2.2.1 Case-Control Study Using RnBeads (page 59)  
2.2.2 Case-Control Study Using ChAMP (page 61)  
2.2.3 Inference of Signal Origin Using eFORGE (page 63)  
2.2.4 Study of Differentially Variable Methylation Sites Using iEVORA (page 63)  
2.2.5 Study of Genomic and CpG Feature Distribution Using GOLDMINE (page 63)  
2.2.6 Study of Common Motifs Amongst Differentially Methylated Regions and 
Positions (page 64)  
2.2.7 Enrichment Analysis of Differentially Methylated Transcription Factor binding 
sites and Differentially Methylated Genes (page 64)  




Group Number Average Age (range) Sex (% F) 






sCJD 114 68.0 (49-85) 50.9 46:23:32 6 (0-20) 
Control 106 69.0 (41-83) 55.7 Unknown 20 
 
Table 5: Demographics of patients and controls whose samples were used in the initial discovery 
cohort. 
 
3.2 Sample Preparation 
3.2.1 DNA Extraction from Whole Blood 
As this project would involve multiple extractions of DNA from EDTA-stored blood, I 
initially compared several extraction protocols as detailed in Section 2.1.2. While the 
Prion Unit Neurogenetics Division has an established protocol (illustra Nucleon 
BACC3 Genomic DNA Extraction Kit) which far exceeded any other method in 
terms of DNA yield as well as yield as a function of input volume, batches of 
samples were limited to six at a time. The PAXgene protocol had similar batch 
constraints and performed the worst out of all methods. Batches for all other 
protocols were limited by the capacity of a benchtop microfuge, allowing 24 samples 
to be processed per batch. DNA yield was low in general, which was the second 
most important limiting factor during optimisation as bisulphite conversion kits 
recommend 500 ng input DNA for optimal conversion and fragment recovery. 
During optimisation 3 EDTA-stored blood samples were processed using each 
method and the average yields are presented in Table 6.  
 










DNA per starting 
volume (ngµl-1) 
ZymoBeads No 50 35 0.3 10.5 0.21 
ZymoBeads No 200 35 0.6 21 0.105 
gDNA 10 min 200 50 11.6 580 2.9 
gDNA Overnight 200 50 1 50 0.25 
gDNA with pellet 
wash step 10 min 200 50 3.4 170 0.85 
PAXgene No 1700 200 0.05 10 0.05 
Prion Unit Protocol No 4000 500 413 206500 51.265 
 
Table 6: Performance of ZymoBeads and gDNA kits (Zymo), PAXgene (Qiagen) and the Prion Unit’s in 




As a function of input sample volume, protocol duration and complexity, throughput, 
and output quantity the Zymo Quick gDNA MiniPrep Kit with a 10-minute proteinase 
K digestion step was best suited for extraction of >500 ng DNA from small volumes 
of blood and was used for all subsequent extractions of genomic DNA from blood. 
3.2.2 Bisulphite Conversion 
As the quality and consistency of bisulphite conversion is essential in studies of 
DNA methylation I compared two conversion kits (Zymo and Qiagen), the main 
difference between which was bisulphite reaction incubation length (150 and 300 
minutes respectively). For each method, 5 patient DNA samples, a methylated 
control and unmethylated control (Zymo) and a commercially-sourced leukocyte 
DNA sample (AMSBIO) were converted and hybridised to two Illumina 450K 
beadchip arrays. 
Preliminary analysis in GenomeStudio showed very poor detection of CpG sites 
(based on signal intensity) in samples converted using the Qiagen kit (Figure 11), 
while Zymo bisulphite conversion kits produced DNA which was successfully probed 
at almost half a million CpG sites according to GenomeStudio’s detection algorithm 
(unpublished). I therefore used the Zymo conversion kit for all subsequent 
experiments. 
As bisulphite-converted DNA resembles RNA in terms of high uracil content and 
single stranded conformation, I analysed the integrity of Zymo bisulphite-converted 
DNA using a high-sensitivity Agilent RNA ScreenTape. Bisulphite converted DNA 
was found to be present in fragments between 25-2000 nucleotides long, as shown 
in Figure 12. As 450K array probes are approximately 100 nucleotides in length, this 
distribution of fragment length after conversion suggests appreciable probe target 







Figure 11: Detection rate of CpGs in bisulphite-converted DNA derived from Qiagen and Zymo 
protocols. Although the exact method is unpublished, detection p is likely calculated from iDAT file 
signal intensity per probe by GenomeStudio software compared to a reference null signal. X-axis 




Figure 12: High-Sensitivity RNA Screentape of bisulphite conversion products of genomic DNA. 
Samples were derived from patients (B1-F1), unmethylated and methylated control DNA (G1 & H1), a 
































3.3 Analysing 450K data using RnBeads  
3.3.1 Pre-processing and Quality Control 
RnBeads is a one-step, powerful analytical pipeline for the analysis of 450K data 
capable of automatically generating thousands of tables, high-resolution plots and 
web browser-based reports. I initially chose RnBeads for analysis because of its 
relatively simple start-to-finish design: options were defined as described in Section 
2.2.1 and the entire analysis was run as one customised function on a remote 
server using 20 cores. Input files were .iDAT files from the 450K array and a .csv file 
containing Sample_ID, Sentrix_ID, Sentix_Position, Sample_Pool, Sample_Well, 
Sample_Group, Gender, Age, Smoking history, MRC Scale Score and Codon129 
genotype. Analysis took 1 d 9 h 23 min 35 s and generated 9.00 Gb data. Due to 
the inflexibility and long runtime of the pipeline, use of RnBeads was eventually 
discontinued and replaced with ChAMP, a more modular analytical pipeline 
described in Section 3.4 Analysing 450K data using ChAMP 
RnBeads initially excluded 29928 array probes which are cross-reactive with 
multiple genomic loci (Y. A. Chen et al., 2013) and 10119 probes which overlap 
commonly occurring SNPs (Zhou, Laird and Shen, 2016). The inbuilt Greedycut 
algorithm iteratively removed unreliable probes and samples based on a probe 
detection p value threshold of 0.05: in other words, probe-wide and sample-wide 
detection significances were optimised. 4954 probes were discarded during this 
process over the course of 5000 iterations. Rnbeads automatically maps the array-
wide density of beta values (a metric between 0 (unmethylated) and 1 (methylated) 
per probe) after this process, as displayed in Figure 13i. 
Beta values were normalised using the SWAN method (Maksimovic, Gordon and 
Oshlack, 2012), the results of which are visualised in Figure 14. 65 technical probes 
and 1270 non-CpG probes were removed, as were 10160 probes on sex 
chromosomes. Array-wide beta density is once again automatically mapped after 
this process and is displayed in Figure 13ii. 
Principle Component Analysis identified 217 components, the first two of which 
explain 13.79% and 11.70% of variance respectively: these are compared in Figure 
15. Association of principle components with metadata was then performed using 
parametric (Pearson) tests where metadata is numeric and non-parametric 
(Wilcoxon or Kruskal-Wallis) tests where data is categorical and has two values, or 
more, respectively. This analysis showed significant associations of Sentrix ID 
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(beadchip number), Sample Group, Codon 129 Genotype and MRC Scale Score 
with Principle components 1 and 2, as shown in Figure 16. 
  
 
Figure 13: Density plots of beta values after RnBeads pre-processing. i) Density of beta values at 
probes removed and retained after excluding cross-reactive probes, probes that overlie commonly 
occurring SNPs, and probes identified as unreliable by Greedycut. ii) Density of beta values at probes 





Figure 14: Histograms of beta shifts as a result of SWAN normalisation. i) Array-wide shifts in beta, 





Figure 15: Principle component analysis of normalised RnBeads data. i) 2-dimensional scatterplot of 
sample distribution across principle components 1 & 2, and ii) cumulative explanatory variance of 





Figure 16: Chessboard plot of associations between the top 8 principle components and technical, 
biological and predicted metadata. Purple cells represent statistically insignificant associations, while 
the number in each magenta cell is the p value of a significant association. 
 
Finally, normalised data was corrected for differences in cellular heterogeneity 
between samples. It is important to note that blood is a heterogeneous tissue and 
imbalances in cell proportions between individuals and sample groups are thought 
to be major sources of bias in studies of methylation data, for which correction is 
“critical” (Jaffe and Irizarry, 2014). While reference-based methods for correcting for 
differences in cell populations exist, RnBeads only permitted reference-free 
methods to be used alongside analyses featuring covariates such as age and sex. 
Therefore RefFreeEwas was used. 
3.3.2 Analysis results 
After processing and DMP calling with RefFreeEwas correction for cellular 
heterogeneity, RnBeads computed 3,842 differentially methylated positions which 
pass a genome-wide significance of p < 0.05 after Bonferroni correction for multiple 
testing. This is more than might be expected given the relatively modest sample 
size, particularly when compared to similar published studies. The genome-wide 
inflation factor value (λ) was calculated and found to be 3.37, indicative of 
appreciable p value inflation which can often be attributed to bias or the influence of 
unaccounted factors in a comparison. This inflation is also visually evident in the 
Manhattan plot of genome-wide significance shown in Figure 17. Without 




Figure 17: Manhattan plot of DMPs as computed by RnBeads. 
 
Figure 18: Quantile-quantile plot of DMP significance before (upper trace) and after (lower trace) 
correction for cellular heterogeneity using RefFreeEWAS. 
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To better interpret the biological relevance of these results, I used a package called 
Goldmine which allows association of genomic location with genetic and epigenetic 
features in user-supplied ChIP-Seq data. I integrated publicly available Roadmap 
Consortium data (Roadmap Epigenomics Consortium et al., 2015) from Monocytes, 
CD4+ T Cells, CD8+ T Cells, B Cells, Natural Killer Cells and Granulocytes into 
Goldmine and found that 47.6% of DMPs were associated with CpG features 
(Island, Shore, Shelf)  while 52.6% were situated in identified Transcription Factor 
Binding Sites and 61.2% at DNaseI hypersensitive sites. 27.6% of DMPs were 
positioned at enhancers.  The majority of DMPs overlapped genomic features such 
as the promoter (34.1%), exons (3.5%), introns (33.7%) or the 3’ region (12.2%), 
while the remaining 16.6% of sites were intergenic. Feature and Genomic 
distributions are displayed in Figure 19. 
 
 
Figure 19: Feature and Genomic contexts of DMPs, computed using RnBeads results and ChIP-Seq 
data from the Roadmap Epigenomics Consortium. CpG Islands are regions of >200bp containing 
>50% GC composition and an observed to expected CpG ratio of >60%. Shores are regions 2kb from 
a CpG Island and Shelves are regions 2kb from a CpG Shore. 
 
Ultimately the inflexibility of RnBeads and the long run times proved an obstacle to 
performing subanalyses, as if the pipeline encountered an error the entire process 
had to be reinitiated. Due to its one-step design, data could not be removed at 
different steps of analysis and compared or modified using other packages. In 
addition, the high level of genome-wide inflation (λ = 3.37) was a concern. As a 






3.4 Analysing 450K data using ChAMP  
3.4.1 Pre-processing and Quality Control 
As an alternative to RnBeads, I also analysed array data using ChAMP, a highly 
modular and comparatively lightweight analytical pipeline. Like RnBeads, ChAMP’s 
champ.load() function imports .iDAT files and a .csv file containing sample metadata 
as described earlier, and  excludes unreliable probes and samples before analysis. 
First probes with a detection p < 0.01 (based on iDAT file data) are discarded. 
Similarly samples where 10% or more probes have a detection p < 0.01 are 
discarded. Then poorly hybridising probes are removed (i.e. probes with less than 
three bead hybridisations in at least 5% of samples). Probes overlapping SNPs with 
a mean allele frequency over 5% (as described by Zhou et al. 2016) are also 
removed from the dataset (Zhou, Laird and Shen, 2016). Next, probes which are 
crossreactive with multiple genomic loci as reported by Nordlund et al. are 
discarded (Nordlund et al., 2013). Finally probes on the X and Y chromosomes are 
discarded. The nature of these steps and numbers of probes discarded during 





Figure 20: Exclusion of 82158 probes and one control sample as a result of the champ.load() function. 
 
Once problematic probes and poorly-hybridised samples have been excluded red 
and green channel intensity are used to compute beta values per probe per sample. 
The champ.QC() function then generates several images for data visualisation 




Figure 21: champ.QC()-generated plot of beta density across the loaded dataset. The majority of data 
trend towards a β of 0 (unmethylated) or 1 (methylated). 
 
Once data were loaded type I and II probe imbalance was corrected through Beta-
MIx Quantile dilation (BMIQ) normalisation (Teschendorff et al., 2013). Compared to 
RnBeads’ SWAN BMIQ performs similarly and is ChAMP’s default normalisation 
method (Liu and Siegmund, 2016). Once normalised, I used Singular Value 
Decomposition (SVD) to associate biological and technical metadata with principle 
components. This serves two purposes: to identify which biological data are 
associated with variability in the dataset, and to identify any confounding biological 
or technical factors which should be corrected.  
Despite the randomisation of samples within a 96 well plate as described in Section 
2.1.5, the 12-slide format of the 450K beadchip array resulted in sCJD and control 
samples being inequally distributed between different slides on the array, and 
across different arrays. In addition, recently published work by Jiao et al. identifies 
strong positional effects on 450K array data, which further explain positional batch 
effects in our data as revealed by SVD using ChAMP and PCA in the RnBeads 
analysis (Jiao et al., 2018). Principle components 1 and 2 were found to associate 
significantly with both slide coordinate and array barcode. I used an established 
statistical tool, ComBAT, to regress for positional effects. Reassuringly, remaining 
metadata associations with principle component 1 were (in decreasing order of 
significance) phenotype (Sample_Group), Codon129 Genotype, MRC Scale Score 
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and Gender, as shown in Figure 22. This shows that disease status and severity do 
indeed affect the methylome and suggests that sex as a covariate should be 
included in a final regression model. 
 
 
Figure 22: Chessboard plots of Singular Value Decomposition Analysis. These show association of 
principle components with sample metadata before and after ComBAT correction for positional batch 
effects at “Slide” and “Array” variables 
 
As mentioned earlier, blood is a heterogeneous tissue and imbalances in cell 
proportions between individuals and sample groups are thought to be major sources 
of bias in studies of methylation data (Jaffe and Irizarry, 2014). I used two 
algorithms, the established Houseman algorithm and Teschendorff’s more recent 
EpiDISH algorithm, to estimate cell proportions in batch-corrected data, after which 
differences in cell proportions were normalised through regression (Teschendorff et 
al., 2017). These algorithms make use of 450K data acquired from DNA derived 
from blood cell populations as separated using FACS. This reference-based 
approach differs from RnBeads’ RefFreeEWAS, which was also developed by 
Houseman who suggests that reference-based correction is more robust where a 
reference dataset exists, while RefFreeEWAS is suitable for DNA derived from 
tissue without a reference (Houseman, Molitor and Marsit, 2014; Houseman et al., 
2016). Both Houseman’s RefBase and Teschendorff’s EpiDISH algorithms 
estimated differences in cell proportions between case and control as well as 
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producing different estimations of cell fractions between each method when applied 
to case and control groups, as shown in Figure 23.  
  
Figure 23: Average estimated cell proportions in the sCJD and Control groups based on epiDISH and 
Houseman algorithms. 
 
Once data had been preprocessed, normalised and corrected for batch effects and 
cellular heterogeneity, I used limma to assess the effects of the pipeline by 
constructing linear regression models of case-control differences in beta after each 
processing step. Quantile-quantile analysis of p value inflation showed high levels of 
inflation after BMIQ normalisation (λ=4.07), which decreased after batch correction 
(λ=2.92) and reached minimum after “Refbase”: reference-based correction for cell 
heterogeneity using the Houseman algorithm (λ=1.40).  These plots are compared 
in Figure 24. EpiDish correction resulted in a comparatively inflated λ of 1.75, and 
so neither it nor RnBeads data (λ=3.37) were taken forward for use in downstream 
analysis. In making this decision, I made an assumption that the dataset exhibiting 
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Figure 24: Quantile-quantile plots of limma linear model results. Traces correspond to results using 
data after BMIQ normalisation, then ComBAT batch correction and finally Houseman reference-based 
(RefBase) correction for cell heterogeneity. 
 
3.4.2 Results: Differentially Methylated Positions in sporadic CJD 
I investigated specific sites which exhibited differential methylation by constructing a 
linear regression model of β ~ Sample_Group + Age + Sex using limma, an 
established software package for analysis of microarray data (Ritchie et al., 2015). 
This identified 38 DMPs (Table 7, Figure 25) which passed Bonferroni corrected 
significance threshold. Goldmine analysis using Roadmap Consortium data 
revealed that the majority of DMPs are within the promoter region of a gene and 
also overlap transcription factor binding sites or enhancers, as well as sites 
hypersensitive to DNAse1 (Figure 26). Two DMPs were situated upstream of the 
TSS of the same gene (AIM2), and sites in AIM2, UHRF1 and CANT1 were also 
found to be overlapped by binding sites for multiple transcription factors. The 




Figure 25: Manhattan plot of differential methylation between sCJD and control calculated using 
ChAMP. Genome-wide statistically significant DMPs lie over the red line (Bonferroni significance 





(%) p Gene Region Position Feature 
cg10636246 -4.05 2.38E-10 AIM2 TSS1500 1:159046973 Open Sea 
cg02481950 1.98 3.03E-10 METTL9; IGSF6 
Body; 
TSS1500 16:21665002 Open Sea 
cg14427590 2.27 3.33E-10 Intergenic 17:60695089 Open Sea 
cg05740793 4.39 9.57E-10 MTRNR2L8 TSS1500 11:10531091 Open Sea 
cg13965201 2.91 4.80E-09 Intergenic 1:150210352 S.Shelf 
cg21540367 0.99 5.76E-09 LRCH4 Body 7:100175462 S.Shelf 
cg05001044 5.33 5.86E-09 MIR1977 TSS1500 1:567312 Open Sea 
cg09048334 3.48 6.76E-09 Intergenic 6:37012640 Island 
cg22519265 1.08 9.77E-09 ATP2A3 3'UTR 17:3828052 Island 
cg02448796 3.28 1.27E-08 KCNAB2 Body 1:6101339 Open Sea 
cg17641710 2.39 1.44E-08 GNAI2 Body 3:50279038 S.Shelf 
cg03819286 2.68 1.54E-08 MGRN1 TSS1500 16:4673974 N.Shore 
cg10855342 0.64 1.57E-08 ALPK1 5'UTR 4:113276902 Open Sea 
cg15197458 1.4 1.96E-08 Intergenic 19:3464765 Island 
cg00832928 2.88 2.08E-08 SELT Body 3:150329458 Island 
cg22688566 2.83 2.29E-08 MYO18A Body 17:27459835 Open Sea 
cg25966751 2.25 2.52E-08 Intergenic 14:74098320 N.Shelf 
cg20056593 1.65 4.27E-08 Intergenic 12:132993150 S.Shelf 
cg27229664 2.21 4.39E-08 KIAA0513 5'UTR 16:85096666 Open Sea 
cg22505006 2.9 5.29E-08 ZBTB7B 5'UTR 1:154981829 Open Sea 
cg05343106 2.03 5.69E-08 DNAJB13 TSS200 11:73661229 Open Sea 
cg17714703 3.31 5.73E-08 UHRF1 Body 19:4912221 S.Shore 
cg07081759 2.5 5.81E-08 FAM53B Body 10:126330905 Open Sea 
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cg13444131 0.92 5.88E-08 DYRK1B 5'UTR 19:40322546 N.Shore 
cg22434506 0.96 6.94E-08 IFFO1 Body 12:6657818 Island 
cg17515347 -4.74 6.97E-08 AIM2 TSS1500 1:159047163 Open Sea 
cg20003976 1.44 6.99E-08 ACADM TSS1500 1:76188832 N.Shore 
cg09007354 2.38 8.11E-08 GLIS1 5'UTR 1:54100163 Open Sea 
cg20285559 1.01 8.30E-08 THAP3 Body 1:6688542 S.Shelf 
cg19769147 1.95 8.61E-08 PACS2 Body 14:105860954 N.Shelf 
cg24843003 2.94 8.72E-08 DAZAP1 Body 19:1409547 S.Shore 
cg03393322 0.85 9.38E-08 SDK1 Body 7:4260883 Open Sea 
cg04757081 1.4 9.47E-08 Intergenic 10:65424432 Open Sea 
cg01084918 2.04 9.53E-08 FAM40A TSS1500 1:110576366 N.Shore 
cg01101459 2.89 1.00E-07 Intergenic 1:234871477 Open Sea 
cg03546163 -5.35 1.07E-07 FKBP5 5'UTR 6:35654363 N.Shore 
cg21393135 0.33 1.11E-07 VARS Body 6:31747255 Open Sea 
cg21155515 -0.75 1.24E-07 CANT1; CANT1 
1stExon; 
5'UTR 17:77005819 Island 
 
Table 7: DMPs between sCJD and control. p values were adjusted using the Bonferroni method with a 
threshold of p < 1.24x10-7. TSS200 and TSS1500 represent regions 200 nt and 1500 nt upstream of a 
gene’s Transcription Start Site, respectively. Body and 1stExon relate to sites in the gene body or the 
first exon of the gene. 5’UTR and 3’UTR are the 5’ and 3’ untranslated regions of the mRNA transcript. 
Intergenic regions are regions that do not fall into the previous categories. CpG Islands are regions 
greater than 200 bp in width which contain greater than 50% GC composition and an 
observed:expected CpG ratio exceeding 60%. Shores are regions 2kb from a CpG Island, shelves are 
regions 2kb from a CpG Shore, and Open Sea regions are >2kb from a CpG Shore (Bird, 1986). 
 
 
Figure 26: Feature and Genomic contexts of DMPs computed using ChAMP results and ChIP-Seq 
data from the Roadmap Epigenomics Consortium. CpG Islands are regions of >200bp containing 
>50% GC composition and an observed to expected CpG ratio of >60%. Shores are regions 2kb from 





Figure 27: Number of overlapping Transcription Factor Binding Sites (TFBS) per DMP probe. 
 
Having identified DMPs, I then associated beta values at these sites within the 
sCJD dataset with patient metadata from the Cohort Study, namely MRC Scale 
Score and MRC Scale Slope, and age of onset using bivariate Pearson’s 
correlation. Codon 129 genotype was associated with beta values using a one-way 
ANOVA with a Dunnett’s two-tailed post hoc test. 
3.4.3 Association between MRC Scale Score and Slope with Methylation in 
sCJD patients 
Association of DNA methylation with measures of disease severity and velocity 
could show promise as peripheral disease biomarkers and might potentially be 
useful in patient management and monitoring of any therapeutic interventions in 
clinical trials. Described briefly in Section 2.1.1, the MRC Scale was developed 
using a Rasch model to measure disease severity based on questionnaire data 
relating to cognitive, general, neurological and psychiatric function (Thompson et al., 
2013). By assessing patient status in relation to expected disease milestones (as 
displayed below in Figure 28), patients can be assigned a score between 20 (able to 
function independently) and 0 (moribund). The clinical milestones in a generalised 

























Figure 28: Disease milestones and functional criteria used to assign an MRC Scale score, from a 
maximum of 20 (highly functioning) to a minimum of 0 (zero independent function). Figure adapted 
from Thompson et al., 2013. 
  
Moreover, by measuring the slope of decline in MRC Scale score, the rapidity of 
disease progression can be compared between patients. I therefore compared the 
MRC Scale scores and slopes of sCJD patients with methylation values at the 38 
identified DMPs. 
As shown in Figure 29 and Table 8, I found that demethylation at two probes within 
the AIM2 promoter (cg01636246 & cg17515347) were found to correlate 
significantly with decreased MRC Scale Score, however no significant associations 






Figure 29: Coefficients of decreased MRC Scale Score with hypomethylation at AIM2. Shown are two 
probes (cg17515347 and cg10636246) with Pearson coefficients of 0.242 (p = 0.031) and 0.423 (p = 
9.40x10-6) respectively. An MRC Scale score of 20 represents a patient who may have symptoms but 
is functionally independent for activities of daily life. An MRC Scale score below 3 indicates a 
comatose state near to death with a patient only able to take perhaps sips of fluid for nutrition and 
make incomprehensible sounds. Asterisks denote Bonferroni-adjusted significance, where an adjusted 

















Site Gene Scale Score 
coefficient 
Scale p Scale Slope 
coefficient 
Slope p 
cg10636246 AIM2 0.423 9.40E-06 -7.693 0.209 
cg02481950 METTL9;IGSF6 0.009 0.939 3.209 0.318 
cg14427590 Intergenic -0.095 0.404 1.201 0.804 
cg05740793 MTRNR2L8 0.142 0.21 0.524 0.927 
cg13965201 Intergenic 0.029 0.798 11.382 0.481 
cg21540367 LRCH4 0.4 0.725 4.521 0.308 
cg05001044 MIR1977 0.179 0.112 4.999 0.570 
cg09048334 Intergenic 0.067 0.555 18.431 0.285 
cg22519265 ATP2A3 -0.023 0.843 2.794 0.547 
cg02448796 KCNAB2 -0.2 0.075 -2.938 0.638 
cg17641710 GNAI2 -0.184 0.102 -9.012 0.075 
cg03819286 MGRN1 0.049 0.663 -3.230 0.576 
cg10855342 ALPK1 -0.007 0.951 1.230 0.558 
cg15197458 Intergenic 0.127 0.263 2.960 0.628 
cg00832928 SELT -0.084 0.456 16.096 0.403 
cg22688566 MYO18A 0.071 0.532 -7.928 0.153 
cg25966751 Intergenic 0.049 0.663 12.298 0.397 
cg20056593 Intergenic -0.007 0.951 1.959 0.680 
cg27229664 KIAA0513 0.127 0.263 -10.778 0.008 
cg22505006 ZBTB7B -0.084 0.456 -8.057 0.195 
cg05343106 DNAJB13 0.071 0.532 5.563 0.573 
cg17714703 UHRF1 -0.046 0.688 -13.876 0.063 
cg07081759 FAM53B -0.107 0.343 0.652 0.905 
cg13444131 DYRK1B -0.003 0.979 2.402 0.532 
cg22434506 IFFO1 -0.225 0.045 2.676 0.280 
cg17515347 AIM2 0.242 0.031 -1.889 0.852 
cg20003976 ACADM -0.058 0.612 2.774 0.611 
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cg09007354 GLIS1 -0.014 0.899 -11.347 0.022 
cg20285559 THAP3 0.067 0.556 1.434 0.820 
cg19769147 PACS2 -0.124 0.273 3.273 0.547 
cg24843003 DAZAP1 -0.161 0.154 -3.762 0.468 
cg03393322 SDK1 0.218 0.052 0.577 0.727 
cg04757081 Intergenic 0.055 0.627 6.759 0.303 
cg01084918 FAM40A 0.041 0.72 14.902 0.246 
cg01101459 Intergenic -0.274 0.014 6.498 0.313 
cg03546163 FKBP5 0.161 0.155 18.034 0.096 
cg21393135 VARS -0.054 0.633 1.220 0.277 
cg21155515 CANT1;CANT1 -0.057 0.616 -3.158 0.460 
 
Table 8: Coefficients of MRC Scale Score and MRC Scale with beta values at identified DMPs. p 
values are unadjusted, Bonferroni threshold is 0.0013. 
 
3.4.4 Association between PRNP codon 129 homozygosity with Methylation 
in sCJD patients 
Increased methylation at a probe within the promoter of DNAJB13 (cg05343106) 
showed a trend towards association with homozygosity (MM, VV) at PRNP codon 
129 via a one-way ANOVA with Dunnett’s post hoc test, as displayed in Table 9 and 
Table 10. However, this trend was modest and the association would not pass 
correction for multiple testing. This might be due to low numbers of samples in each 
group as a result of splitting the data, but the very low levels of change between 
MM/VV and MV genotypes do not support differential methylation at DNAJB13 








Location Sum of Squares df 
Mean 
Square F Sig. 
cg10636246 AIM2 0.005 2 0.003 1.378 0.258 
cg02481950 METTL9 0.000 2 0.000 0.043 0.958 
cg14427590 Intergenic 0.002 2 0.001 1.626 0.203 
cg05740793 MTRNR2L8 0.001 2 0.001 0.239 0.788 
cg13965201 Intergenic 0.005 2 0.003 2.502 0.088 
cg21540367 LRCH4 0.000 2 0.000 1.783 0.174 
cg05001044 MIR1977 0.002 2 0.001 0.309 0.735 
cg09048334 Intergenic 0.005 2 0.002 1.249 0.292 
cg22519265 ATP2A3 0.001 2 0.000 2.633 0.078 
cg02448796 KCNAB2 0.001 2 0.000 0.167 0.846 
cg17641710 GNAI2 0.000 2 0.000 0.024 0.977 
cg03819286 MGRN1 0.003 2 0.001 1.111 0.334 
cg10855342 ALPK1 0.000 2 0.000 1.909 0.155 
cg15197458 Intergenic 0.001 2 0.000 1.009 0.369 
cg00832928 SELT 0.005 2 0.002 1.848 0.164 
cg22688566 MYO18A 0.002 2 0.001 0.670 0.514 
cg25966751 Intergenic 0.003 2 0.001 1.780 0.175 
cg20056593 Intergenic 0.000 2 0.000 0.030 0.971 
cg27229664 KIAA0513 0.002 2 0.001 1.635 0.201 
cg22505006 ZBTB7B 0.000 2 0.000 0.036 0.965 
cg05343106 DNAJB13 0.007 2 0.003 5.145 0.008 
cg17714703 UHRF1 0.010 2 0.005 2.128 0.125 
cg07081759 FAM53B 0.001 2 0.000 0.262 0.770 
cg13444131 DYRK1B 0.000 2 0.000 1.598 0.208 
cg22434506 IFFO1 0.000 2 0.000 0.840 0.435 
cg17515347 AIM2 0.017 2 0.009 1.967 0.146 
cg20003976 ACADM 0.002 2 0.001 2.498 0.088 
cg09007354 GLIS1 0.000 2 0.000 0.019 0.981 
cg20285559 THAP3 0.000 2 0.000 1.214 0.302 
cg19769147 PACS2 0.001 2 0.000 0.621 0.540 
cg24843003 DAZAP1 0.003 2 0.001 1.053 0.353 
cg03393322 SDK1 0.000 2 0.000 0.601 0.550 
cg04757081 Intergenic 0.001 2 0.000 1.531 0.222 
cg01084918 FAM40A 0.002 2 0.001 1.727 0.184 
cg01101459 Intergenic 0.006 2 0.003 1.800 0.172 
cg03546163 FKBP5 0.009 2 0.004 0.793 0.456 
cg21393135 VARS 0.000 2 0.000 1.845 0.164 
cg21155515 CANT1 0.000 2 0.000 0.079 0.924 
 
Table 9: ANOVA of beta values at identified DMPs between codon 129 genotypes. p values are 




















MM MV -0.0228 0.0071 0.0036 -0.0387 -0.0069 
VV MV -0.0168 0.0076 0.0530 -0.0337 0.0002 
 
Table 10: Dunnett's post-hoc test results for association between codon 129 genotype and increased 
methylation at DNAJB13 (cg05343106). In Dunnett's tests one group is used as a control and the other 
two genotypes compared against it. 
 
3.4.5 Association between age of onset with Methylation in sCJD patients 
Age of onset in the array dataset varies between 49 and 85, with most patients 
surviving between 6-12 months after clinical presentation. Age of onset was 
determined by the National Prion Clinic in the National Prion Monitoring Cohort 
study as the age at which the first symptom started that subsequently developed 
into the disease syndrome. A linear regression of Beta ~ Age + Sex was 
constructed in limma and one site achieved genome-wide statistical significance, as 
shown in Table 11. 
Site Coefficient (β) p value 
Adjusted p 
value Gene 
cg16867657 0.419699 7.13E-08 0.03 ELOVL2 
 
Table 11: A significant association between DNA methylation at a CpG site overlapped by ELOVL2 
and age of onset in sCJD patients. Bonferroni threshold was p < 1.22x10-7. 
ELOVL2 encodes Fatty Acid Elongase 2, and is well documented as becoming 
increasingly hypermethylated with age (Florath et al., 2014; Bacalini, Boattini, et al., 
2015; Marttila et al., 2015). Given the prior associations with hypermethylation at 
this gene with age, it is unlikely that methylation of this site predisposes to an earlier 
age of onset rather than simply reflects the age of the patients. 
3.4.6 Differentially variable methylation in sCJD and Controls 
iEVORA is an algorithm which detects significantly different variability at CpG sites, 
even where the median of the distribution at those sites may not differ between 
sCJD and control (Teschendorff et al., 2016). Initially used to identify field defects – 
stochastic and heterogeneous alterations in DNA methylation amongst cells which 
are prone to become cancerous –  Differentially Variably Methylated Positions 
(DVMCs) have also been observed in type 1 diabetes patients at genetic elements 
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which regulate cell metabolism (Teschendorff et al., 2012; Paul et al., 2016). I 
applied the iEVORA algorithm to the array dataset and identified 252 DVMPs. As a 
striking example, all probes overlapped by MCCC1 showed increased variance in 




Figure 30: Increased variability in MCCC1 methylation in sCJD compared to control. Differences in 




















cg19782061 0.120 0.095 1.781 8.80E-10 1.85E-06 Intergenic 
cg07989851 0.314 0.297 1.350 2.45E-06 8.49E-04 Intergenic 
cg16598420 0.888 0.872 -1.367 1.27E-06 5.18E-04 Intergenic 
cg16740640 0.963 0.959 -1.316 3.03E-06 9.87E-04 Intergenic 
cg25525687 0.015 0.017 -1.504 1.08E-07 7.74E-05 Intergenic 
cg02294420 0.955 0.947 -1.528 6.82E-08 5.56E-05 Intergenic 
cg06171329 0.942 0.935 -1.460 2.42E-07 1.52E-04 Intergenic 
cg13447295 0.897 0.869 -1.749 8.07E-10 1.76E-06 Intergenic 
cg21445918 0.973 0.968 -1.425 4.53E-07 2.40E-04 Intergenic 
cg00961415 0.931 0.937 1.451 4.41E-07 2.37E-04 Intergenic 
cg22681255 0.040 0.050 -1.764 5.90E-10 1.35E-06 Intergenic 
cg15155360 0.933 0.923 -1.341 2.00E-06 7.24E-04 Intergenic 
cg04825429 0.058 0.066 -1.719 1.52E-09 2.90E-06 Intergenic 
cg11946719 0.174 0.144 1.486 2.37E-07 1.50E-04 Intergenic 
cg06037631 0.033 0.029 1.433 5.97E-07 2.90E-04 Intergenic 
cg03760138 0.932 0.922 -2.040 1.18E-12 7.10E-09 Intergenic 
cg11467506 0.076 0.085 -1.580 2.48E-08 2.54E-05 Intergenic 
cg26338473 0.841 0.816 -1.388 8.76E-07 3.91E-04 Intergenic 
cg13910174 0.943 0.951 1.682 6.18E-09 8.98E-06 Intergenic 
cg16651900 0.964 0.968 1.386 1.33E-06 5.39E-04 Intergenic 
cg25448687 0.800 0.831 1.460 3.79E-07 2.15E-04 Intergenic 
cg07136920 0.865 0.852 -1.503 1.09E-07 7.80E-05 Intergenic 
cg05203206 0.964 0.958 -1.390 8.49E-07 3.83E-04 Intergenic 
cg03632120 0.914 0.900 -1.432 4.05E-07 2.24E-04 Intergenic 
cg19698348 0.025 0.028 -1.678 3.53E-09 5.69E-06 Intergenic 
cg23439966 0.073 0.054 1.438 5.52E-07 2.76E-04 Intergenic 
cg23721533 0.967 0.962 -1.338 2.08E-06 7.46E-04 Intergenic 
cg02531516 0.078 0.086 -1.320 2.83E-06 9.36E-04 Intergenic 
cg17117718 0.057 0.078 -1.727 1.29E-09 2.53E-06 Intergenic 
cg17401808 0.924 0.931 1.435 5.83E-07 2.86E-04 Intergenic 
cg24052284 0.972 0.969 -1.671 4.06E-09 6.38E-06 Intergenic 
cg27273227 0.918 0.878 -2.043 1.10E-12 6.78E-09 Intergenic 
cg03094193 0.020 0.025 -1.729 1.23E-09 2.44E-06 Intergenic 
cg04115185 0.969 0.965 -1.762 6.16E-10 1.39E-06 Intergenic 
cg12169233 0.051 0.056 -1.438 3.57E-07 2.05E-04 Intergenic 
cg19632836 0.950 0.944 -2.603 5.66E-19 1.37E-14 Intergenic 
cg23450377 0.918 0.892 -1.466 2.17E-07 1.40E-04 Intergenic 
cg26879339 0.973 0.969 -2.159 6.61E-14 5.46E-10 Intergenic 
cg24529615 0.912 0.905 -1.400 7.13E-07 3.36E-04 Intergenic 
cg23402824 0.937 0.930 -1.798 2.81E-10 7.21E-07 Intergenic 
cg26311454 0.936 0.940 1.661 9.31E-09 1.20E-05 Intergenic 
cg26179679 0.025 0.029 -1.358 1.49E-06 5.88E-04 Intergenic 
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cg17738169 0.056 0.063 -1.747 8.49E-10 1.82E-06 Intergenic 
cg09519326 0.957 0.942 -2.534 3.77E-18 7.08E-14 Intergenic 
cg10130155 0.964 0.957 -1.541 5.28E-08 4.58E-05 Intergenic 
cg27581660 0.907 0.927 1.375 1.61E-06 6.20E-04 Intergenic 
cg24711482 0.940 0.925 -1.535 5.92E-08 5.03E-05 Intergenic 
cg21173402 0.954 0.963 2.067 1.95E-12 1.10E-08 Intergenic 
cg13390004 0.052 0.057 -1.647 6.57E-09 9.34E-06 Intergenic 
cg08893692 0.054 0.057 -1.364 1.35E-06 5.43E-04 Intergenic 
cg15593426 0.960 0.964 1.836 2.85E-10 7.26E-07 Intergenic 
cg08063340 0.060 0.064 -1.321 2.77E-06 9.27E-04 Intergenic 
cg08962087 0.043 0.046 -1.585 2.24E-08 2.36E-05 Intergenic 
cg24684816 0.973 0.971 -1.441 3.42E-07 1.97E-04 Intergenic 
cg21005683 0.902 0.862 -1.432 4.03E-07 2.23E-04 Intergenic 
cg26576978 0.907 0.928 1.503 1.76E-07 1.18E-04 Intergenic 
cg27422407 0.935 0.940 1.897 7.87E-11 2.46E-07 Intergenic 
cg03268463 0.960 0.957 -1.467 2.14E-07 1.39E-04 Intergenic 
cg06224751 0.043 0.046 -2.074 5.22E-13 3.46E-09 Intergenic 
cg22230604 0.051 0.056 -1.321 2.80E-06 9.30E-04 Intergenic 
cg10760240 0.821 0.875 1.604 2.75E-08 2.77E-05 AATF 
cg06952291 0.025 0.028 -1.618 1.18E-08 1.44E-05 ABHD8 
cg03053358 0.917 0.889 -1.493 1.30E-07 9.02E-05 ABR 
cg04334422 0.963 0.960 -1.319 2.89E-06 9.50E-04 ACOX3 
cg07595943 0.977 0.973 -1.625 1.03E-08 1.30E-05 ADAD2 
cg02842496 0.133 0.143 -1.331 2.35E-06 8.22E-04 ADCY8 
cg15691252 0.055 0.038 1.536 9.69E-08 7.23E-05 ADK;AP3M1 
cg19245381 0.079 0.085 -1.648 6.53E-09 9.31E-06 ADORA2B 
cg10791966 0.903 0.895 -1.645 6.94E-09 9.68E-06 ALDH3A1 
cg07249488 0.944 0.938 -1.780 4.19E-10 1.00E-06 ANKLE2 
cg11035303 0.016 0.041 -2.155 7.35E-14 5.92E-10 ANO10 
cg19136183 0.022 0.024 -1.585 2.26E-08 2.37E-05 APAF1;IKBIP 
cg13289321 0.950 0.943 -1.327 2.53E-06 8.66E-04 ASB10 
cg00734483 0.020 0.023 -1.967 6.51E-12 2.97E-08 BACE2 
cg15639842 0.925 0.917 -1.639 7.82E-09 1.06E-05 BAHCC1 
cg26386740 0.016 0.017 -1.318 2.92E-06 9.59E-04 BCL11A 
cg02781618 0.043 0.048 -1.692 2.63E-09 4.54E-06 BEND4 
cg02699635 0.926 0.920 -1.524 7.34E-08 5.83E-05 C11orf94 
cg02922913 0.951 0.942 -1.721 1.45E-09 2.81E-06 C19orf6 
cg06651299 0.953 0.957 1.545 8.24E-08 6.39E-05 C19orf6 
cg24304712 0.029 0.032 -1.547 4.69E-08 4.21E-05 C1orf101 
cg19620452 0.027 0.029 -1.352 1.66E-06 6.32E-04 C1orf74 
cg02192528 0.948 0.942 -1.398 7.35E-07 3.44E-04 C4orf23 
cg12975295 0.035 0.040 -1.716 1.60E-09 3.02E-06 C9orf64 
cg25160190 0.931 0.922 -1.554 4.11E-08 3.82E-05 CACNG4 
cg07605269 0.896 0.877 -1.317 3.00E-06 9.77E-04 CAMTA1 
cg17143900 0.931 0.921 -1.369 1.22E-06 5.04E-04 CAMTA1 
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cg17096979 0.917 0.894 -1.533 6.14E-08 5.11E-05 CAPN9 
cg09444327 0.097 0.088 2.235 4.00E-14 3.47E-10 CCDC48 
cg11616380 0.040 0.043 -1.614 1.28E-08 1.50E-05 CCDC48 
cg17256192 0.952 0.947 -1.461 2.39E-07 1.51E-04 CDH6 
cg09159068 0.037 0.031 1.374 1.64E-06 6.26E-04 CFD 
cg27519392 0.806 0.795 -1.434 3.87E-07 2.18E-04 CHD7 
cg04071104 0.957 0.963 2.246 3.08E-14 2.82E-10 CHDH 
cg10418044 0.046 0.059 -1.521 7.78E-08 6.10E-05 CHRM2 
cg14997413 0.169 0.183 -1.365 1.32E-06 5.38E-04 COBL 
cg10364041 0.084 0.089 -1.487 1.47E-07 1.01E-04 COL12A1 
cg09111258 0.040 0.044 -1.378 1.05E-06 4.51E-04 COPZ2;MIR152 
cg26623575 0.853 0.831 -1.616 1.24E-08 1.48E-05 CST2 
cg26923863 0.237 0.223 -2.261 5.18E-15 5.48E-11 CTBP1 
cg23184518 0.934 0.924 -1.341 1.98E-06 7.19E-04 CTNNA1;LRRTM2 
cg13132577 0.048 0.041 1.531 1.06E-07 7.65E-05 CYP2J2 
cg07430760 0.077 0.063 1.591 3.54E-08 3.35E-05 CYP2J2 
cg20690488 0.074 0.063 1.601 2.92E-08 2.90E-05 CYP2J2 
cg18292664 0.066 0.073 -1.539 5.47E-08 4.72E-05 DBX1 
cg05327967 0.938 0.933 -1.589 2.10E-08 2.25E-05 DLGAP4 
cg17343385 0.927 0.894 -1.506 1.03E-07 7.50E-05 DNAJC5 
cg19256292 0.055 0.060 -1.464 2.24E-07 1.44E-04 DNMT3A 
cg19477942 0.967 0.962 -1.373 1.14E-06 4.82E-04 DSCAM 
cg22355889 0.083 0.124 -2.164 5.90E-14 4.99E-10 ELMOD1;LOC643923 
cg11058154 0.021 0.025 -1.585 2.25E-08 2.36E-05 FAM20A 
cg05761971 0.947 0.940 -1.433 3.98E-07 2.22E-04 FAM82A1 
cg19250315 0.954 0.958 1.395 1.15E-06 4.85E-04 FASN 
cg22753962 0.939 0.924 -1.515 8.75E-08 6.68E-05 FOXK1 
cg15277906 0.104 0.114 -1.454 2.71E-07 1.66E-04 GDF6 
cg12949975 0.045 0.049 -1.614 1.28E-08 1.50E-05 GDF7 
cg25308242 0.933 0.941 1.730 2.42E-09 4.24E-06 GLB1L 
cg02612335 0.967 0.959 -1.683 3.17E-09 5.26E-06 GLT1D1 
cg26234787 0.045 0.048 -1.448 3.02E-07 1.81E-04 GPR39 
cg04657588 0.048 0.053 -1.457 2.53E-07 1.58E-04 GPRC5C 
cg08230483 0.023 0.026 -1.361 1.41E-06 5.60E-04 GRID1 
cg19640303 0.953 0.948 -1.510 9.50E-08 7.13E-05 GRIK3 
cg19160878 0.979 0.976 -1.329 2.45E-06 8.49E-04 GTF3C3 
cg20503652 0.941 0.914 -2.440 4.79E-17 7.72E-13 H1FNT 
cg22101174 0.943 0.936 -1.451 2.83E-07 1.72E-04 HDAC4 
cg17755964 0.025 0.028 -1.516 8.58E-08 6.58E-05 HES5 
cg05428770 0.058 0.063 -1.370 1.20E-06 4.99E-04 HLA-L 
cg17512353 0.035 0.039 -1.795 3.04E-10 7.50E-07 HLA-L 
cg09463047 0.020 0.021 -1.475 1.83E-07 1.22E-04 HNF1B 
cg21337717 0.896 0.884 -1.329 2.45E-06 8.49E-04 HRK 
cg16595484 0.037 0.032 1.664 8.77E-09 1.16E-05 HSPBAP1 
cg23448729 0.173 0.161 1.446 4.84E-07 2.52E-04 HTR1A 
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cg23639308 0.909 0.898 -1.520 7.89E-08 6.18E-05 IGSF9 
cg06176987 0.937 0.951 1.781 8.66E-10 1.83E-06 INPP4B 
cg04570208 0.961 0.955 -1.842 1.08E-10 3.20E-07 INPP5A 
cg21528729 0.946 0.956 1.664 8.86E-09 1.17E-05 INSIG1 
cg14908255 0.025 0.029 -1.620 1.15E-08 1.41E-05 IQSEC3 
cg12984729 0.061 0.069 -1.418 5.21E-07 2.65E-04 ISL2 
cg25395559 0.044 0.046 -1.414 5.59E-07 2.77E-04 ITGB8 
cg23984080 0.921 0.915 -1.321 2.79E-06 9.30E-04 KIAA0495 
cg14922732 0.890 0.879 -1.607 1.47E-08 1.65E-05 KIAA0562 
cg13239126 0.810 0.864 1.434 5.90E-07 2.88E-04 KIAA1026 
cg17001430 0.898 0.891 -1.462 2.33E-07 1.48E-04 KIF25 
cg08287334 0.962 0.957 -1.354 1.59E-06 6.14E-04 KLF16 
cg26832639 0.930 0.942 1.931 3.86E-11 1.36E-07 KLK5 
cg25929399 0.146 0.079 1.608 2.54E-08 2.60E-05 KRT38 
cg24827600 0.370 0.357 -1.846 9.99E-11 3.04E-07 LASS6 
cg14492293 0.034 0.037 -1.663 4.81E-09 7.31E-06 LHX3 
cg00894289 0.033 0.037 -1.545 4.94E-08 4.35E-05 LMO2 
cg23497383 0.070 0.097 -1.801 2.63E-10 6.85E-07 LOC151174;LOC643387 
cg13530938 0.046 0.066 -1.935 1.35E-11 5.42E-08 LOC151174;LOC643387 
cg07323141 0.046 0.058 -1.426 4.47E-07 2.39E-04 LOC151174;LOC643387 
cg11904906 0.058 0.079 -1.669 4.24E-09 6.60E-06 LOC151174;LOC643387 
cg02249713 0.053 0.057 -1.705 2.01E-09 3.64E-06 LOC285780 
cg15911153 0.982 0.980 -1.343 1.92E-06 6.99E-04 LOC389333 
cg14379854 0.103 0.114 -1.419 5.07E-07 2.61E-04 LOC91149;RAPGEF4 
cg27155168 0.975 0.972 -1.609 1.41E-08 1.61E-05 LRP5 
cg15079934 0.853 0.840 -1.527 6.95E-08 5.63E-05 LSP1 
cg26011692 0.937 0.932 -1.477 1.78E-07 1.19E-04 LTBP2 
cg21944491 0.033 0.036 -1.392 8.24E-07 3.76E-04 LTBP4 
cg11098525 0.958 0.955 -1.596 1.82E-08 2.00E-05 MAEA 
cg02228913 0.842 0.781 -1.646 6.80E-09 9.58E-06 MAPT 
cg08395365 0.078 0.066 1.645 1.28E-08 1.50E-05 MCCC1 
cg23166970 0.031 0.023 1.639 1.42E-08 1.61E-05 MCCC1 
cg02616966 0.056 0.042 1.926 4.27E-11 1.49E-07 MCCC1 
cg25441771 0.034 0.023 1.915 5.44E-11 1.79E-07 MCCC1 
cg22211233 0.044 0.036 1.639 1.44E-08 1.63E-05 MCCC1 
cg04991337 0.056 0.042 1.714 3.31E-09 5.43E-06 MCCC1 
cg05496383 0.037 0.028 2.006 7.45E-12 3.27E-08 MCCC1 
cg03318940 0.041 0.033 1.974 1.50E-11 5.97E-08 MCCC1 
cg00890010 0.081 0.072 1.456 4.03E-07 2.23E-04 MCCC1 
cg07634101 0.046 0.039 2.004 7.80E-12 3.34E-08 MCCC1 
cg07464924 0.048 0.037 2.241 3.46E-14 3.08E-10 MCCC1 
cg00161968 0.047 0.035 1.773 1.02E-09 2.09E-06 MCCC1 
cg00693240 0.963 0.959 -1.631 9.15E-09 1.19E-05 MGRN1 
cg16208863 0.910 0.902 -1.571 2.98E-08 2.94E-05 MLLT1 
cg03146452 0.034 0.040 -1.369 1.22E-06 5.03E-04 MSL3L2 
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cg21013756 0.097 0.112 -1.426 4.48E-07 2.39E-04 MSL3L2 
cg01565659 0.948 0.955 1.403 1.01E-06 4.38E-04 MSRA 
cg15020726 0.038 0.045 -1.700 2.25E-09 4.01E-06 MTMR15 
cg17035899 0.074 0.093 -1.463 2.29E-07 1.45E-04 MYL5 
cg09010067 0.966 0.963 -1.534 6.08E-08 5.10E-05 MYO1D 
cg16904092 0.809 0.757 -1.717 1.58E-09 3.01E-06 MYPOP 
cg06804705 0.749 0.772 1.404 9.85E-07 4.29E-04 NCRNA00114 
cg16262215 0.934 0.941 2.156 2.53E-13 1.90E-09 NDUFA7;KANK3 
cg20153196 0.069 0.073 -1.461 2.39E-07 1.51E-04 NEUROD2 
cg04239375 0.068 0.074 -1.620 1.13E-08 1.40E-05 NIPSNAP3B 
cg16174680 0.015 0.017 -1.715 1.66E-09 3.08E-06 NKX6-3 
cg05421673 0.054 0.058 -1.391 8.33E-07 3.78E-04 NOG 
cg14654471 0.918 0.878 -1.389 8.64E-07 3.88E-04 NPHP4 
cg02739500 0.041 0.044 -1.625 1.03E-08 1.30E-05 NPW 
cg22367989 0.028 0.030 -1.429 4.23E-07 2.31E-04 NRP2 
cg01164094 0.934 0.946 1.367 1.84E-06 6.76E-04 NT5DC3 
cg20405174 0.022 0.025 -1.719 1.51E-09 2.90E-06 PACSIN1 
cg13670316 0.055 0.059 -1.556 4.00E-08 3.74E-05 PCSK5 
cg27543403 0.030 0.033 -1.457 2.56E-07 1.59E-04 PDE4D 
cg11153768 0.958 0.951 -1.846 9.86E-11 3.03E-07 PDE6B 
cg05266497 0.937 0.932 -1.568 3.18E-08 3.08E-05 PGBD5 
cg26268742 0.902 0.911 1.420 7.51E-07 3.49E-04 PLA2G4C 
cg04202736 0.957 0.949 -1.473 1.90E-07 1.26E-04 PLA2G4D 
cg01078276 0.036 0.039 -1.332 2.33E-06 8.18E-04 PLAU;C10orf55 
cg16393928 0.952 0.947 -1.880 4.72E-11 1.61E-07 PRDM16 
cg13583586 0.919 0.931 1.491 2.17E-07 1.40E-04 PTDSS2 
cg08274544 0.967 0.959 -1.578 2.60E-08 2.65E-05 PTPN21 
cg01878724 0.078 0.062 1.579 4.43E-08 4.02E-05 RAET1L 
cg23231670 0.048 0.037 1.831 3.13E-10 7.68E-07 RAET1L 
cg08119607 0.150 0.138 1.678 6.73E-09 9.53E-06 RAET1L 
cg03118417 0.915 0.899 -2.291 2.38E-15 2.69E-11 RANBP3 
cg03711182 0.017 0.020 -1.632 8.98E-09 1.18E-05 RASGRF1 
cg05944207 0.051 0.059 -1.687 2.96E-09 4.95E-06 RASL10A 
cg27395839 0.951 0.919 -1.349 1.73E-06 6.52E-04 RORA 
cg24132791 0.062 0.052 1.459 3.81E-07 2.15E-04 RPSAP58 
cg04490178 0.034 0.037 -1.519 8.02E-08 6.25E-05 S1PR4 
cg25619287 0.742 0.763 1.771 1.08E-09 2.19E-06 SDF4 
cg08129848 0.021 0.024 -1.695 2.51E-09 4.38E-06 SEPHS2 
cg08113562 0.038 0.047 -1.564 3.40E-08 3.24E-05 SH3D20 
cg03610867 0.088 0.097 -1.721 1.45E-09 2.81E-06 SHH 
cg09327378 0.935 0.927 -1.410 5.94E-07 2.89E-04 SLC5A1 
cg00007644 0.097 0.105 -1.450 2.90E-07 1.75E-04 SLC6A5 
cg13823936 0.907 0.888 -1.423 4.76E-07 2.49E-04 SPOPL 
cg25533220 0.041 0.044 -1.456 2.61E-07 1.61E-04 SPPL2B;LSM7 
cg06092244 0.874 0.889 1.400 1.05E-06 4.51E-04 STON1-GTF2A1L 
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cg05806180 0.054 0.065 -1.495 1.27E-07 8.86E-05 SULF1 
cg05845592 0.037 0.030 1.388 1.29E-06 5.26E-04 SULT1A1 
cg22436429 0.049 0.052 -1.364 1.34E-06 5.40E-04 TFAP2E 
cg14557510 0.037 0.040 -1.658 5.35E-09 7.93E-06 TFCP2L1 
cg02567119 0.029 0.032 -1.691 2.70E-09 4.63E-06 TLX1;TLX1NB 
cg03548490 0.955 0.949 -1.545 4.88E-08 4.31E-05 TMC7 
cg08466517 0.937 0.945 2.073 1.68E-12 9.63E-09 TNIP3 
cg07965986 0.949 0.955 2.328 4.29E-15 4.68E-11 TRAK1 
cg06900571 0.968 0.963 -1.775 4.66E-10 1.10E-06 TRAPPC9 
cg22309983 0.956 0.952 -1.776 4.58E-10 1.08E-06 TRPV1 
cg22490255 0.054 0.057 -1.413 5.70E-07 2.81E-04 TSPAN31 
cg18106434 0.069 0.057 1.453 4.29E-07 2.33E-04 TUBGCP5 
cg22670128 0.866 0.848 -1.509 9.80E-08 7.26E-05 UBE2J2 
cg19908577 0.042 0.046 -1.585 2.28E-08 2.38E-05 UGT8 
cg18646207 0.055 0.059 -1.365 1.32E-06 5.37E-04 VAX1 
cg08584627 0.060 0.064 -1.349 1.73E-06 6.51E-04 VWA3B 
cg22867714 0.903 0.916 1.371 1.73E-06 6.51E-04 VWF 
cg00405190 0.355 0.345 1.703 4.15E-09 6.49E-06 WIPF1 
cg18579862 0.043 0.048 -1.544 5.05E-08 4.41E-05 ZIK1 
cg19033875 0.027 0.029 -1.364 1.33E-06 5.39E-04 ZNF395 
cg03405173 0.033 0.037 -1.344 1.88E-06 6.90E-04 ZNF441 
cg25591573 0.061 0.069 -1.950 9.71E-12 4.00E-08 ZNF442 
cg08847636 0.057 0.065 -1.873 5.44E-11 1.79E-07 ZNF442 
cg00850039 0.038 0.041 -1.496 1.25E-07 8.70E-05 ZNF442 
cg21727178 0.031 0.036 -1.825 1.59E-10 4.53E-07 ZNF709 
cg02878907 0.028 0.033 -1.901 2.96E-11 1.11E-07 ZNF709 
cg02934221 0.026 0.030 -1.511 9.35E-08 7.08E-05 ZNF709 
cg17317439 0.043 0.047 -1.371 1.18E-06 4.94E-04 ZNF763 
cg18483269 0.026 0.028 -1.689 2.80E-09 4.76E-06 ZNF823 
cg04681963 0.057 0.064 -1.411 5.85E-07 2.87E-04 ZNF879 
 
Table 12: Differentially Variably Methylated Positions (DVMPs), as computed by iEVORA. Variance is 
assigned as ±1.96 standard deviations (95% of a normal distribution), difference in variance is 
displayed as log[V1/V0], and p and FDR-corrected q values are displayed with a significance threshold 
of 0.001. 
 
Goldmine analysis revealed that 53.6% of DVMPs were situated in gene promoters, 
48.0% in CpG Islands, and 66.7% in transcription factor binding sites. Only 12.3% 





I used Enrichr to perform enrichment analysis of genes overlapping DVMPs. Based 
on the ChEA dataset I observed enrichment of factors which target the polycomb 
protein SUZ12 (p = 1.6x10-7, Q=1.5x10-5, Z-score=-1.54, Combined Score=24.12), 
and EZH2 (p = 1.3x10-6, Q=6. 1x10-5, Z-score=-1.75, Combined Score=23.76) 
which alongside SUZ12 forms part of Polycomb Repressive Complex 2.  
I also analysed genes overlapping DVMPs in terms of ontology using DAVID, 
though no ontologies were significantly associated after Benjamini-Hochberg 
correction for multiple testing.   
 
 
Figure 31: Genomic and Feature contexts of DVMPs computed using ChAMP results using iEVORA 
and ChIP-Seq data from the Roadmap Epigenomics Consortium. CpG Islands are regions of >200bp 
containing >50% GC composition and an observed to expected CpG ratio of >60%. Shores are regions 
2kb from a CpG Island and Shelves are regions 2kb from a CpG Shore. 
 
3.4.7 Inferring cellular origin of signal through overlap between DMPs and 
underlying cell-specific chromatin modifications 
eFORGE (Breeze et al., 2016) is a tool which associates CpG sites with chromatin 
modifications known to be present in a wide range of tissue types. I input the 
differentially methylated probes to eFORGE and found significant (Adjusted p > 
0.001) associations between DMPs and H3K36me3 marks in Primary Monocytes 
and Primary B Cells, as well as marginal association (0.05 > p > 0.001) with the 
same mark in Primary Natural Killer Cells. This suggests a population-specific origin 




3.4.8 Results: Differentially Methylated Regions in sporadic CJD 
Regional differences in DNA methylation are thought to be particularly biologically 
relevant as they may reflect areas of epigenetic dysregulation which may overlap 
multiple DNA-protein interaction sites, or be indicative of a region of underlying 
chromatin modifications (Jones, 2012). I first used Bumphunter (Jaffe et al., 2012) to 
tile adjacent probes and test for regional differences in methylation with Bonferroni 
threshold reduced by virtue of a reduction in data dimensionality through tiling. I 
identified 41 differentially methylated regions (DMRs), detailed in Table 13. The top-
ranked DMR consisted of 48 probes (2379nt) overlapping the HOXA5 promoter 
region (FWER = 0.012, p = 3.3x10-5), while subsequent DMRs had higher Family-
Wise Error Rates and showed lower effect sizes between case and control. Genes 
overlapped by DMRs were input to  Enrichr (E. Y. Chen et al., 2013; Kuleshov et al., 
2016) for gene set enrichment analysis, which revealed a significant association 
with Leukotriene receptor partners (p = 8.5x10-5, q = 0.007, Z-score = -1.55, 
Combined Score = 14.57).  
To assess the biological context of these DMRs, sequences were input to Goldmine 
using the previously mentioned Roadmap Consortium data. I found that all DMRs 
overlapped with transcription factor binding sites, and around 40% of DMRs 
overlapped enhancers in Monocytes, CD4+T Cells, CD8+ T Cells, B Cells, 
Neutrophils or Natural Killer Cells (Figure 32).  Then I used MEME-Suite (Bailey et 
al., 2009) to identify two motifs which are enriched in the DMRs (Figure 33), which I 
then associated with Gene Ontology Terms using MEME-Suite’s GOMo function 
(Buske et al., 2010). These are detailed in Table 14. To examine whether these 
motifs were represented in lists of transcription factor binding sites, I performed 
TOMTOM analysis which yielded two lists of transcription factors (Table 15) which I 
also input to Enrichr. The gene set of transcription factors with a q-value<0.05 (all of 
which corresponded to the first motif) was found to be significantly enriched for 
factors which target the polycomb protein SUZ12 (p = 8.2x10-9, q = 6.0x10-7, Z-score 
= -1.54, Combined Score = 28),based on the ChEA dataset (Lachmann et al., 
2010). These findings are intriguing as SUZ12 is involved in HOXA5 silencing and 




































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Figure 32: Feature and Genomic context of DMRs, computed using bumphunter results and ChIP-Seq 
data from the Roadmap Epigenome Consortium (Roadmap Epigenomics Consortium et al., 2015). 
CpG Islands are regions of >200bp containing >50% GC composition and an observed to expected 
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Table 14: Gene Ontology Results from MEME-SUITE’s GOMo function. Term types are organised into 









Motif Gene p value q value Overlap Target Overlap Strand 
1 CPEB1 8.53E-08 2.15E-04 17 AAAAAAAAAAATAAAAA - 
1 FUBP1 5.45E-06 3.92E-03 12 AAAAAAACACAA - 
1 ARI3A 8.22E-06 3.92E-03 22 AATTAATCGAAATCAAATTAAA + 
1 FOXL1 9.96E-06 3.92E-03 19 AAAAGTAAACAAACAAACA - 
1 ANDR 1.09E-05 3.92E-03 18 AGCAAACAAAAAAGAACA - 
1 FOXG1 1.40E-05 4.42E-03 17 AAAAAAATATAAACAAT - 
1 SRY 2.69E-05 6.79E-03 9 AAAACAAAA - 
1 LMX1A 5.94E-05 0.01 19 TTAATTAAATAATTAATTA - 
1 HXC10 6.38E-05 0.01 19 GTAATAAAAAAATTAAAAA - 
1 FOXJ3 9.01E-05 0.02 13 AAAAAATAAACAA - 
1 PRDM6 1.36E-04 0.02 13 AAAAAGAAAAAAA + 
1 AIRE 1.68E-04 0.02 18 TTAACCAATATAACCAAT - 
1 HMX1 2.79E-04 0.04 17 ATTAAAAAGCAATTAAC - 
1 FOXF1 3.24E-04 0.04 11 AAAATAAACAT - 
1 PO3F3 3.91E-04 0.05 17 AAATTTGCATAATTTAT - 
1 FOXJ3 4.20E-04 0.05 13 TAAACAAAAACAA - 
1 ZN713 5.25E-04 0.06 19 ATAGAAAAAAGACATGAAA + 
1 FOXJ2 6.19E-04 0.06 10 TAAATAAACA - 
1 FOXP1 8.24E-04 0.08 9 ATAAACAAA - 
1 ONEC3 8.38E-04 0.08 12 AAAAAATCAATA - 
1 Z354A 9.60E-04 0.08 24 ACATTAAATGTAAATGGACTAAAT - 
1 SOX5 1.07E-03 0.08 8 TAACAATA - 
1 ONEC2 1.11E-03 0.08 20 AAAAAAAATCAATAACAAGAC - 
1 LHX9 1.14E-03 0.08 18 TAATTAATAGCTAATTAG - 
1 STAT1 1.22E-03 0.08 17 AAGAAAATGAAACTGAAAG + 
1 BPTF 1.31E-03 0.09 12 GAAAACAACAAA - 
1 STAT2 1.53E-03 0.10 17 AGGAAAATGAAACTGAAAG + 
1 NFAC1 1.75E-03 0.11 15 ATGGAAAAAAAGAAA + 
1 SHOX 2.01E-03 0.12 17 AAAAATTAACTAATTAG - 
1 HXD11 2.22E-03 0.13 11 AGTAATAAAAA - 
1 DLX1 2.47E-03 0.14 16 TAATTAGCATAATTTA - 
1 HXC6 2.55E-03 0.14 15 AAAGTAATAAATCAT - 
1 HMX2 2.78E-03 0.15 11 AACCAATTAAA - 
1 FOXD1 2.89E-03 0.15 15 CTTAAGTAAACAAAG - 
1 FOXD2 3.00E-03 0.15 19 TTAAATAAATATTTACATA - 
1 MEF2D 3.81E-03 0.18 12 CTAAAAATAGCA - 
1 FOXD3 3.92E-03 0.18 15 TGCTAAGTAAACAAA - 
1 MEF2A 4.28E-03 0.19 13 GCTAAAAATAGAA - 
1 SHOX2 4.52E-03 0.20 17 TAAAATTAACTAATTAG - 
1 FOXQ1 4.67E-03 0.20 12 AAATAAACAATT - 
1 IRF1 5.22E-03 0.21 19 GAAAATGAAAGTGAAAGTAA + 
1 FOXP3 5.59E-03 0.22 9 AAACAAATT - 
1 GSX1 5.60E-03 0.22 15 ATTAAAAACTAATTA - 
1 HNF6 5.73E-03 0.22 11 AAATCAATAAA - 
1 MEF2C 5.90E-03 0.22 13 GCTAAAAATAGCA - 
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1 MNX1 6.33E-03 0.23 18 TTAAGGGTTATTAAAATAG - 
1 PO3F4 6.65E-03 0.24 17 TAATTTGCATAATTTAT + 
1 ZFP28 7.06E-03 0.25 20 TGACACAAGAAGAAATAGAA - 
1 EVX2 7.13E-03 0.25 13 AAGGCCATAAAAC - 
1 MYNN 7.40E-03 0.25 17 TTTCAAAATAAAAGTCC - 
1 LEF1 7.58E-03 0.25 14 AGCAAATCAAAGGA - 
2 NKX25 1.72E-04 0.08 8 CCTCTCCA - 
2 ETS2 1.96E-04 0.08 13 TCCTCTTCCTTCC - 
2 E2F7 2.66E-04 0.08 13 CCTTTCCCGCCCC - 
2 ZN467 2.86E-04 0.08 15 CCCCCCCCCCCCTCCCCTCCCC - 
2 PTF1A 3.76E-04 0.08 15 CCAGCTGCCCCCTTTCCC + 
2 VEZF1 3.83E-04 0.08 15 CCCCTCCCCCTCCCCCCTCCCC - 
2 E2F1 3.83E-04 0.08 14 CTTTCCCGCCCCCC - 
2 SP4 5.00E-04 0.08 15 CCCGGCCCCGCCCCCTTCCC - 
2 ZBTB6 5.07E-04 0.08 13 CGGCTCCAGCACC - 
2 PATZ1 5.08E-04 0.08 14 CCTCCCCCCCCGCCCCCTCCCC - 
2 WT1 6.29E-04 0.08 15 CCCCCCCTCCTCCCCCGCCC - 
2 TFDP1 8.79E-04 0.11 14 TTTTCCCGCCCCCC - 
2 E2F6 1.18E-03 0.13 13 CCCTTCCCGCCCC - 
2 KLF15 1.38E-03 0.13 15 CCCCCCCCTGCTCCTCCCC - 
2 ZFX 1.45E-03 0.13 15 CCCCGGCCTCCGCCCCC - 
2 MAZ 1.50E-03 0.13 15 CCCCCCCCCCCCCCCCTCCCCC - 
2 ZN148 1.86E-03 0.15 14 CCCCTCCCCCACCCC - 
2 ZBT17 1.94E-03 0.15 14 CTTCCCCTCCCCCACCCTC - 
2 EGR2 2.10E-03 0.15 14 CCCCCGCCCACGCCCC - 
2 CREB3 2.11E-03 0.15 13 TGCCACGTCACCA - 
2 ERG 2.41E-03 0.17 13 CCACTTCCTGCCC - 
2 ZN263 2.64E-03 0.18 15 CTCCTCCTCTCCCTCCTCCC - 
2 ZN341 3.22E-03 0.21 15 GCTCTTCCCTCCCCCCCCCCCC - 
2 FLI1 3.84E-03 0.23 13 CCACTTCCTGCCT - 
2 EGR1 3.85E-03 0.23 15 CCCCCGCCCACGCCCTC - 
2 MAZ 3.90E-03 0.23 11 CCCCCTCCCTC - 
2 EGR2 5.06E-03 0.28 15 CCCCTCCCACACCCCCCC - 
2 NFAC1 5.92E-03 0.31 14 TTTCTTTTTTTCCAT - 
2 SP2 6.10E-03 0.31 14 CCCCCGGCCCCGCCCCCCCCCC - 
2 ETV5 6.78E-03 0.31 14 CTCACTTCCTGCTC - 
2 ETS1 6.80E-03 0.31 13 CCACTTCCTGTCT - 
2 NR0B1 7.22E-03 0.31 10 TCTCCCACGC - 
2 NFAT5 7.30E-03 0.31 9 CCTTTTCCTCT - 
2 ZN740 7.32E-03 0.31 14 CCCACCCCCCCCCC - 
2 VEZF1 7.44E-03 0.31 11 CCCCCTCCCCCT - 
 
Table 15: Transcription Factors which recognise 2 motifs enriched in the DMR dataset as called by 
TOMTOM. p values are calculated through comparison of the query motif (1 or 2) with target overlap 






During the early stage of the project I optimised a low-input high-yield protocol for 
extraction of genomic DNA from blood, as well as a bisulphite conversion protocol 
which produced bisulphite converted DNA of sufficient quality for 450K Beadchip 
array analysis. I went on to perform the first genome wide methylation association 
study conducted on human prion disease. I identified 38 Differentially Methylated 
Positions (DMPs), 41 Differentially Methylated Regions (DMRs) and 252 
Differentially Variably Methylated Positions (DVMPs). As DVMPs are of ambiguous 
biological relevance and the DMRs I identified have high Family-Wise Error Rates, 
the most reliable results from this study are the DMPs, which will be taken forward 
for further analysis. Pathway, enrichment and motif analyses produced some 
positive associations between results and pathways, ontologies, functions and 
common sequences, but these associations were slight and not particularly 
convincing. Loci associated with sCJD were associated with disease severity and 
rate of decline, as loci unchanged between disease and control were thought 
unlikely to correlate with either metric under the study’s statistical power. An 
association between demethylation at the AIM2 promoter and increased disease 
severity shows promise as a peripheral prognostic biomarker. Effects seen in blood-
derived DNA are relatively large compared to those seen in published studies of 
neurodegeneration. Yet genome-wide significance inflation was higher than optimal, 
and so to exclude false positives replicating these findings in a second study of DNA 
methylation in blood taken from a separate cohort of sCJD patients and controls 















4 Validating, replicating and exploring 450K Beadchip Array 
findings using CpG-sensitive pyrosequencing 
Having successfully identified 38 loci differentially methylated between sporadic 
CJD patients and control volunteers, the logical next step was to replicate findings 
using a second cohort of samples and a different technology. This serves several 
purposes, the first being to minimise the false positive risk by controlling for 
variability unique to the first cohort or technically inherent to the 450K Beadchip 
array. Secondly, by using a sequencing approach rather than a probe-based 
approach, locally proximal CpG sites can also be interrogated. As CpG methylation 
can be highly locally correlated this provides the opportunity to strengthen the 
impact of the discovery findings by identifying additional adjacent loci with similarly 
differential levels of methylation (L. Zhang et al., 2017; Song, Ren and Lei, 2017). 
Finally, as site-specific sequencing data cannot be adjusted for cellular 
heterogeneity or subjected to the preprocessing data from the 450K Beadchip array 
was, these results being an artifact of data manipulation can be ruled out. 
In this chapter I aim to design pyrosequencing assays for biologically interesting loci 
identified during the previous chapter, validate pyrosequencing’s complementarity to 
the 450K Beadchip array by assaying samples whose methylation levels at 
cg10636246 (AIM2) and cg03546163 (FKBP5) had been previously investigated, and 
replicate discovery study results in a second set of different sCJD patients and 
controls. Finally, I aim to test the specificity of any successfully replicated findings to 
sporadic CJD by performing the replication assays on blood-derived DNA from 
Alzheimer’s Disease, iatrogenic CJD and Inherited Prion Disease patients.  
4.1 Relevant Methods and Sample Demographics 
2.1.2 Extraction of genomic DNA from blood (page 56)  
2.1.3 DNA Quality Control (page 58)  
2.1.4 Bisulphite Conversion (page 58) 
2.3 Validation and Replication Using Pyrosequencing (page 65)  
2.3.1 Sample Selection (page 65)  
2.3.2 Bisulphite PCR for Pyrosequencing (page 65)  
2.3.3 Pyrosequencing (page 69)  
2.4 Testing Disease Specificity of Replicated Differentially Methylated Sites Using 
Pyrosequencing (page 69) 




Group Number Average Age (range) Sex (% F) 






sCJD 72 59.9 (26-86) 58.3 54:23:23 4.5 (0-20) 
Control 114 78.2 (61-93) 64.9 Unknown 20 
AD 59 71.8 (58-87) 47.5 Unknown NA 
iCJD 18 46.4 (41-53) 11.1 27:73:0 11.7 (1-18) 
IPD 11 48.5 (38-68) 72.7 44:44:12 18.6 (13-20) 
 
Table 16: Demographics of patients and controls whose samples were used in the 
replication/specificity phase. 
 
4.2 Assay design 
4.2.1 Probe Selection 
Technologies for replication of observed effects at single loci are by definition less 
high-throughput than the 450K array. This places a limitation on the number of 
DMPs which could be brought forward to replication and necessitates selection of 
DMPs from the list of 38. I selected DMPs for replication based on statistical 
significance, effect size, genomic location and features, and biological function. Two 
probes in AIM2 (cg10636246 & cg17515347) were selected due to their presence in 
the gene’s promoter region and their association with MRC Scale score (Section 
3.3.4). A CpG bordering the promoter of FKBP5 (cg03546163) was selected as it 
exhibited the largest case-control difference (Δβ = - 0.055). Two additional probes 
overlapped by FKBP5 (cg00052684 & cg25114611) were identified as differentially 
methylated using the EpiDISH algorithm (Box 2) and were also chosen for 
replication. A CpG in the body of UHRF1 (cg04286737) and another in the body of 
METTL9 (cg02481950) were selected due to their biological function: UHRF1 
facilitates DNMT1 recruitment to hemi-methylated DNA whilst METTL9, while 
uncharacterised, bears homology to methyltransferases.  A probe in the body of 
KCNAB2 (cg02448796) was chosen for replication as bioinformatic analysis of 
sCJD GWAS data (currently unpublished, personal communication from Dr Holger 
Hummerich, MRC Prion Unit at UCL) indicated an enrichment in factors associated 
with potassium channels, and a CpG upstream of MTRNR2L8 – Humanin-like 
protein 8 – was also chosen due to previous association with humanin-like proteins 
with neuroprotection in prion disease and Alzheimer’s disease (Hashimoto et al., 
2001; Sponne et al., 2004; Bodzioch et al., 2009).  Because of their relevance to 
prion disease and epigenetics of neurodegeneration, and partly because no 
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statistically significant change was observed at these loci in the discovery stage, 
probes in ANK1 (cg11823178) and PRNP (cg00168514) were also selected (Lloyd, 
Mead and Collinge, 2011; De Jager et al., 2014; Lunnon et al., 2014). Distribution of 
beta values between groups at these probes are visualised in Figure 34 and a 
summary of selection rationale is displayed in Table 17. 
 
 
Figure 34: Array-derived methylation values at selected DMPs, as well as loci in ANK1 and PRNP 
which showed no significant change between control (red) and sCJD (turquoise) groups. Asterisks 
denote Bonferroni-adjusted significance, where an adjusted threshold of 0.05 has been surpassed  



















Functional connection to: 
Neurodegeneration? Epigenetics? 
cg10636246 AIM2 Yes Yes Yes Yes No 
cg02481950 METTL9 Yes No No No Yes 
cg05740793 MTRNR2L8 Yes Yes Yes Yes No 
cg05001044 MIR1977 Yes Yes Yes No Yes 
cg02448796 KCNAB2 Yes No Yes No No 
cg17714703 UHRF1 Yes No Yes No Yes 
cg17515347 AIM2 Yes Yes Yes Yes No 
cg03546163 FKBP5 Yes Yes Yes Yes No 
cg11823178 ANK1 No No No Yes No 
cg00168514 PRNP No No No Yes No 
 
Table 17: Criteria for replication as fulfilled per CpG site chosen for replication. 
 
4.2.2 Bisulphite-PCR primer design 
Producing an amplicon less than 200 bp in length at probe sites surrounded by 
particularly dense CpG clusters is technically challenging as forward and reverse 
PCR primers cannot overlap CpG sites. This would bias the reaction towards 
amplification of methylated or unmethylated fragments, depending on whether the 
complementary nucleotide at the CpG’s cytosine is A (unmethylated) or G 
(methylated) after bisulphite conversion. This was the case for many of the PRNP 
probes, including cg00168514 which had been chosen as a negative control. 
Instead an assay was designed for cg04286737, which is located upstream of 
PRNP’s TSS. Fortunately, an assay for the second negative control CpG in ANK1 
(cg11823178) was designed without difficulty.  
MTRNR2L8 presented a different challenge, as it is one of 15 nuclear-encoded 
descendants of a mitochondrial peptide (Bodzioch et al., 2009). As such the DNA 
sequence surrounding cg05740793 was highly conserved across the Humanin 
homologues and generating a specific amplicon shorter than 200 bp proved 
impossible. Moreover, the bordering sequences were enriched for cytosine and 
thymine, which after bisulphite conversion resulted in stretches of thymine homo-
polymers which are refractory to primer design. This is due in part to increased 
sequence redundancy and thus reduced hybridisation specificity, but also because 
interactions between A/T rich sequences are weaker than those between G/C rich 
sequences. Nested bisulphite PCR of a larger specific amplicon and then production 
of a shorter amplicon for sequencing was attempted but in all cases the second 
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reaction failed. Regrettably upstream differential methylation of MTRNRL2L8 was 
therefore not able to be replicated. The local genomic contexts of PRNP and 
MTRNRL2L8 probes as displayed in the PyroMark assay design software are 
shown in Figure 35. 
Despite the technical challenges of designing primers for bisulphite PCR followed by 
sequencing, assay design for the remaining selected probes was less problematic 
and in some instances allowed profiling of multiple adjacent CpG sites (up to a total 





Figure 35: Screenshots from PyroMark Assay Design 2.0 software. Numbers correspond to nucleotide 
position around the CpG of interest (CpG ± 500 nt), orange bars and red circles correspond to melting 
temperature and Gibbs free energy per location. Blue bars correspond to CpG cytosines, shaded blue 
sequence represents target sequences. Grey shadows and beige blocks correspond to potential 
primer positions and generated primer sequences. (i) PRNP probe cg00168514 (position 501) is 
situated in a CpG island and so surrounded by CpG sites (light blue shading), over which many of the 
generated primer sequences (grey shadows, beige blocks) overlap. (ii) MTRNRL2L8 probe 
cg05740793 (position 501), as well as being surrounded by sequences conserved elsewhere in the 
genome, is flanked by homo-thymine polymers after bisulphite conversion which are refractory to 
specific primer hybridisation. The downstream flank is shown; orange colour in the sequence indicates 
paired thymine/adenine produced by bisulphite conversion of paired cytosine/guanine. (iii) Multiple 
sites adjacent to ANK1 probe cg11823178 (position 501) are eligible for profiling during sequencing 
extension. As maximum pyrosequencing read length is approximately 40 nucleotides, of the targeted 
five adjacent CpGs only the first four generated sufficient quality data for analysis. 
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4.3 Validation of AIM2 and FKBP array-derived methylation values 
using pyrosequencing 
To lend confidence in the results of a genome-wide discovery study, it is important 
to firstly validate and then replicate the results in a second cohort of samples, ideally 
using a different technology. Not only does this reduce the influence of the basal 
false positive rate, but in the latter instance discounts the effects of technical biases 
particular to the technology used from contributing to this error rate. 
Pyrosequencing was originally used to validate raw 450K array data and found to 
have a Spearman’s R of 0.86 and p below 0.0001 (Roessler et al., 2012). However, 
it is possible that the corrective techniques which have emerged since the platform’s 
release may have an effect on complementarity between the two technologies. As a 
pilot study, 10 sCJD samples and 6 control samples which had been profiled on the 
array were assayed at cg10636246 (AIM2) and cg03546163 (FKBP5) using 
pyrosequencing. Pyrosequencing provides DNA methylation values in percentage 
rather than β, and data is not processed as with array values. Perhaps as a 
consequences of this, absolute methylation values were approximately 10-20% 
lower as measured by pyrosequencing, but differences between means remained 
consistent between array and pyrosequencing results for FKBP5 (Δβ = -0.069, Δ% 
= -6.1%) and AIM2  (Δβ = -0.095, Δ% = -8.2%), as shown in Figure 36. Spearman’s 
R between pyrosequenced and array values were 0.844 (p = 2.83x10-4) and 0.911 
(p = 1.87x10-7) respectively. This demonstrates that despite the differences between 
the two platforms, pyrosequencing remains an appropriate method of validating and 
replicating 450K array data, at least at these two DMPs. As such a second, 
separate cohort of sCJD and control blood-derived DNA was assembled for 





Figure 36: Validation of 450K array results using pyrosequencing. Shown are control and sCJD 
methylation values (Beta) at FKBP5 and AIM2 DMPs as measured by 450K array (gold) and 
Pyrosequencing (red). 
 
4.4 Replication of DMPs using pyrosequencing  
 
4.4.1 Power calculations and cohort selection 
Now that estimates of effect sizes and beta distributions were known, it became 
possible to calculate sample numbers (N) needed to achieve 95% power per DMP 
assay. Using G*Power 3.1 (Faul et al., 2009) N per assay was calculated, which 
ranged from 7 to 50 as shown in Table 18. In the event of altered distribution of 
array methylation values and pyrosequencing values per assay or methylation 
distributions in the new sample group being different, an excess of samples (72 
sCJD, 114 controls) were selected and bisulphite DNA stocks generated as 
previously described. In addition, 59 Alzheimer’s disease (AD) patient-derived 
samples (see methods for sample sources and diagnosis of patients) were 
converted in order to test the specificity of observed changes to prion disease, 
rather being a general consequence of neurodegeneration. To test the specificity of 
these DMPs to sporadic prion disease, 18 iatrogenic CJD (iCJD) and 9 inherited 
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prion disease (IPD) patient samples (carrying the following PRNP mutations: 
A117V, 5-octapeptide repeat insertion, D178N, P102L (x 6)) were also selected for 
comparison, with the caveat that not all assays would be powered in these 
comparisons and that iCJD caused by inoculation with contaminated cadaveric 
pituitary gland-derived growth hormone disproportionately affected men, thus only 2 
of 18 patients were female. Iatrogenic CJD is a very rare disease which also limited 
sample size.  













cg10636246 AIM2 0.25 0.02 0.21 0.02 0.02 7 7 0.969 
cg02481950 METTL9 0.82 0.03 0.8 0.02 0.03 50 50 0.95 
cg05740793 MTRNR2L8 0.16 0.02 0.21 0.025 0.025 7 7 0.969 
cg05001044 MIR1977 0.19 0.025 0.245 0.035 0.035 10 10 0.958 
cg02448796 KCNAB2 0.749 0.034 0.781 0.4 0.4 35 35 0.95 
cg17714703 UHRF1 0.21 0.016 0.242 0.02 0.02 10 10 0.96 
cg17515347 AIM2 0.6 0.04 0.55 0.045 0.045 19 19 0.956 
cg03546163 FKBP5 0.55 0.047 0.49 0.05 0.05 16 16 0.95 
 
Table 18: Power calculations for replication assays. Shown are sample numbers (N) required to 
replicate findings per site at 95% power calculated from Δβ between sCJD and control array values. To 
ensure stringency the largest of the two standard deviations (SD used) was used in the power 
calculation. 
 
4.4.2 Replication of DMPs in second control and sCJD cohort 
Raw methylation values in percent were output by the PyroMark Q96. Failed calls 
were discarded manually whilst calls highlighted for manual checking were 
discarded based on unrealistic values (e.g. 0%) or common discrepancies in the 
assay. For example, if pyrogram peak height was consistently different from 
expected height at a position up/downstream of the assay site, this was not 
considered to be disqualifying. sCJD and control samples were converted in a 
single batch on two 96-well plates and no assays which contained a non-CpG 
cytosine as a control for bisulphite conversion efficiency (cg01636246, cg11823178, 
cg00052684, cg25114611, cg05001044, cg02448796, cg02481950) showed errors 
related to incomplete bisulphite conversion. As eight genes in total were being 
assayed, albeit in some instances at several proximal sites, nominal significance 
threshold was adjusted to p < 0.00625 (0.05 ÷ 8) and analysis was performed using 
a linear regression model with age and sex as covariates.  
Of 9 DMPs, 6 were replicated, and the two negative controls remained unaffected 
by disease/control status. 
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In FKBP5, hypomethylation of cg03546163 was found to be increased from -5.55% 
in the first cohort to -11.00% in the second, with unadjusted statistical significance 
being of the order of p ~ 10-8 in both groups. In addition, a CpG 4 nucleotides 
downstream was also found to be significantly hypomethylated (-7.08%, p = 6.42 
x10-10). Of the two additional loci identified using EpiDISH, cg00052684 showed 
similar effect size between cohorts (-4.95% and -5.35% for the first and second 
cohorts respectively), but significance, although nominal, was reduced (unadjusted 
p = 4.86x10-8 (first cohort) to p = 0.002 (second cohort)). The second EpiDISH CpG 
(cg25114611) did not pass the threshold for statistical significance of p < 0.00625 (-
3.31%, p = 2.45x10-10 (first cohort), -3.29%, p = 0.029 (second cohort)). 
Both DMPs in AIM2 were replicated in the second cohort. Hypomethylation of 
cg17515347 was also found to be increased from -4.72% to -10.33% and 
significance was increased by two orders of magnitude (p = 7.56x10-8 (first cohort) 
to p = 2.02x10-10 (second cohort)). In addition, a CpG 14 nucleotides downstream 
was found to be similarly altered (-7.74%, p = 7.69x10-10). In contrast, cg10636246 
also replicated at increased significance and with a greater effect size (-4.05%, p = 
2.38x10-10 (first cohort), -5.99%, p = 5.51x10-13 (second cohort)), but a CpG 36 
nucleotides upstream was not found to be significantly altered between sCJD and 
control. 
The DMP at cg02481950 in METTL9 was also replicated in the second cohort with 
similar effect size and significance (+1.93%, p = 8.65x10-10 (first cohort), +2.41%, p 
= 8.00x10-6 (second cohort)), but cg02448796 in KCNAB2 (+3.15%, p = 4.36x10-8 
(first cohort), +1.96, p = 0.087 (second cohort)) and cg05001044 in MIR1977 
(+5.23%, p = 9.82x10-9 (first cohort), +0.70, p = 0.34 (second cohort)) did not show 
differential methylation on replication. All three CpGs in the UHRF1 assay showed 
hypermethylation (+2.06%, + 4.34%, +2.12%) which was nominally significant (p = 
0.002, 0.001, 0.003), but reduced compared to the array results corresponding to 
the second CpG (cg17714703) in the pyrosequencing assay (+3.44%, p = 2.15x10-
8). 
Although both cg04286737 and cg00168514 are located in the body of PRNP, the 
former is 2,107 bp downstream of the latter and so methylation values at these sites 
cannot be expected to correlate. However, cg04286737 was not found to be 
differentially methylated between sCJD and control (-0.47%, p = 0.037). In ANK1 
lack of differential methylation at cg11823178 was confirmed (-0.46%, p = 0.819). 
Thus, of seven DMPs calculated using Houseman correction five were replicated 
Page 124 
 
and two did not replicate, while of two additional EpiDISH-calculated DMPs one 
replicated and one did not. Replication results including array data for comparison 


































 6:35,654,360 FKBP5   -7.08 6.42x10
-10
 





cg00052684 6:35,694,246 FKBP5 -4.95 4.86x10
-8
 -5.35 0.002 
cg25114611 6:35,696,871 FKBP5 -3.31 2.45x10
-10
 -3.29 0.029 
 6:35,696,887 FKBP5   -0.68 0.764 





 1:159,047,178 AIM2   -7.74 7.69x10
-10
 
 1:159,046,937 AIM2   +1.66 0.349 





cg04286737 20:4,665,646 PRNP   -0.47 0.037 
 20:4,665,649 PRNP   -0.21 0.28 
 19:4,912,212 UHRF1   +2.06 0.002 
cg17714703 19:4,912,222 UHRF1 +3.44 2.15x10
-8
 +4.34 0.001 
 19:4,912,224 UHRF1   +2.12 0.003 
cg05001044 1:567,312 MIR1977 +5.23 9.82x10
-9
 +0.70 0.34 
 1:567,347 MIR1977   +0.92 0.004 
 1:567,357 MIR1977   +0.79 0.014 
 1:567,375 MIR1977   +0.12 0.93 





 1:6,101,332 KCNAB2   +2.00 0.91 
cg02448796 1:6,101,339 KCNAB2 +3.15 4.36x10
-8
 +1.96 0.087 
cg11823178 8:41,519,399 ANK1 -0.29 0.54 -0.46 0.819 
 8:41,519,411 ANK1   +1.04 0.290 
 8:41,519,417 ANK1   -4.05 0.023 
 8:41,519,420 ANK1   -1.75 0.113 
 8:41,519,440 ANK1   -0.80 0.286 
 
Table 19: Results from DMP replication study. Probes selected for replication are in the first column, 
where assay permitted measurement of DNA methylation at adjacent CpG sites their genomic 
coordinates are displayed in column two. For ease of comparison methylation values are given in 
percent for both array (Δβ x 100) and pyrosequencing data, and p values are unadjusted with the 




I then tested the association between MRC Scale score and hypomethylation at the 
AIM2 probe cg10636246 in data from sCJD-derived samples in the replication 
cohort. Although effect size and significance were diminished compared to the 
discovery cohort, this effect was replicated in the second cohort (Pearson = 0.281, p 




Figure 37: Correlation of hypomethylation at cg10636246 (AIM2) with decrease in MRC Scale score is 
replicated in a second cohort of sCJD patient samples (r = 0.281, p = 0.013). An MRC Scale score of 
20 represents a patient who may have symptoms but is functionally independent for activities of daily 
life. An MRC Scale score below 3 indicates a comatose state near to death with a patient only able to 
take perhaps sips of fluid for nutrition and make incomprehensible sounds. Asterisks denote 
significance (* = p < 0.05) 
 
4.5 DNA methylation at replicated DMPs in iatrogenic CJD, inherited 
prion disease and Alzheimer’s disease 
Five replicated assays at AIM2 (cg17515347, cg10636246), FKBP5 (cg03546163), 
METTL9 (cg02481950) and UHRF1 (cg17714703) loci were applied to DNA derived 
from iCJD, IPD and AD patient blood. In summary, changes observed in sCJD were 
not observed in the other diseases profiled, although the METTL9 assay was not 
powered in the case of iCJD and IPD. In this instance, analysis of iCJD data 
excluded sex as a covariate from the regression model as there was a strong 
imbalance of sex between iCJD and control groups (as explained in Section 4.3.1). 




with sex, it is unlikely that this exclusion masked any biological effect. As five 
assays were used, Bonferroni threshold for disease group specificity assays was set 
at 0.01. Comparisons of raw pyrosequencing data between groups per assay are 
displayed in Figures 38-41, while summary statistics are tabulated in Table 20: 
Statistics for differences between AD, iCJD, IPD compared to control group per 
replicated DMP. p values are unadjusted, Bonferroni-adjusted significance threshold 
is p < 0.01 
. 
  
Figure 38: Pyrosequencing results at cg10636246 (AIM2). The assay shows no significant differential 
methylation at the first interrogated CpG, while at the probe-targeted CpG differential methylation is 
only observed between control and sCJD groups (ΔM = -5.99%, p = 5.5x10-13). Bonferroni threshold is 
0.00625 for sCJD-control comparisons and 0.01 for comparisons between control and non-sCJD 
diseases. Asterisks denote adjusted significance, where a threshold of 0.05 has been surpassed  






Figure 39: Pyrosequencing results at cg17515347 (AIM2). The assay shows significant 
hypomethylation at both targeted CpG sites in the sCJD group only (ΔM = -10.33%, p = 2.02x10-10; ΔM 
= -7.74%, p = 7.69x10-10). Bonferroni threshold is 0.00625 for sCJD-control comparisons and 0.01 for 
comparisons between control and non-sCJD diseases. Asterisks denote Bonferroni-adjusted 
significance, where an adjusted threshold of 0.05 has been surpassed  
(* = p< 0.05, ** = p< 0.01, *** = p<0.001). 
 
  
Figure 40: Pyrosequencing results at cg03546163 (FKBP5). The assay shows significant 
hypomethylation at both targeted CpG sites in the sCJD group only (ΔM = -7.08%, p = 6.42x10-10; -
11.00%, p = 1.70x10-8). Bonferroni threshold is 0.00625 for sCJD-control comparisons and 0.01 for 
comparisons between control and non-sCJD diseases. Asterisks denote Bonferroni-adjusted 
significance, where an adjusted threshold of 0.05 has been surpassed  












Figure 41: Pyrosequencing results at cg02481950 (METTL9) and cg17714703 (UHRF1). The assay for 
cg02481950 shows significant hypermethylation in the sCJD group only (ΔM = +2.41%, p = 8.0x10-6), 
while the assay targeting cg17714703 shows nominally significant but minor hypermethylation in the 
sCJD group only at all three loci (ΔM = +2.06%, p = 0.002; ΔM = +4.34%, p = 0.001; ΔM = +2.12%, p = 
0.003). Bonferroni threshold is 0.00625 for sCJD-control comparisons and 0.01 for comparisons 
between control and non-sCJD diseases. Asterisks denote Bonferroni-adjusted significance, where an 
adjusted threshold of 0.05 has been surpassed  




















































































































































































































































































































































































































































































































In summary, two thirds of DMPs taken forward for replication successfully 
replicated, and five novel CpG sites captured in the pyrosequencing assays were 
also found to be differentially methylated between sCJD patients and control 
volunteers. Excitingly, association of hypomethylation at the promoter of AIM2 
(cg10636246) with decreased MRC Scale score was also observed in the second 
cohort of sCJD patients, validating this site’s potential as a biomarker of disease 
severity. The differential methylation observed in both sCJD cohorts was not found 
to be a feature of Alzheimer’s disease, iatrogenic CJD or Inherited Prion Disease. 
This is significant not just because it suggests the signature observed in sCJD is 
specific to sporadic prion disease rather than prion disease or neurodegeneration in 
general, but also because drugs prescribed to treat symptoms of sCJD, IPD and 
iCJD are broadly similar (anti-epileptics, benzodiazepines), meaning the observed 
signature is unlikely to be a result of differences in therapeutic intervention between 
disease groups.  
Having confirmed several of the array findings, the logical next step was to consider 
the functional relevance of implicated genes. Based on FKBP5 promoter 
demethylation I decided to investigate serum cortisol levels, while also measuring 
methylation at replicated sites in brain-derived DNA and further dissecting the 











5 Further investigation: Blood-brain concordance, cortisol 
concentrations and cell-specific effects 
As explained in Section 1.8, blood was selected as the tissue of study during this 
project because of its comparative accessibility in a clinical setting, making it an 
ideal tissue for biomarker discovery. Moreover, all sCJD patients have blood taken 
for diagnostics and in many cases consent is given for research samples to be 
taken too, while postmortem brain tissue is available from fewer patients and is a 
much more difficult tissue to work with, on account of infectivity risk. Using blood-
derived DNA allowed sufficient sample numbers to power a genome-wide study of 
DNA methylation and now that candidate loci have been identified and replicated it 
is much easier to study brain-derived DNA in search of similar effects. The logical 
next step is to profile DNA samples taken from brain tissue (specifically frontal 
cortex, as this region of brain is known to contain high prion titre and exhibit 
spongiform degeneration (Hill et al., 2003)) using the pyrosequencing assays 
designed during the 450K replication stage. 
As mentioned in Section 3.3.8, eFORGE revealed that the array DMPs overlapped 
with functional elements known to be active in monocytes. As monocytes circulate 
in the periphery but are capable of infiltrating tissues, it would be interesting if the 
observed changes were amplified in this leukocyte population compared to other 
circulating cells: not only would this explain the relatively modest effect size seen in 
whole blood but could also provide more insight into why changes in DNA 
methylation in the periphery are observed. Frozen blood cannot be sorted into cell 
fractions as cells are lysed on freezing, so this experiment would require fresh blood 
samples to be prospectively collected from patients and relatives/spouses during 
clinic visits. While this presents an issue regarding collecting sufficient samples from 
patients of a rare disease to power pyrosequencing assays, if the effect size is 
magnified in a particular cell lineage differences may be detectable at lower sample 
numbers than calculated previously (Table 18). 
But firstly, the discovery of differential methylation of FKBP5 lead me to consider 
profiling serum cortisol in sCJD patients compared to controls. Hypomethylation of 
FKBP5’s promoter suggests upregulation, and a known stimulus for this is 
increased levels of circulating cortisol. 
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5.1 Relevant Methods and Sample Demographics 
2.5 Testing Tissue Specificity of Replicated Differentially Methylated Sites Using 
Pyrosequencing (page 67)  
2.6 Testing Leukocyte Specificity of Replicated Differentially Methylated Sites Using 
Magnet Assisted Cell Sorting and Pyrosequencing (page 68)  
2.6.1 Sample Selection (page 68)  
2.6.2 Magnet Assisted Cell Sorting (page 68) 
2.7 Statistics and Graphics (page 69) 
 
Group Number Average Age (range) Sex (% F) 






sCJD 39 68.9 (49-79) 64.1   
Control 52 55.3 (24-98) 53.8 Unknown 20 
FFI 6     
 
Table 21: Demographics of patients and controls whose samples were used in cortisol screening. 
 
 
Group Number Average Age (range) Sex (% F) 






sCJD 58 68.8 (40-87) 42.9 65:25:10 0 
Control 33 74.0 (41-89) 54.2 Unknown 0 
 
Table 22: Demographics of patients and controls whose samples were used to investigate brain-
derived DNA methylation. 
 
 
Group Number Average Age (range) Sex (% F) 






sCJD 7  42.9   
Control 11  36.4 Unknown  
 
Table 23: Demographics of patients and controls whose samples were used to investigate leukocyte-
enriched DNA methylation. 
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5.2 Comparing circulating cortisol concentrations between sCJD 
patients and healthy controls 
5’-UTR hypomethylation of FKBP5 is in sCJD is suggestive of gene upregulation, 
and indeed FKPB5 transcript levels are found to be increased in sCJD patient blood 
(currently unpublished, personal communication from Dr Emmanuelle Viré, MRC 
Prion Unit at UCL). FKBP5 has many functions, one of which is inhibition of the 
cellular response to cortisol through binding to the Glucocorticoid Receptor 
(Wochnik et al., 2005). Hypercortisolaemia is a reported feature of sheep scrapie 
(Gayrard et al., 2000), prompting us to investigate whether cortisol concentration in 
sCJD blood is elevated, as a potential causal mechanism for hypomethylation at 
FKBP5 as these two observations might suggest. One of the hypotheses 
underpinning my work concerns the relevance of blood methylation to a brain 
disease. The opportunity to identify a mechanism of FKBP5 involvement through the 
effect of CJD on the hypothalamic-pituitary axis, the endocrine system, and thus 
peripheral gene expression and methylation was important to explore. Increased 
FKBP5 expression and demethylation of its promoter may be a result of a negative 
feedback response to increased circulating cortisol levels. 
 
As well as 39 sCJD and 52 control sera, serum from 6 patients with Fatal Familial 
Insomnia (FFI) were profiled as the thalamus is dramatically affected in FFI, thus 
disruption of the hypothalamic-pituitary-adrenal axis might be expected. 20 of the 
sCJD patients were part of the cohort which had been profiled on the 450K array as 
reported in Chapter 3, allowing us to compare FKBP5 methylation and cortisol 
concentration in these individuals. Controls were healthy and without cognitive 
impairment. No sCJD patients had received steroid injections. Blood samples were 
taken between approximately 10am-4pm. Cortisol was measured by The Doctors’ 
Laboratory (Sonic Healthcare Ltd.) using an electrochemiluminescence 
immunoassay (Elecsys Cortisol II assay, Roche) and serum concentrations were 
delivered by email. Cortisol was found to be elevated in sCJD sera within and above 
the normal circadian range of 133-537 nM. In control sera the mean concentration 
was 239.8 nM, while in sCJD sera the mean concentration was 387.6 nM (p = 
6.6x10-5). FFI mean sera concentration was 271.3 nM (p = 0.434). Interestingly, 
methylation at cg03546163 (FKBP5) did not correlate with [Cortisol] (Pearson’s 
Correlation = -0.047, p = 0.845). Distributions of values per group and [Cortisol] 
compared with methylation at cg03546163 are shown below in 








Figure 42: [Cortisol] (nM) in sera extracted from Controls, FFI and sCJD patients. Cortisol was 
significantly elevated in sCJD patients compared to controls (+147.8 nM, p = 6.6x10-5). Significance 
threshold was set at p < 0.05. Asterisks denote significance  
(* = p< 0.05, ** = p< 0.01, *** = p<0.001). 
 
Figure 43: No correlation of methylation at cg03546163 (FKBP5) with [Cortisol] (nM) in 20 sCJD 






5.3 Measuring DNA methylation at DMPs in post-mortem brain-derived 
DNA from sCJD and control donors 
In some instances DNA is extracted from post-mortem brain, typically if the patient 
is too ill to have blood taken or if neuropathology differs from what is typically seen 
in sporadic CJD. Having described epigenetic changes in blood, I decided to test for 
the same changes in brain-derived DNA. A concordant signature would suggest that 
peripheral DNA methylation mirrors cortical DNA methylation, with obvious 
implications for the suitability of sites other than AIM2 (at which DNA 
hypomethylation correlates with increased disease severity) as peripheral 
biomarkers of sCJD. It would also open the possibility that altered DNA methylation 
may emerge from risk factors present in the germline that not detected in the sCJD 
GWAS, rather than be a product of the disease. Conversely, if DMPs are not 
observed in the brain then perhaps the signature observed is unique to the 
periphery, which suggests a second, non-central aspect to the disease and would 
prompt further investigation into the interplay between brain and blood in sCJD. 
 
This experiment comes with a number of caveats: firstly although DNA was taken 
from the same brain region (frontal cortex, a region susceptible to prion aggregation 
and deposition (Hill et al., 2003)), and same subregion by the same pathology team 
(Professor S. Brandner and Dr Z. Jaunmuktane), the tissue remains heterogeneous 
in terms of neuronal layers, subtypes and gray/white matter. As these samples are 
to be pyrosequenced at single loci these effects cannot be regressed out as per the 
original array study of blood as it was not possible to also pyrosequence the 
Houseman reference probes. Similarly, post mortem examination in CJD can be 
delayed related to patient locations around the UK. If delay in hours is known it can 
be adjusted for by including it as a covariate in a linear regression model (Wockner 
et al., 2014), but research using mouse, pig and human brain tissue has shown that 
DNA methylation levels remain stable more than 72 hours post mortem (Jarmasz et 
al., 2019). Conversely, final illnesses that result in death (eg. respiratory failure, 
sepsis etc.) could have profound influences on methylation profiles, unrelated to 
prion disease. Nevertheless, as an exploratory study of DNA methylation in 32 
control and 54 sCJD brain samples were profiled at replicated DMP sites using 
pyrosequencing. As seven genes were being assayed I continued to use a strict 
Bonferroni threshold of p < 0.007, albeit with the consideration that this experiment 
is limited by sample availability and potentially confounded by cellular heterogeneity, 




In FKBP5, significant hypomethylation of cg03546163 was not observed (-3.06%, p 
= 0.457), nor was hypomethylation of the downstream adjacent CpG (-1.84%, p = 
0.641). cg10636246 was not found to be differentially methylated in AIM2 (-3.72%, p 
= 0.439), similarly cg17515347 and a second downstream CpG showed no case-
control difference (-1.42%, p = 0.711; +0.11%, p = 0.976). 
None of the three sites at UHRF1 which showed nominally significant difference in 
sCJD blood were found to be similarly affected in the brain (-0.08%, p = 0.903; 
+0.54%, p = 0.747; 0.28, p = 0.699), nor was cg02481950 in METTL9 (+0.68%, p = 
0.426). Interestingly the second site in the PRNP assay for cg04286737 showed a 
nominally significant decrease in methylation (-9.38%, p = 0.054; -12.01%, p = 
0.021), although not after correction for multiple testing. These results are displayed 
below in Figure 44. 
ANK1 was also profiled as hypermethylation in the entorhinal and prefrontal cortex 
is associated with increase in Braak Staging in Alzheimer’s Disease (De Jager et 
al., 2014; Lunnon et al., 2014). The specific CpG, cg11823178, was not found to be 
differentially methylated (-0.14%, p = 0.929), but interestingly of the 4 adjacent 
CpGs one approached and one passed nominal significance but not after 
consideration of multiple testing (+1.96%, p = 0.056; +0.01%, p = 0.994; +3.42%, p 
= 0.04; +0.69%, p = 0.652). The effect sizes of these two sites are in the same 
direction of and of approximately similar magnitude to those observed in the cohorts 
studied by Lunnon et al. (London: +2.05%, Mt Sinai: +2.97%). Distribution of 




Figure 44: Methylation of control and sCJD brain-derived DNA as profiled in assays for replicated 
DMPs and PRNP. Bonferroni significance threshold was set at p < 0.007 and no sites reached 
significance, although two sites at PRNP trended towards significance (ΔM = -9.38%, p = 0.054; ΔM = 









Figure 45: Methylation of control and sCJD brain-derived DNA at cg11823178 (ANK1) and 4 adjacent 
sites. Bonferroni significance threshold was set at p < 0.007 and no sites reached significance, 
although two sites at 8:41,519,411 and 8:41,519,420 trended towards significance (ΔM = +1.96%, p = 
0.056; ΔM = +3.42%, p = 0.04). 
 
5.4 Determining cell-specific origin of differential methylation in whole 
blood from sCJD patients 
In most contexts blood cells are sorted using Fluorescence Assisted Cell Sorting 
(FACS), but due to health and safety issues connected to using blood derived from 
prion disease patients, FACS was not a viable option. Instead I opted to sort cells 
using Magnet Assisted Cell Sorting (MACS), which uses disposable columns and 
permits relatively rapid fractionation of leukocytes from fresh whole blood. 
5.4.1 MACS protocol optimisation 
Blood donated from two individuals was used to optimise MACS separation of B 
Cells, T Cells, Monocytes and Granulocytes. The first individual’s blood was 
collected into an EDTA vacutainer tubes before being separated after venepuncture 
and then again after being stored for 1 week at 4oC, while the second blood sample 
was collected into two vacutainers, separated after venepuncture, after storage at 
4oC for 3 days, and finally after 1 week of storage. As well as the effects of storage 
Page 140 
 
time on DNA yield, the effects of including the optional filtration and pellet/wash 
steps were tested for. During the first separation trial (Individual 1, Day 0) due to a 
procedural error the magnetic columns were not separated from the QuadroMACS 
separator before fraction elution of the no filter/no wash and filter/no wash samples, 
meaning cells were retained in the column matrix and were discarded along with the 
columns. This is reflected in Table 24 and Figure 46, which detail yields of DNA per 
ml of input blood. 
 
  DNA/1ml input (ng/µl) 
Individual Day NFNW FNW NFW FW 
1 0 0 0 650 610 
1 7 450 650 675 590 
1 0 325 242.5 635 840 
2 3 292.5 282.5 585 600 
2 7 248 482 570 510 
AVG 
 
328.875 414.25 623 630 
 
Table 24: Comparing the performance of MACS protocols. Shown are yields of DNA (ng/µl) from 1 ml 
of whole blood from two individuals across four separation methods (NFNW = No Filter & No Wash; 
FNW = Filter & No Wash; NFW = No Filter & Wash; FW = Filter & Wash). 
 
 
Figure 46: Comparison of MACS method efficiency per method and days between venepuncture and 
separation. NFNW = No Filter & No Wash; FNW = Filter & No Wash; NFW = No Filter & Wash; FW = 

































The wash steps appeared to have the greatest effect in terms of increased DNA 
yield, perhaps as resuspension of cells in separation buffer may improve retention 
of labelled cells in the column matrix. The effect of filtration may be negligible in the 
samples studied but was included in subsequent separations as filtration is 
recommended by the manufacturer as it reduces the presence of cell aggregates. 
As such all subsequent samples were pre-filtered and pelleted and resuspended in 
separation buffer after microbead annealing. 
5.4.2 Pyrosequencing of AIM2 and FKBP5 in sorted cell fractions 
The average of control sample methylation values per fraction were subtracted from 
each of six sCJD patient blood samples to produce % change in methylation 
compared to the control group. These were compared via one-way ANOVA with a 
post-hoc Dunnett t-test, where whole blood values were designated as controls and 
expected effect direction was negative, as both targets are hypomethylated in sCJD 
blood compared to control. The threshold for significance was p < 0.05. 
The assay targeting cg17515347 (AIM2) was applied to separated blood fractions 
and ANOVA significance was 0.017. The post hoc Dunnett test showed no 
significant effect in T cells (+5.76%, p = 0.977), monocytes (-1.73%, p = 0.68) or B 
cells (+0.97%, p = 0.845), but a nominally significant effect was seen in neutrophils 
(-14.6%, p = 0.029). The second downstream CpG captured by the assay also 
showed nominal ANOVA significance (p = 0.013) and, as before, no post-hoc effect 
in T cells (+6.99%, p = 0.987), monocytes (-1.86%, p = 0.673) or B cells (+2.84%, p 
= 0.916), while the effect compared to that in whole blood was nominally significant 
for neutrophils (-14.13%, p = 0.037). The differences between means per fraction 





Figure 47: DNA methylation in separated sCJD and control blood fractions at the AIM2 probe 
cg17515347 and a CpG 14 nucleotides downstream. Changes in Neutrophils compared to Whole 
Blood (WB) were statistically significant at both sites (ΔM = -14.6%, p = 0.029; ΔM = -14.13%, p = 
0.037). Asterisks denote significance (* = p< 0.05, ** = p< 0.01, *** = p<0.001). 
 
Conversely, ANOVA for both positions captured in the assay for FKBP5, 
cg03546163 and a CpG 4 nucleotides upstream, did not pass nominal significance 
(p = 0.400, p = 0.182). Nevertheless, post-hoc tests were conducted and as 
expected, effects significantly different to those observed in whole blood were not 
found at either position in T cells (+2.43%, p = 0.937; +4.72%, p = 0.956), 
monocytes (-0.94%, p = 0.721; -6.61%, p = 0.376), B cells (-5.52%, p = 0.260; -
10.36%, p = 0.173), or neutrophils (+1.08%, p = 0.871; -3.22%, p = 0.616). 






Figure 48: DNA methylation in separated sCJD and control blood fractions at a CpG 14 nucleotides 
upstream of cg03546163 and at the probe target itself. There was no statistically significant change in 
any enriched leukocyte fraction compared to Whole Blood (WB) 
 
While not nominally significant, B Cell fraction mean difference is markedly greater 
than the effect observed in whole blood in the FKBP5 assay. However, also of note 
is the potentially decreased separation between sCJD and control values observed 
in the T Cell fraction in both FKBP5 and AIM2 assays. Ultimately, this experiment is 
extremely limited in terms of N, and further recruitment of patient and control 
samples may be necessary to power the assays for changes specific to different cell 
fractions. 
5.5 Summary 
The observation of elevated serum cortisol (albeit partially within a normal 10am-
4pm circadian range) in sCJD lends further weight to the connection between 
FKBP5 dysregulation and sCJD. Cortisol is an anti-inflammatory agent and a 
chemical messenger connecting the brain with the periphery: dysregulation of 
cortisol metabolism has exciting implications in sCJD which will be discussed later 
in the thesis.  
While the MACS experiment outcome is extremely preliminary, it is surprising that 
the cell lines inferred to carry more sizable differential methylation by eFORGE were 
not observed to be markedly affected compared to other cell lines. Sadly limitations 
Page 144 
 
in this experiment make it difficult to draw firm conclusions, but the roles of B cells 
and granulocytes may be worth considering when trying to frame other data in a 
physiological context. 
Finally, failing to detect differential methylation in sites affected in sCJD blood in 
brain-derived DNA raises several questions and potentially the exciting prospect of 
a new dimension to sCJD pathology. Taken in tandem with the suggestion of 
cortisol dysmetabolism and the connection between AIM2 hypomethylation and 
disease severity, connections can be drawn which will be discussed later in the 
thesis. 
Having further investigated the physiology of sCJD epigenetics based on the 
replication stage of the project, I decided to return once more to the 450K data to 
see if, as well as be useful in prognosis of sCJD in the case of cg10636246 (AIM2), 


















6 Classifying sporadic CJD status using 450K array data and 
machine learning  
6.1 Machine Learning classification 
While the linear regression models used in previous chapters are also examples of 
machine learning, classification is a commonly encountered form of supervised 
learning. Whether it be social media algorithms trained to recognise faces in 
photographs, targeted advertising or domestic appliances such as Amazon’s Alexa, 
much effort has been dedicated to developing ways of training models to make 
decisions based on complex and multifactorial input data. Clinically, this approach 
has been enormously successful in oncology, where machine learning has been 
demonstrated to estimate susceptibility, prognosis and recurrence likelihood with 
high accuracy using a variety of data types across a range of cancer types (Cruz 
and Wishart, 2006; Exarchos et al., 2014). Using 450K array data it is possible to 
train a model to classify disease/control status; although aspects of model design 
must be carefully considered in relation to data type and complexity between 
groups. 
6.1.1 Trees or neurons? 
Two popular classifier models are the Random Forest and Neural Network models. 
Random Forest models operate by building a “forest” of randomly generated 
decision trees which make classification decisions based on different combinations 
of input data (Ho, 1995; Breiman, 2001). Unlike a standard decision tree, by using 
the mode of the forest’s classification decisions to make a final classification 
Random Forests can make decisions in situations where some input data are 
missing or novel, unseen data is included.  
Gradient Boosted Machine learning (GBM) is similar to Random Forest (RF) 
classification, but where RF classification builds a model from a “forest” of 
independent decision trees which are considered in parallel, GBM generates its 
decision trees sequentially, with each tree’s design informed by the usefulness of 
predictor variables in previous trees. These training differences between models are 




Figure 49: Random Forest (upper) and Gradient Boosted Machine (lower) models. Random Forest 
models pass data to randomly generated decision trees, their output in parallel is then used to classify 
phenotype based on a function such as modal averaging. Gradient Boosted Machine models generate 
decision trees sequentially based on the performance of previous trees, the best performing of which is 
used to classify phenotype. 
 
Neural Networks are loosely analogous to biological neuronal networks as they are 
composed of layers of “neurons”. Input data can trigger activation of different 
combinations of input neurons which connect to output neurons via a user-defined 
number of hidden layers, between all of which are connections weighted during 
model training. In this way activation thresholds of each neuron are adjusted so that 
complex, low variance datasets can be classified. A simplified schematic of a neural 





Figure 50: Simplified neural network. Input data (probes) can trigger activation of input neurons, which 
will then transmit a signal to hidden layers of neurons based on weighted connection thresholds, which 
are adjusted during model training. Signal from the hidden layers is passed to the output layer and 
phenotype is classified. 
 
Neural Networks typically require greater computational power and training and 
prediction runtimes than Random Forest models but are capable of superior 
classification accuracy when data variance between classes is subtle. However, 
Neural Networks are more sensitive to bias and prone to overfitting errors, for 
example when training datasets are limited. In this context, Random Forests are 
bias-resistant and tend towards superior accuracy (Han et al., 2018). 
Differences between sCJD and control in 450K array data are indeed relatively 
subtle as the greatest significant mean change with phenotype is -5.35%, 
suggesting a Neural Network approach may be suitable. However, the dataset is 
limited in terms of sample number and only 38 probes passed genome-wide 
significance, which in turn suggests it may be appropriate to train a Random Forest 
model. I therefore decided to test a combination of models and datasets to explore 
the effects changes in model design would have on accuracy of classification.    
6.1.2 Feature Selection 
423,742 probes are available in our 450K array dataset, but to train the model using 
all these data would be both computationally expensive and result in the inclusion of 
many redundant, insignificant and false positive variables. Random Forests require 
model features to be defined before model training, which can be achieved in 
several ways. The most obvious is to only include probes which exhibit genome-
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wide significant differences between phenotypes. However, there may be probes 
which are different between sCJD and control groups but fail to pass significance 
thresholds due to, for example, the heterogeneity of the disease or the limited 
number of samples studied. A second approach, therefore, is to include genome-
wide insignificant probes based on unadjusted p or magnitude of change. As p is a 
proxy indicator of interquartile range separation between groups, selection of probes 
for inclusion based on unadjusted p may be more likely to include probes with 
diagnostically useful yet sub-genome wide significant variance between sCJD and 
control. 
Good practice, particularly when working with extremely large datasets, is to remove 
data which correlate. For example, cg10636246 and cg17515347 are both located 
in AIM2 and methylation values at both probes are correlated (Pearson’s coefficient 
= 0.737, p = 8.78x10-39). Due to this high degree of correlation these probes may be 
redundant: methylation values at cg10636246 provide as much useful variance 
between phenotypes as both probes combined. While one additional probe might 
not cause much of a problem, many redundant probes would reduce the efficiency 
and increase the runtime of the model, so highly correlating probes should be 
excluded from the dataset.  
When classifying groups based on data with known associations (e.g. classifying 
sex using age and height data) manual feature selection may be justified. In the 
absence of prior associations or hypotheses, exactly which probes to include in the 
model to provide optimum accuracy can be determined by Recursive Feature 
Elimination (RFE). This process begins by training the model with all features – in 
this case probes – present, before iteratively removing a user-defined number of 
features at random and then retraining and testing the model’s performance. This 
continues until an optimum minimum number of probes is reached. To enable a 
training/testing cycle, the training data is typically split into a user-defined number of 
“folds”. For example, in 10-fold RFE the training data is split into deciles, and each 
decile is sequentially used to test models built from the remaining 9 folds. As RFE’s 
iterative feature removal process is random, each cycle is repeated several times 
(the number of which is again defined by the user), which serves to reduce bias. In 
summary, the number of probes to remove per iteration, the number of permutations 
of training/testing data to use, and the number of times RFE should be repeated per 
permutation can all be defined by the user, allowing for stringent yet computationally 
expensive feature selection or less granular and computationally faster feature 
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To test the effect of different feature selection approaches, features were selected 
from the following combinations of input data: 
1. 38 genome-wide significant DMPs 
2. Features selected from 500 probes ranked by P value after removal of 
correlated probes and 10-fold 10-repeat RFE removing 1 probe per iteration 
3. Features selected from 5000 probes ranked by P value without further 
feature selection  
An important note is that these processes rely on random number generators 
(RNGs) which, while themselves are random, can be “seeded” to provide the same 
series of random numbers in future experiments for the sake of repeatability and 
reproducibility. The RNG seed for all models was set as 4444. 
Figure 51: Model of 10-fold 10-repeat crossvalidation. Crossvalidation of model training and tuning 
involves the division of individuals in the training set into 10 groups, or “folds”. 9 folds (grey) are used 
to train a model which is tested on the remaining fold (green). This random training process is repeated 
10 times, before the second fold is used for testing models built on the remaining 9 folds, which is 
again repeated 10 times. This continues until all folds have been used for model testing. 
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6.2 Relevant Methods and Sample Demographics 
2.1.1 Sample Selection (page 54) 
2.2.2 Case-Control Study Using ChAMP (page 61) 
2.2.8 Machine Learning Classification of 450K Dataset (page 64) 
2.7 Statistics and Graphics (page 72) 
 
Group Number Average Age (range) Sex (% F) 






sCJD 114 68.0 (49-85) 50.9 46:23:32 6 (0-20) 
Control 105 69.0 (41-83) 55.7 Unknown 20 
 
Table 25: Demographics of patients and controls whose 450K Beadchip Array data were used to train 
disease classification models. 
 
6.3 Gradient Boosted Machine classification 
6.3.1 Gradient Boosted Machine classification using 38 genome-wide 
significant DMPs 
Beta values from the genome-wide significant DMPs per individual, age and sex 
were used as predictor variables. Individuals were partitioned into a training set 
(75%) of 165 and a testing set (25%) of 54, and the first set was used to train a 
GBM model with 10-fold 10-repeat cross-validation. 50,100 and 150 trees (boosting 
iterations) were constructed with between 1 and 3 decision nodes (tree depth). 
Model accuracy across the training process did not vary appreciably across training 
parameters, as graphically represented in Figure 52. 
A confusion matrix, principle component analysis (PCA) and model report were 
generated: model accuracy as measured by Receiver Operating Characteristic 
(ROC) was found to be 81.48% versus a No Information Rate of 51.85% (p = 
5.869x10-6). Sensitivity was 76.92% and specificity was 85.71%. PCA found that 28 
variables could explain 95% of total variance. The confusion matrix, which indicates 
true (reference) versus model (prediction) classification, is displayed below in Table 
26 where true positive and negative predictions are shown in lower right and upper 
left cells, while false positive and false negative predictions are shown in lower left 
and upper right cells, respectively. Positive Predictive Value (PPV) and Negative 
Predictive Value (NPV) was 85.7% and 83.3% respectively, calculated by dividing 
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true positive and true negative predictions by total positive and negative predictions 
respectively. 
 Reference 
Prediction Control sCJD 
Control 20 4 
sCJD 6 24 
 
Table 26: Confusion matrix of untuned gbm model classification of sCJD status using 38 DMPs, age 





Simple models such as this can be improved through tuning. This is achieved by 
adjusting model parameters to improve the fit and can be technically challenging 
and lead to model overfitting. In this instance the two major parameters as shown 
above in Figure 52 are number of boosting iterations and tree depth. A more 
complex model might perform better or worse, depending on the complexity of the 
data, so I decided to increase iterations to 250 in incrementations of 50 iterations, 
and increase tree depth to 5. Once again, the model was trained using 10-repeat 
Figure 52: Accuracy of gbm model trained using DMPs as measured by ROC. Shown are values across a number 
of boosting iterations (number of trees sequentially generated) and tree depth, where tree depth is the number 
of nodes between the root node and decision nodes. 
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10-fold cross-validation and a depth of 1 with 50 boosting iterations were selected. 
Interestingly the tuned model had decreased accuracy of 74.07% (p = 7.006x10-4), 
and although sensitivity was improved (80.77%), specificity had decreased 
(67.86%). The confusion matrix and model accuracy across tuning are displayed 
below in Table 27 and Figure 53 respectively. Positive Predictive Value (PPV) and 
Negative Predictive Value (NPV) was 79.6% and 80.7% respectively, calculated by 




Prediction Control sCJD 
Control 21 9 
sCJD 5 19 
 
Table 27: Confusion matrix of tuned GBM model classification of sCJD status using 38 DMPs, age and 
sex as predictor variables. 
 
 
Figure 53: Accuracy of gbm model trained using DMPs after tuning as measured by ROC. Shown are values 
across a number of boosting iterations (number of trees sequentially generated) and tree depth, where tree 
depth is the number of nodes between the root node and decision nodes. 
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This model was trained using manual feature selection (38 DMPs). Next, I decided 
to select features from the top 500 most significantly ranked probes using RFE. 
6.3.2 Gradient Boosted Machine classification using 33 probes identified by 
Recursive Feature Elimination 
In the top 500 probes, 28 probes were found to have Pearson’s correlations 
exceeding 0.75 and were removed. The remaining 472 probes were processed 
using RFE with 10-repeat 10-fold cross-validation. As elimination iterations removed 
one probe per turn this was a computationally demanding process which took two 
days to complete, after which 33 probes were selected for training (displayed below 
in Table 28).  
Using the same training/testing partitions as before, a gbm model was trained using 
10-repeat 10-fold cross-validation. Again, model accuracy across the training 
process and final variable weights were extracted and are graphically represented in 
Figure 54. 
A confusion matrix, principle component analysis (PCA) and model report were 
generated: on classification of the testing set model accuracy was found to be 
79.63% versus a No Information Rate of 51.85% (p = 2.263x10-5). Sensitivity was 
84.62% and specificity was 75.00%. PCA found that 29 variables could explain 95% 
of total variance. The confusion matrix, which indicates true/false positive/negative 
classification, is displayed below in Table 29. Positive Predictive Value (PPV) and 
Negative Predictive Value (NPV) was 75% and 84.6% respectively, calculated by 











Probe Gene Location Feature 
cg05948372 ABHD3 Body N_Shore 
cg20003976 ACADM TSS1500 N_Shore 
cg15691252 ADK;AP3M1 TSS1500;5'UTR N_Shore 
cg10636246 AIM2 TSS1500   
cg17515347 AIM2 TSS1500   
cg02243276 AZIN1 5'UTR N_Shelf 
cg04057956 CD9 Body   
cg13599258 CUX2 Body   
cg04137490 DOCK5 Body   
cg00052684 FKBP5 5'UTR N_Shore 
cg03546163 FKBP5 5'UTR N_Shore 
cg25114611 FKBP5;LOC285847 TSS1500;Body S_Shore 
cg18023065 FUT4 1stExon Island 
cg19382697 GNG7 5'UTR S_Shore 
cg14195992 KIAA0146 Body   
cg05336268 KIAA0556 Body   
cg13696490 LOC201651 TSS1500   
cg05218245 LY6G6D Body   
cg02481950 METTL9;IGSF6 Body;TSS1500   
cg20290360 NFASC Body   
cg03891318 NMNAT3 5'UTR   
cg17163138 PIN1 Body S_Shelf 
cg03071209 THADA TSS200 Island 
cg17714703 UHRF1 Body S_Shore 
cg21643513 ZNF547;TRAPPC2P1 TSS1500;TSS1500 N_Shore 
cg05740793 MTRNR2L8  TSS1500   
cg04590451     S_Shore 
cg11227822     Island 
cg12992827       
cg09964921       
cg10972973     N_Shore 
cg25771026       
cg14427590       
 









Prediction Control sCJD 
Control 22 7 
sCJD 4 21 
 
Table 29: Confusion matrix of untuned gbm model classification of sCJD status using 33 probes 




Interestingly this model performs slightly worse overall than one trained using the 
DMPs. To test whether the performance could be improved by training a more 
complex model, I performed the same tuning process as before of increasing 
boosting iterations to 250 in incrementations of 50 iterations and increasing tree 
depth to 5. Once again, the model was trained using 10-repeat 10-fold cross-
validation and a depth of 5 with 150 boosting iterations were selected. After tuning 
model accuracy was found to be 87.04% versus a No Information Rate of 51.85% (p 
= 4.922x10-8), while sensitivity was 88.46% and specificity was 85.71%. The 
confusion matrix is displayed below in Table 30, and model accuracy over the 
tuning process are displayed in Figure 55. Positive Predictive Value (PPV) and 
Figure 54: Accuracy of gbm model trained using 33 RFE-identified probes as measured by ROC. Shown are values 
across a number of boosting iterations (number of trees sequentially generated) and tree depth, where tree 
depth is the number of nodes between the root node and decision nodes. 
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Negative Predictive Value (NPV) was 85.7% and 88.5% respectively, calculated by 
dividing true positive and true negative predictions by total positive and negative 
predictions respectively. 
 Reference 
Prediction Control sCJD 
Control 23 4 
sCJD 3 24 
 
Table 30: Confusion matrix of tuned gbm model classification of sCJD status using 33 probes selected 
from the 500 most significantly altered between sCJD and control, age and sex as predictor variables. 
 
 
Encouragingly accuracy after tuning was superior to any of the previous three 
models. However, 33 and 38 probes are very small fractions of the total number of 
array probes, and it is possible that large numbers of small effects at less 
significantly ranked probes may still prove useful predictors. Thus, the final dataset - 
the top 5,000 probes ranked by significance - was run through the same pipeline. 
 
Figure 55: Accuracy of tuned gbm model trained using 33 RFE-identified probes as measured by ROC. Shown are 
values across a number of boosting iterations (number of trees sequentially generated) and tree depth, where 
tree depth is the number of nodes between the root node and decision nodes. 
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6.3.3 Gradient Boosted Machine classification using 5,000 probes as ranked 
by genome-wide significance 
The top 5000 most differentially methylated probes, ranked by significance, were 
used to train a third model. This model performed poorly with an accuracy of 
65.38% (p = 0.018), a sensitivity of 80.77% and a specificity of 50.00%. PCA 
required only 127 variables to explain 95% of the variance. The confusion matrix of 
classification efficacy is presented below in Table 31 and model accuracies over the 
training process are displayed in Figure 56. Positive Predictive Value (PPV) and 
Negative Predictive Value (NPV) was 50% and 80.8% respectively, calculated by 







Prediction Control sCJD 
Control 21 13 
sCJD 5 13 
 
Table 31: Confusion matrix of GBM model classification of sCJD status using 5000 probes most 







Figure 56: Accuracy of model trained using the 5000 most differentially methylated probes (as ranked 
by significance) as measured by ROC. Values are shown across a number of boosting iterations 
(number of trees sequentially generated) and tree depth, where tree depth is the number of nodes 
between the root node and decision nodes. 
 
I attempted to tune the model in the same manner as the previous two, but after 48 
hours the process was still running so, given the model’s poor performance at the 
outset, tuning was abandoned. 
 
6.4 Averaged Neural Network classification 
6.4.1 Averaged Neural Network classification using 38 genome-wide 
significant DMPs 
An averaged neural network was trained using this dataset with tuning parameters 
set as the number of hidden neuronal layers and weight decay value. Weight decay 
is a number approaching 1 serving as a function by which weights are adjusted after 
each training iteration to prevent them from growing too large. Tuning results set 
optimum parameters as 8 layers and a weight decay value of 0; accuracy across 




Figure 57: Accuracy of tuned avNNet model trained using 38 DMPs as measured by ROC. Values are 
shown across a number of hidden neuronal layers and weight decay. At 10 hidden units the model 
fails, as this number of hidden neuronal layers cannot be supported by only 38 variables. 
  
The model was then used to classify the testing set and a confusion matrix was 
generated, displayed below in Table 32. The model’s accuracy was 77.78% versus 
a No Information Rate of 51.85% (p = 7.839x10-5), with sensitivity of 76.92% and 
specificity of 78.57%. Positive Predictive Value (PPV) and Negative Predictive 
Value (NPV) was 78.5% and 76.9% respectively, calculated by dividing true positive 
and true negative predictions by total positive and negative predictions respectively. 
 
 Reference 
Prediction Control sCJD 
Control 20 6 
sCJD 6 22 
 
Table 32: Confusion matrix of tuned averaged Neural Network model classification of sCJD status 




6.4.2 Averaged Neural Network classification using 33 probes identified by 
Recursive Feature Elimination 
Using the dataset of 33 probes selected by RFE, a model was tuned in an identical 
way. Here parameters were again optimised to 8 layers and a weight decay value of 
0, but the model’s accuracy was increased to 81.48% (p = 5.869x10-6), sensitivity 
increased to 84.62% while specificity remained the same as before at 75.87%. The 
confusion matrix and model accuracies over the training process are displayed 
below in Figure 58 and Table 33 respectively. Positive Predictive Value (PPV) and 
Negative Predictive Value (NPV) were 78.6 and 84.6% respectively, calculated by 




Figure 58: Accuracy of tuned avNNet model trained using 33 RFE-identified probes as measured by 
ROC. Values are shown across a number of hidden neuronal layers and weight decay. At 10 hidden 










Prediction Control sCJD 
Control 22 6 
sCJD 4 22 
 
Table 33: Confusion matrix of tuned avNNet model classification of sCJD status trained using 33 
probes identified using RFE from the top 500 probes ranked by significance. 
 
6.4.3 Averaged Neural Network classification using top 5000 probes as 
ranked by significance 
I attempted to tune a neural network model using the third dataset, but as with the 
GBM model tuning runtime exceeded 48 hours, and so this attempt was 
abandoned. 
 
6.5 Putting it all together: Stacking models using generalised linear 
regression 
6.5.1 General Linear Model using 33 probes identified by Recursive Feature 
Elimination 
As the previous sections illustrate, model performance (and thus utility) depend not 
only on the data used to train them, but also the type of model used, and the 
parameters used to tune it. In this final section the performance of five different 
models will be compared and then unified using a generalised linear model (GLM) 
to provide a meta-model, which in principle should perform at least as well as any of 
the models produced so far. 
The RFE-identified dataset of 33 probes, having produced the best model so far, 
was used to train models using five models: a random forest model (ranger), a 
gradient boosted model (gbm), a multivariate adaptive regression splines model 
(earth), a support vector machine model (svmRadial), and a neural network model 
(avNNet). Once again, model training was executed using 10-fold 10-repeat cross-
validation, and performance metrics were exported. In terms of mean accuracy 
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ranger performed the best (94.75%). Gbm was the most sensitive (83.61%) while 
the most specific model was ranger (89.64%). Accuracy, sensitivity and specificity of 
these models are displayed in Figure 59. 
 
 
Figure 59: Accuracy (ROC), sensitivity and specificity of models trained using 33 RFE-selected probes. 
 
A generalised linear model was then constructed using these models and used to 
classify the test dataset, again using 10-fold 10-repeat cross-validation. Accuracy 
was 87.04% (p = 7.839x10-5), sensitivity was 82.14% and specificity was 92.31%. 
The confusion matrix is presented below as Table 34. Positive Predictive Value 
(PPV) and Negative Predictive Value (NPV) was 82.1% and 92.3% respectively, 
calculated by dividing true positive and true negative predictions by total positive 









Prediction Control sCJD 
Control 24 5 
sCJD 2 23 
 
Table 34: Confusion matrix of generalised linear model classification of sCJD status using five models 
trained with 33 probes selected using RFE from the top 500 probes ranked by significance 
 
6.5.2 General Linear Model using 38 DMPs  
For the sake of comparison, I trained a second series of models in the same way 
using the 38 DMPs dataset. Once again, ranger provided best mean accuracy 
(86.00%), gbm was the most sensitive (74.30%) and ranger was most specific 
(81.00%). Model accuracies during the training process are displayed in Figure 60. 
 
Figure 60: Accuracy (ROC), sensitivity and specificity of models trained using 38 DMPs. 
 
 Noting that these models overall seemed to perform less well than those trained 
with the RFE-selected probes, I once again constructed a GLM from the models 
which could classify with an accuracy of 77.78%, a sensitivity of 73.08%, and a 
specificity of 82.14%. The confusion matrix is displayed below in Table 35. Positive 
Predictive Value (PPV) and Negative Predictive Value (NPV) was 82.1% and 73.1% 
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respectively, calculated by dividing true positive and true negative predictions by 
total positive and negative predictions respectively. 
 
 Reference 
Prediction Control sCJD 
Control 19 5 
sCJD 7 23 
 
Table 35: Confusion matrix of generalised linear model classification of sCJD status using five models 
trained with 38 DMPs. 
 
6.6 Summarising suitability of different datasets and different modelling 
approaches to machine learning classification of sCJD status 
Overall, I found that the top 5000 probes were least suitable for classification, 
possibly due to insufficiently significant differences between sCJD and control 
groups. The list of 38 DMPs performed well in models that did not require tuning, 
but the 33 probes selected by RFE outperformed any dataset when model tuning 
was part of the pipeline. Had RFE been been performed earlier in the course of the 
project, it would have been interesting to see whether using unsupervised variable 
selection to choose candidates for replication yields a higher successful replication 
rate than manual selection based on p-values, effect sizes and potential biological 
relevance. Interestingly the generalised linear model combination of five different 
models produced the joint greatest accuracy, providing increased specificity but 
decreased sensitivity compared to a tuned GBM model alone. The summary 
statistics per model and dataset are compared in Table 36 and ROC area under the 
curve values per predictor for the tuned 33-RFE identified variable-trained GBM 
model are displayed below in Figure 61. It should be noted that while ROC AUC 
values seem extremely high (in one instance 100%) in this plot, these values relate 
to the classification efficiency during cross-validation of the training set rather than 



















gbm 38 DMPs 81.48 76.92 85.71 74.07 67.86 80.77 
gbm 33 probes 79.63 84.62 75.00 87.04 88.46 85.71 
gbm 
5000 
probes 65.38 80.77 50.00       
avNNet 38 DMPs       77.78 76.92 78.57 
avNNet 33 probes       81.48 84.62 78.57 
avNNet 
5000 
probes             
GLM 33 probes 87.04 92.31 82.14       
GLM 38 DMPs 77.78 73.08 82.14    
 
Table 36: Comparison of summary statistics of models trained using different datasets. Shown are 
performance metrics of gradient boosted machine (gbm), averaged neural network (avNNet) and 
generalised linear models (GLMs) after training and tuning. The 5000 probe dataset and GLMs could 
not be tuned, and avNNet model parameters were tuned as part of training. 
 
 
Figure 61: Density plot of area under the curve of receiver-operator characteristic per variable identified using 








In this project I initially profiled genome-wide DNA methylation in 114 sCJD patients 
and 105 non-cognitively impaired controls. A case-control comparison using a linear 
regression model, with age and sex included as covariates, identified 38 loci that 
were significantly differentially methylated between the two groups. Interestingly, 
loss of DNA methylation at one of these loci (AIM2, cg10636246) correlated with 
disease severity in sCJD patients only, as measured by the MRC Scale score. 
Using a tiling approach, I also identified 42 regions across which DNA methylation 
was significantly altered.  
Of these 38 differentially methylated positions (DMPs), I chose 8 to take forward for 
replication based on the size of mean difference between sCJD and control groups, 
and the biological role of underlying genes. Although assays could only be designed 
for 7 loci, 5 were found to replicate in a second cohort of 72 sCJD patients and 114 
controls. In addition, using pyrosequencing for the replication stage allowed 
interrogation of adjacent CpG sites, revealing 5 additional sites which were 
significantly altered in sCJD. The association of hypomethylation of cg10636246 (in 
AIM2) with disease severity was also observed in this second cohort of sCJD 
patients 
Having confirmed 5 out of seven array-profiled differentially methylated CpG loci 
and discovered 5 additional loci, I then tested the specificity of these changes to 
sCJD by repeating the DMP assays using samples derived from Alzheimer’s 
disease, inherited prion disease and iatrogenic prion disease. Although some 
assays were underpowered (cg02481950 (METTL9) for iCJD and IPD, cg17515347 
(AIM2) for iCJD and IPD, cg03546163 (FKBP5) for IPD), none of the changes 
observed in sCJD were found in other disease groups suggesting that the observed 
changes are either specific to sCJD rather than to prion disease or 
neurodegeneration in general. 
One of the most interesting findings was a decrease in DNA methylation upstream 
of the transcription start site of FKBP5. This gene plays a role in supressing cellular 
response to cortisol, leading me to wonder whether circulating cortisol levels are 
affected in sCJD patients. I curated a group of serum samples from sCJD patients 
and controls and sent them to The Doctor’s Laboratory for cortisol profiling. Cortisol 
was indeed elevated in sCJD patients within and above the 10am-4pm range (which 
Page 167 
 
is when most samples would have been taken) compared to controls, although 
cortisol concentration did not correlate with FKBP5 methylation levels in patients 
profiled on the array where serum was also available. Because cortisol levels vary 
according to a circadian pattern, it is perhaps not surprising that blood-derived DNA 
methylation at FKBP5 does not correlate with cortisol concentration in sCJD 
patients: if blood for DNA extraction and blood for serum fractionation were taken at 
the same time for each patient a correlation might be revealed. Similarly, taking 
blood for serum fractionation from patients and controls at a fixed time of day would 
reduce the effects of the circadian pattern and may result in a larger separation of 
mean concentrations between the groups. 
I then addressed the question of where the difference in DNA methylation was 
coming from. First, to test whether the signature observed in the blood was 
reflective of a signal in the central nervous system, I repeated the pyrosequencing 
assays on DNA samples derived from frontal cortex of sCJD patients and non-
demented individuals. Strikingly, while none of the effects observed in the blood 
were found in the brain, sites both in ANK1 and PRNP were found to be significantly 
differentially methylated in sCJD. While in blood ANK1 methylation does not differ 
between sCJD and control, ANK1 hypermethylation has been repeatedly observed 
in Alzheimer’s disease cortex (De Jager et al., 2014; Lunnon et al., 2014) and 
observing it in sCJD suggests it is involved in neurodegeneration, in line with recent 
findings in Huntington’s disease and Parkinson’s disease (Smith et al., 2019). PRNP 
has an obvious role in sCJD and so observed hypomethylation upstream of PRNP 
in sCJD cortex is an intriguing discovery. However, PRNP mRNA has been reported 
to be decreased in sCJD cortex (Llorens et al., 2013), which, if both findings are 
correct, runs counter to the convention of demethylation of the 5’-UTR leading to 
upregulation. Wider profiling of PRNP methylation in brain-derived DNA may 
provide an explanation.  
Having found no evidence of the peripheral signal being reflective of changes in the 
brain, I then decided to investigate the cellular origin of the signal by assaying blood 
fractions enriched for certain lineages of leukocytes. Sample numbers were 
extremely limited, so only assays targeting FKBP5 and AIM2 were performed. While 
all fractions showed hypomethylation in sCJD compared to control, these changes 




Finally, I trained several machine learning models to classify sCJD/control status 
using 450K array data, testing the accuracy of each model using different 
configurations of input data and then tuning parameters to increase accuracy. Using 
recursive feature elimination, I identified a set of 33 array probes which could be 
used to predict phenotype with greater accuracy than the 38 significant findings. 
Using an optimised random forest model, I could classify patient/control status with 
an accuracy of 87.04%. 
7.2 Genome-wide investigation revealed site-specific differences in 
methylation of blood-derived DNA from sCJD patients  
38 DMPs were identified using a linear regression model with age and sex as 
covariates, and with Bonferroni correction for multiple testing. While statistically 
stringent, to have confidence that the genome-wide loci identified as differentially 
methylated were not false positive results it was important to replicate the 
experiment using a second set of patient/control samples and a second technology. 
Regrettably there was only scope to reassess a fraction of the 38 DMPs, which 
were selected based on whether the CpG was in the promoter of a gene, the 
biological role of that gene’s product, the effect size between sCJD and control at 
that CpG, and association with clinical metrics of disease severity. The expanded 
rationale for selecting each of the CpGs is detailed below. 
7.3 Possible relevance of differentially-methylated genes to sCJD 
7.3.1 AIM2: cg10636246 and cg17515347 
AIM2 is an acronym for Absent in Melanoma 2, despite this gene being highly 
expressed in primary melanoma (De Koning et al., 2014). AIM2 is one of several 
pattern recognition receptors (PRRs) which identify molecular signatures of infection 
or cell damage and form cytokine-mobilising inflammasomes. In particular, AIM2 
nucleates and encourages inflammasome assembly on binding to cytosolic double-
stranded DNA (Hornung et al., 2009), or spontaneously when upregulated, by 
interferons for example (Veeranki et al., 2011). PRRs are complexes composed of a 
PRR, procaspase-1 and ASC, although some PRRs such as NLRC4 and NLRP1 
can form inflammasomes without ASC (Latz, Ts and Stutz, 2013). ASC is a prion-
like protein (Cai et al., 2014) which forms complexes of dimers referred to as ASC 
specks, through which it brings procaspase-1 monomers together allowing trans-
hydrolysis and release of caspase-1 (Dick et al., 2016). Caspase-1 is responsible 
for interleukin-1β production and its sustained activation can lead to apoptosis 
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(Pablo et al., 2009). A model of AIM2 inflammasome activation is shown below in 
Figure 62.  
Aim2 is the most highly expressed PRR in murine neuronal culture (Wu et al., 
2016), and its ablation has been found to reduce brain injury in response to 
ischemia (Denes et al., 2015). In culture Aim2 promotes axonal but inhibits dendritic 
growth, and deletion in mice promotes anxious behaviour such as hugging corners 
of boxes and increased passing of urine and stools (Wu et al., 2016). This gene 
therefore appears to have a neurotrophic role with regards to its capacity for 
inflammation, but also functions as a mediator of psychological stress. Indeed, in 
humans a study of post-traumatic stress disorder (PTSD) found that serum C-
reactive protein, a biomarker of peripheral inflammation, was elevated in US 
veterans suffering from PTSD and that this increase and PTSD diagnosis both 
significantly associated with demethylation of blood-derived DNA at cg10636246 in 





Figure 62: A model of AIM2 inflammasome formation. Shown is AIM2 oligomerisation leading to ASC 
filament nucleation, recruitment of procaspase-1 dimers and release of caspase-1. Although in this 
figure AIM2 hexamers form around cytosolic double-stranded DNA, with increased expression an 
increased expression an increased basal oligomerisation rate becomes sufficient for inflammasome 






Prion disease has a strong inflammatory component associated with microgliosis 
and apoptosis of neurons (Aguzzi, Barres and Bennett, 2013). Implication of AIM2 in 
sCJD is therefore interesting, particularly as two probes in the transcription start site 
of the gene are affected, one of which (cg1036246) has been associated with 
peripheral inflammation in the literature. Association of hypomethylation at these 
probes with decrease in MRC Scale score, a measure of disease severity, supports 
a genuine connection between demethylation at this gene’s promoter region and 
sCJD phenotype. It is, however, surprising to not observe differential methylation of 
AIM2 in the sCJD brain, which suggests peripheral inflammation in sCJD patients is 
distinct from neuroinflammation, or occurs in a cell type more abundant in the 
periphery than the brain. 
The role of cytokines in prion disease is unclear, partially due to studies reporting 
cytokine profiles from different transgenic mice of different backgrounds, infected 
with different prion strains at different stages of the disease. An early study found 
that levels of IL-1α, IL-1β, and TNF-α mRNA in the brain were elevated at clinical 
onset in swiss (SWR/j) mice infected with the mouse-adapted Chandler strain of 
scrapie (Campbell et al., 1994). PrPSc deposition was later linked spatially and 
temporally with increased production of IL-1β and TNF-α by perivascular 
macrophages in a VM/DK scrapie mouse model of infected with the 301V strain of 
scrapie (Williams et al., 1997). A study of IM mice describes elevated levels of NF-
κβ and IL-6 brains 300 days after infection with the mouse-adapted 87V strain of 
scrapie (Kim et al., 1999). Conversely, no increase in IL-1β, IL-6 or IFN-γ was 
observed in a study of black-6 (C57BL/6J) mice sacrificed between 56 and 168 days 
after inoculation with mouse-adapted ME7 prions (Walsh, Betmouni and Perry, 
2001). A study which followed CV/DK mice from inoculation with mouse-adapted 
ME7 prions all the way until terminal disease found steady elevation of IL-1β mRNA 
levels from 180 days post inoculation (preclinical stage) to a maximum at end-stage, 
with some mice showing slight elevations in TNF-α and IL-6 mRNA at end-stage 
(Brown et al., 2003). The authors comment that only IL-1β is markedly elevated and 
not to such an extent what could explain extensive microgliosis. Functional insight is 
provided by observation that knocking IL-10 out of the 129/Sv agouti mouse halved 
the disease duration upon inoculation with RML 5.0 prions compared to 129/Sv 
controls (Klein et al., 2004). Taking into account the periods of disease studied, it 
would seem that cytokine production is likely a feature of the toxic stage of prion 
pathogenesis, rather than the infectious stage, as per the model proposed by 
Sandberg et al. (Sandberg et al., 2014). This fits neatly with the association of AIM2 
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demethylation with disease severity in humans, suggesting activation of this 
inflammatory pathway may be a feature of clinically presenting prion disease. Of 
course, other features of sCJD (incontinence, reduced coughing, predisposition to 
bedsores) may also cause susceptibility to infections and therefore peripheral 
inflammation. This is an important point and will be addressed in Section 7.6. 
7.3.2 FKBP5: cg03546163 (and cg00052684 and cg25114611) 
Demethylation of 5.35% in the 5’ region of FKBP5 is the largest significant change 
seen in this dataset. FKBP5 was originally identified as a component of 
progesterone receptor complexes and named immunophilin p54 (Smith, Faber and 
Toft, 1990). Now mostly referred to as FKBP5 or FKBP51 (FK506-Binding Protein 
5), this gene has been extensively studied, particularly in its original context as a 
receptor chaperone. FKBP5 was found to decrease the affinity of the Glucocorticoid 
Receptor (GR) to ligand agonists and delay translocation of activated GR to the 
nucleus (Wochnik et al., 2005), in dynamic opposition to the similarly named 
homologue FKBP52 (Smith et al., 1993), now more frequently named FKBP4. 
FKBP5 also serves as a chaperone for AKT and PHLPP, a protein phosphatase 
which inactivates AKT and thus negatively regulates multiple biological survival and 
growth pathways (Wang, 2011). FKBP5 thus serves as a major regulator of the 
glucocorticoid response pathway: a simplified model of this is presented below in 





Figure 63: Model of FKBP5’s role in inhibition of the glucocorticoid response. Glucocorticoids enter the 
cytoplasm (a) and activate the glucocorticoid receptor (GR) complex. FKBP5 can associate with the 
complex and reduce binding affinity of glucocorticoids to the GR, thus delaying translocation of the GR 
to the nucleus. Exchange of FKBP5 for FKBP4 (b) permits GR translocation to the nucleus (c). The GR 
can either interact as a monomer with other transcription factors (d) or form a homodimer that binds to 
DNA at glucocorticoid response elements, allowing transactivation or transrepression of a large 
number of genes. The FKBP5 gene is highly responsive to GR, but responsiveness depends on 
FKBP5 polymorphisms and methylation status (e). FKBP5 mRNA translocates to the cytoplasm (f) 
where it is translated into FKBP5 protein. FKBP5 then inhibits GR activity by not only forming an ultra-
short, intracellular negative feedback loop of GR signaling but also modulating several other biological 
pathways (g). This figure and legend are adapted from an excellent review of FKBP5’s function and 
regulation by Zannas, Wiechmann, Gassen and Binder 2016. 
 
As well as functioning as a scaffold for protein assembly, FKBP5 has a cis/trans-
peptidyl-prolyl-isomerase (PPIase) function, common to the FKBP family which are 
named according to the inhibition of the PPIase domain by FK506. PPIase function 
also contributes to FKBP5’s role as a chaperone, for example in its inactivation of 
cyclin-dependent kinase 4 by isomerisation of the T172-P173 peptide bond, by 
which phosphorylation of T172 is inhibited, thus promoting myogenesis (Ruiz-
Estevez et al., 2018).  
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There is a connection between FKBP family members and prion disease in the 
literature. FK506 (also known by its pharmaceutical name, tacrolimus) was identified 
in a drug screen in murine N2a cell culture as preventing prion propagation 
(Karapetyan et al., 2013). Further work revealed that FK506 decreases levels of 
PrPC through blocking import into the endoplasmic reticulum, leading to increased 
degradation in the cytoplasm, identifying endoplasmic reticulum-associated Fkbp10 
as the target of FK506 (Stocki et al., 2016). The same work revealed that FK506 
could also decrease levels of PrPC and PrPSc in chronically infected ScN2a cells. 
Knockdown of Fkbp9 in a prion-propagating derivative of N2a cells (PK1) was later 
found to significantly reduce prion propagation while not altering base levels of PrPC 
(Brown et al., 2014). Worth noting is that mutations at P102 or P105 of PrP can 
cause Gerstmann-Straussler-Scheinker disease, an inherited form of prion disease 
(Kraus et al., 2015). Of the canonical amino acids, proline exerts the greatest 
constraint on conformational potential at the level of secondary structure, 
suggesting that these disease-causing polymorphisms may act through increasing 
the conformational freedom of PrP. If this is the case, the effects of FKBP family 
PPIase activity on PrP conformation may be worth considering. 
FKBP5 has also been associated with other neurodegenerative and psychiatric 
diseases. Upregulation of Fkbp5 in mice expressing humanised P301L tau resulted 
in accumulation of toxic tau oligomers and progressive neurodegeneration (Blair et 
al., 2013). Conversely, Fkbp5-/- mice have lower levels of total brain tau and 
phospho-tau and show resilience to experimental stress conditions compared to 
wildtype mice in terms of reduced depressive behaviour and anxiety, improved 
quality of sleep and lower levels of circulating corticosterone, the rodent equivalent 
of cortisol (O’Leary et al., 2011; Touma et al., 2011; Albu et al., 2014). 
Overexpression of Fkbp5 was observed in the hippocampus and prefrontal cortex of 
rats subjected to chronic stress (Guidotti et al., 2013). Strikingly, significant and 
correlated decreases in DNA methylation of Fkbp5 were observed in the blood and 
hippocampi of mice supplied with corticosterone-laced water (Ewald et al., 2014). In 
humans dysregulation of FKBP5 is also observed in the context of stress, notably in 
survivors of the holocaust and their offspring, where a CpG overlapped by one of 
FKBP5’s glucocorticoid response elements (GRE) is hypermethylated and 
hypomethylated in parents and children respectively (Yehuda et al., 2015). Dawn 
cortisol levels in children are also elevated compared to age-matched non-exposed 
Jewish controls, in inverse correlation with demethylation of the GRE. In Cushing’s 
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Syndrome, a psychiatric disorder caused by hypercortisolaemia, FKBP5 is also 
found to be hypomethylated. (Resmini et al., 2016).  
Because of its diverse functions, its existing connection with prion research, and the 
magnitude of hypomethylation observed in the array results, FKBP5 is an exciting 
candidate gene for further study. It is also interesting to note that cortisol is an anti-
inflammatory agent, and hypercortisolaemia has been observed in scrapie-infected 
sheep (Gayrard et al., 2000). There may therefore be an inflammatory component 
connecting dysregulation of AIM2 and FKBP5. 
One CpG (cg03546163) was identified in the sCJD-control comparison using 
Houseman-corrected data. However, EpiDISH correction for cellular heterogeneity 
identified this probe and two others (cg00052684 and cg25114611). While it was 
encouraging to observe additionally affected loci in the same gene, this also 
presented an opportunity to assess the ability of EpiDISH to identify significantly 
affected loci which the Houseman algorithm could not, therefore all three probes 
were taken forward as candidates for replication. 
7.3.3 MTRNR2L8: cg05740793 
MTRNR2L8, or humanin-like Protein 8, is a paralogue of 15 nuclear-encoded 
descendants of a putative ancestral mitochondrial gene (Bodzioch et al., 2009). A 
mere 24 amino acids in length, the original humanin was identified through 
expression screening of a cDNA library generated from the occipital cortex of an 
Alzheimer’s disease patient, and allegedly named after its discoverer’s hope that 
this peptide was the key to restoring the humanity of AD patients (Hashimoto et al., 
2001; Lee, Yen and Cohen, 2013). Hashimoto et al. found that treatment with 
purified humanin was sufficient to protect cells transfected with amyloidogenic 
mutant amyloid-precursor protein or treated with amyloid-beta oligomers. Later work 
found that similar treatments of humanin could protect cortical neurons from 
apoptosis induced by a codon 118-135 fragment of PrP (Sponne et al., 2004). In 
vivo, interperitoneal injection of a synthetic humanin mimic peptide was found to 
reduce memory deficits, amyloid plaque counts and neuroinflammation in an AD 
mouse model (Zhang et al., 2012). 
Its neuroprotective functions make Humanin a fascinating candidate gene, but 
investigation was stymied by the high degree of conservation of the sequence 
around the CpG of interest. I was unable to design a pyrosequencing assay specific 
for humanin-like protein 8. This is particularly unfortunate as, despite differential 
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expression of 10 of the humanin proteins across different tissues (five are thought to 
be pseudogenes), which humanin paralogue encodes the “original” humanin peptide 
isolated from the brain remains a matter of contention.  
7.3.4 UHRF1 and METTL9: cg17714703 and cg02481950 
UHRF1 was introduced at the introduction of this thesis: it recruits DNMT1 to 
hemimethylated DNA to establish symmetrical DNA methylation at CpG sites. 
Methyltransferase-like 9 is so called because it contains an SAM-dependent 
methyltransferase domain, however which biological substrate it methylates has not 
been confirmed. METTL9 is also named DORA Reverse Strand Protein (DREV1) as 
it is encoded by the opposite strand of a region overlapping IGSF6, or DORA, an 
immunoglobulin associated with inflammatory bowel disease which is specifically 
expressed in haemoatopoetic cells (Bates et al., 2000). While UHRF1 has been 
subject to much research, METTL9 remains uncharacterised. However, its potential 
role in DNA methylation, alongside UHRF1’s established role, made them 
interesting candidates for replication. Dysregulation of UHRF1 in particular might 
explain the increased genome-wide inflation seen in the array results: if 
spontaneous DNA methylation is being differentially converted to symmetrical DNA 
methylation at CpG sites by dysregulated UHRF1, I would expect to see greater 
background differences in DNA methylation between sCJD and control groups. 
7.3.5 KCNAB2 and MIR1977: cg02448796 and cg05001044 
KCNAB2 encodes Kvβ2, a subunit of potassium voltage-gated channels, and was 
selected primarily as bioinformatic analyses of other data gathered from sCJD 
samples indicated enrichment of potassium voltage-gated channel family members. 
While potassium channels manage a wealth of biological functions, Kcnab2 deletion 
was found to impair memory and learning in mice (Perkowski and Murphy, 2011), 
while both polycomb-targeted repression and knockdown of Kcnab2 was found to 
improve resistance to ischaemia in murine culture (Stapels et al., 2010).  
Conversely, MIR1977 is a mitochondrially-encoded microRNA which is thought to 
target and silence the mitochondrial transfer RNA gene TRNN (Bandiera et al., 
2011), although this has not been confirmed. While this miRNA’s function remains 
unknown, the Δβ between sCJD and control is the second largest in the dataset and 





7.4 Genome-wide significance inflation in 450K datasets is common 
and is unlikely to detract from this study 
As shown in Section 3.3.1, pre-processing suppressed genome-wide significance 
inflation (λ) to a final value of 1.4, which is higher than reported in most Genome-
Wide Association Studies (GWAS). While this may reflect the clinical heterogeneity 
of the disease or “noisy” epigenetic dysregulation across the genome, p value 
inflation in Epigenome-Wide Association Studies (EWAS) is a recognised 
phenomenon (Iterson, Zwet and Heijmans, 2017). While GWAS are studies of 
genotypes (ordinal data), EWAS of DNA methylation study continuous numerical 
data which is more vulnerable to the biases described in Chapter 2. Alternatively, 
sCJD could have extremely heterogeneous effects on genome-wide DNA 
methylation. In terms of whether this inflation is greater than expected, λ of 1.3-1.4 
have been reported in other studies using the 450K array and blood-derived DNA 
(Ahsan et al., 2016; Joehanes et al., 2016). It is therefore unclear whether further 
correction of λ would reflect a legitimate decrease in technical bias or over-fitting of 
the data to conform to standards established in GWAS, although such correction 
could be achieved using statistical techniques such as surrogate variable analysis.  
The greatest decrease in λ is observed before and after correction for leukocyte 
population heterogeneity. Briefly, this uses reference methylome datasets from 
FACS purified leukocyte-derived DNA to weight 450K array data in terms of 
estimated leukocyte proportions, and then normalises the data based on those 
estimates. In doing so, differential methylation based on differences in cell 
populations, rather than epigenetic dysregulation, is discounted (Jaffe and Irizarry, 
2014). In our dataset both Houseman and EpiDISH algorithms estimate significant 
differences between leukocyte proportions in sCJD and control groups, albeit within 
normal physiological ranges. This raises two questions:  are there legitimate 
differences in cell populations in sCJD compared to control, and what is driving the 
discrepancy between the Houseman and EpiDISH algorithms? Regrettably blood 
counts of sCJD patients were not accessible at the time of the study, and 
prospectively counting blood cell populations to statistically power a difference 
between sCJD and controls, assuming both are within normal physiological ranges, 
would take months to years. To answer the second question, a large battery of 
blood samples from more than one phenotypic group should be subjected to 
leukocyte population counting and 450K or 850K profiling, so as to rate the 
comparative accuracy of the two algorithms. This has been done on a small scale 
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by the authors of the EpiDISH algorithm, but bears repeating (Teschendorff et al., 
2017). 
7.5 Genome-wide investigation revealed regional differences in 
methylation of blood-derived DNA from sCJD patients 
41 differentially methylated regions (DMRs) were identified using the Bumphunter 
package. The reduction of data dimensionality through tiling regions of adjacent 
CpG probes allowed sites that did not exhibit genome-wide significance after 
Bonferroni correction for multiple testing to pass a false-discovery rate corrected 
significance threshold of 0.05. p values are generated by creating a 250 series of 
“null” regions and calculating the percentage of null regions that are greater in width 
and have a higher value than the observed DMR. The package’s authors advise 
that such p values “should be interpreted with care as the theoretical properties are 
not well understood” (Aryee et al., 2019). A second metric of error, the Family Wise 
Error Rate (FWER) is the proportion of series of null regions that contain at least 
one region as wide and with an equal or greater value than the observed DMR. 
FWER is a more stringent measure of error and the one by which I decided to 
interpret DMR results. 
The most significant DMR by both metrics (p = 3.3x10-5, FWER = 0.012) overlaps 
three genes: HOXA-AS3, HOXA5 and HOXA6. Less significant DMRs tend to have 
sequentially higher p values, while FWER increases linearly. The second most 
significant DMR as ranked by Bumphunter has an FWER of 0.056, meaning that 
5.6% of null series contain an equivalently “significant” DMR in terms of difference 
between mean methylation and total width.  The FWER reaches 90.4% at DMR 
number 21 and so, whilst nominally significant in terms of p value, it seems probable 
that many of the identified DMRs are unreliable. 
Nevertheless, I went on to study the genomic distributions of these regions. Perhaps 
unsurprisingly most DMRs overlapped CpG-dense islands rather than CpG-
depleted open sea regions, and as a result also overlapped gene promoters. Using 
publicly available ChIP-Seq data from purified blood cell types in the Goldmine 
package (Bhasin and Ting, 2016), I also found that all DMRs contained transcription 
factor binding sites (TFBSs). I decided to see whether these DMRs shared any 
common motifs or binding partners and identified two motifs as being enriched 
across the sequence, namely TATTTTTTTATTAACAAAATATAACATTA and 
TTTTCTTCCTCTCCA (Motifs 1 and 2 from Figure 33 respectively). 86 transcription 
factors were significantly associated with the motifs, although after adjustment for 
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false discovery rate only 14 remained significantly associated with the first motif 
only.      
7.5.1 HOXA5  
The DMR least likely to be a false positive (1.2% of null regions show equivalent or 
greater effects) overlaps HOXA5. HOX genes are developmental transcription 
factors (Krumlauf and Hill, 1994) which are expressed in different combinations 
across distinct anatomical segments, thus directing local development of anatomical 
structure. HOXA5 in particular contributes to the development of the respiratory and 
digestive systems, thyroid and mammary glands, and regulates the balance 
between myelopoiesis and erythropoiesis in the bone marrow (Jeannotte, Gotti and 
Landry-Truchon, 2016). Besides their normal physiological role in development, 
dysregulation of HOX genes, including HOXA5, have been implicated in 
neurodegeneration. In blood-derived DNA from patients with Down Syndrome, 
which confers a high risk of developing Alzheimer’s Disease with age, 
hypomethylation (as opposed to hypermethylation as observed in sCJD) has been 
described across HOXA2, HOXA4, HOXA5 and HOXA6 (Bacalini, Gentilini, et al., 
2015). In Huntington’s disease HOX genes have been found to be upregulated in 
prefrontal cortex, alongside upregulation of five HOX-targeting miRNAs, some of 
which were not expressed at all in non-Huntington’s control cortex (Hoss et al., 
2014). Perhaps most striking is the recent publication of a 48 kilobase DMR 
spanning the HOXA cluster in prefrontal cortex and superior temporal gyrus-derived 
DNA across Braak stage in Alzheimer’s Disease patients (Smith et al., 2018). The 
seventh DMR (as ranked by significance) identified in this report overlaps HOXA5 
and HOXA-AS3 (Chr7:27,183,133-27,184,853), a region of DNA overlapped by the 
DMR identified in this study (Chr7:27,183,133-27,185,512). Both DMRs are regions 
of hypermethylation. 
7.5.2 Further work 
It is clear from the studies cited above that HOXA5 plays a neurotrophic role. It may 
be that hypermethylation at binding sites within DMRs is reflective of 
hypermethylation at other binding sites which could connect to differential 
expression of genes not identified in this study. However, this would only be the 
case if the substrate binding of these transcription factors is methyl-sensitive. This 
assumption is driven solely by in silico observations but could be tested through a 
number of follow-up experiments: 
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1. Replication of the HOXA5 DMR using targeted bisulphite sequencing: 
Because bisulphite treatment fragments DNA, a 2,379 bp region may 
require shotgun sequencing or primer walking, where small sections of this 
region are sequenced and fragments combined to create a profile of the 
whole region. 
2. qPCR of HOXA5: If HOXA5 is indeed dysregulated, this should be 
confirmed by measuring its expression levels in sCJD and control blood. 
3. Chromatin Immunoprecipitation of DNA sequences bound to identified 
transcription factors, e.g. CPEB1: if hypermethylation of motifs within DMRs 
is altering binding of transcription factors to these sequences, precipitation 
of CPEB1-bound chromatin and subsequent sequencing (or qPCR targeted 
around these motifs) should give an indication of magnitude and direction of 
effect. 
Even given these hypotheses, the disease relevance of blood-based changes in 
methylation, expression and activity of these genes is not easy to connect to prion 
pathology in the brain. It may be possible the observed changes are present in the 
brain too, or that they are symptomatic of PCR2 dysfunction related to altered 
haematopoiesis in response to neuronal or peripheral inflammation, which will be 
discussed in the next section. 
7.6 Five out of seven candidate DMPs were found to be replicable in a 
second cohort of patients and controls 
As mentioned in Section 4.1.2, assays for all loci were designed and optimised with 
the exception of the assay for MTRNR2L8, due to CpG density in the surrounding 
region. A MTRNR2L8-specific 300bp amplicon was generated but failed to 
sequence, while nested PCR of a smaller amplicon from a larger, specific amplicon 
failed to provide a product. 
Five out of seven assays based on the Houseman-corrected data showed 
significant differences between sCJD and control, while two (MIR1977, KCNAB2) 
failed to replicate. One of the two EpiDISH identified assays (cg00052684) 
replicated but at dramatically reduced significance (p = 0.002). The second assay 
(cg25114611) did not reach significance after correction for multiple testing (p = 
0.029). It is possible that, based on a lower replication rate and a higher λ in the 
EpiDISH dataset, that EpiDISH is subject to a higher false positive rate, although 
more EpiDISH DMPs would need to be replicated to confirm this. 
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Because of the extensive correction measures employed during array data analysis, 
overfitting of the data was a concern. Apart from inclusion of age and sex as 
components in the linear model, pyrosequencing data is not corrected. Therefore, 
the replicated DMPs are not artefacts of data as they are present in both corrected 
and uncorrected data. 
It is possible that the replicated DMPs are consequences of prion disease, dementia 
or illness in general. To exclude these possibilities the replicated assays were 
performed on groups of iatrogenic CJD and inherited prion disease patients, as well 
as Alzheimer’s disease patients. There are two caveats to this experiment: firstly 
only the AD group was powered in the assay for METTL9, this requiring 50 samples 
for both disease and control groups. Secondly, because the majority of iCJD 
patients are male, in these analyses sex was not included as a covariate in the 
linear model to prevent bias. As sex did not correlate significantly with differences in 
methylation between disease/control replication groups, this is unlikely to have 
adversely affected results. 
Strikingly, no DMPs identified in sCJD patients were observed in other disease 
groups. Not only does this support the specificity of the DMPs to sCJD, but also 
rules out the effects being induced by disease treatment as drugs prescribed to treat 
symptoms of sCJD, IPD and iCJD are broadly similar (anti-epileptics, 
benzodiazepines). Consultation with clinical fellows who treat prion disease patients 
suggests no form of the disease carries a disproportionate risk of infection as a 
comorbidity, which could also be responsible for altered DNA methylation 
(particularly of AIM2 and FKBP5). These results and observations support the 
specificity of these DMPs to sporadic human prion disease.  
7.7 Differential DNA methylation in sCJD patient blood is not observed in 
frontal cortex-derived DNA  
Differential DNA methylation in blood is a useful biomarker and can give insight into 
downstream consequences of the disease or germline susceptibility factors, while 
altered DNA methylation in the disease tissue may identify mechanistically relevant 
candidate genes and pathways. Having identified DMPs in peripheral blood of sCJD 
patients, investigating these loci in brain tissue was a natural next step. 
Fortunately frontal-cortex derived sCJD and non-sCJD control DNA was available, 
and in sufficient sample numbers to power assays for FKBP5, AIM2, and UHRF1. 
Assays for ANK1 and PRNP were included, but this time not as negative controls. 
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cg11823178 in ANK1 is hypermethylated in Braak stage IV-VI Alzheimer’s disease 
frontal cortex compared to Braak stage I-III (De Jager et al., 2014; Lunnon et al., 
2014), and DNA methylation of PRNP has yet to be investigated in human brain. 
In an ideal, prospective study of brain-derived DNA, tissue would be sampled from 
the same region of the frontal cortex, specifically the grey matter which contains the 
neuronal soma rather than the white matter which contains neuronal axons. In this 
case the DNA is derived from bulk frontal cortex which would not have been 
systematically sampled in this way. Despite this limitation, it is interesting to observe 
no changes in DNA methylation levels at AIM2, UHRF1 or FKBP5 loci between 
sCJD and non-sCJD control brain-derived DNA. While the METTL9 assay was not 
powered, the distribution of the data when plotted does not suggest that increasing 
sample numbers would reveal an effect. 
Interestingly, I found that a CpG located 21 bp downstream of cg11823178 (ANK1) 
was found to be hypermethylated in sCJD brain. This CpG (8:41,519,420) has 
recently been identified as hypomethylated in entorhinal cortex in Huntington’s 
disease (HD) and Parkinson’s disease (PD) (Smith et al., 2019), though notably the 
three upstream CpGs in this assay, while hypermethylated in HD, PD and AD, are 
not in sCJD. Laser capture of cells from AD hippocampi revealed a four-fold 
upregulation of ANK1 mRNA compared to controls in microglia, but not neurons or 
astrocytes (Mastroeni et al., 2017). As extensive microgliosis is a feature of sCJD, it 
is possible that ANK1 may also be worthy of study in different regions of the brain 
and at different omic levels in prion disease. 
PRNP showed significant hypomethylation at position 20:4,665,649, 3 base pairs 
downstream of cg04286737. While methylation at a CpG 576 bp upstream of Prnp’s 
transcription start sight has been found to affect expression in mice (Dalai et al., 
2017), this assay probes a site even further upstream of PRNP. Yet studies of 
cortical expression of PRNP show decreased mRNA levels in the cortex, which in 
turn correlates with decreased PrPC in cerebrospinal fluid, which in turn correlates 
with sCJD severity (Llorens et al., 2013). This discrepancy between observations in 
mice and humans warrants further study of PRNP methylation and expression in 
vivo and in vitro, as Llorens’ observations may reflect normal or increased 
transcription of PRNP but subsequent mRNA dysmetabolism, as observed in other 
neurodegenerative diseases (Liu, Cali and Lee, 2017). 
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7.8 Differences in DNA methylation may be associated with specific 
leukocyte classes 
eFORGE analysis suggests that the DMPs are enriched in loci overlapped by the 
histone moiety H3K36me3 in monocytes, B cells and natural killer cells. Methylation 
of lysine 36 in Histone protein 3 is associated with active transcription, as SET2, a 
H3K36 methyltransferase, binds to phosphorylated RNA Polymerase II during 
transcript elongation (Krogan et al., 2003; Li et al., 2003). Resultantly H3K36me3 
abundance correlates with expression levels and, mirroring RNAP II association, 
this mark is more frequently found in exons rather than introns (Schwartz, Meshorer 
and Ast, 2009). H3K36me3 is also recognised by MRG15 which recruits PTP, a 
negative regulator of alternative splicing (Luco et al., 2010). Altered DNA 
methylation at these sites may indicate changes in chromatin organisation from 
condensed to unpacked, which in turn may allow methylation or demethylation of 
H3K34me3.  
The presence of functional chromatin modifications at these DMPs in particular 
lineages of leukocytes allows inference of a cell-specific origin for the observed 
changes in DNA methylation. This would also explain the comparatively modest 
effect sizes observed: monocytes comprise ~5% of total leukocytes in adults, so a 
change in DNA methylation of 10% in FKBP5 specifically in monocytes would 
actually be a change of 50% between sCJD and control, diluted out by no change in 
DNA from other cell fractions. I set out to test this by prospectively enriching 
leukocyte populations using Magnet Assisted Cell Sorting (MACS). 
7.8.1 Strengths and limitations of MACS methodology and results 
The greatest strength of MACS is that it allows fractionation of leukocytes rapidly, 
with minimal preparation and under less mechanically stressful conditions than 
FACS. However, validation of MACS efficiency is rarely performed in the literature 
and the manufacturer’s validation uses FACS. One of the practical reasons for 
choosing MACS to fractionate cells is that FACS was not a viable method due to 
health and safety issues connected with handling of prion patient samples, ruling 
this out as a validation technique. Instead, qPCR of cell surface markers was 
decided upon as a means of measuring enrichment of the cell type of interest in 
each fraction. This required the eluted fraction to be effectively halved in volume to 
allow for both DNA and RNA extraction. While DNA yields were sufficient for 
bisulphite conversion and pyrosequencing, RNA yields were low. Eventually, time 
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did not permit for the qPCR assays to be performed, meaning the MACS results 
have not been validated and should be considered with caution. 
Another limitation is that blood samples had to be recruited prospectively as 
leukocytes lyse on freezing, meaning frozen samples could not be used. While clinic 
visits to patients are relatively frequent given the rarity of the disease (1-2 per 
week), on several occasions patients were too unwell to have blood taken. Because 
of this only 11 controls and 9 sCJD patient bloods were collected. Moreover, in 
some instances the volume of blood taken was insufficient to purify all chosen 
fractions, in which case monocyte and B cell fractions were prioritised. A final 
limitation was delay before sample processing, as some samples were processed 
within hours of venepuncture whereas others were processed a few days after 
venepuncture.  
Surprisingly all cell fractions tested showed a trend towards demethylation in the 
AIM2 loci, but a statistically significant difference was only observed in granulocytes, 
a cell lineage not identified by eFORGE. Conversely, while all cell lineages showed 
a trend towards demethylation at FKBP5, the ANOVA was not significant. However, 
the post hoc test, and the data when visualised, point towards an enrichment of 
demethylation in B cells. This assay is underpowered and recruiting more samples 
may lead to a significant difference in this lineage being revealed. 
The granulocyte lineage is made up of neutrophils, eosinophils and basophils, all 
characterised by their ability to secrete granules containing cytotoxic or signalling 
molecules (Geering et al., 2013). In blood neutrophils are the most abundant 
granulocyte and persist for up to 5 days in circulation. However, spontaneous 
apoptosis of neutrophils is inhibited by both glucocorticoids and Interleukin-1β (Cox 
et al., 1995; William et al., 1998), signalling molecules whose effects are regulated 
by FKBP5 and AIM2 respectively.  Both EpiDISH and Houseman algorithms 
estimated greater proportions of granulocytes in sCJD (+8% and +11% 
respectively), suggesting that increased granulocyte (and specifically neutrophil) 
survival and thus prevalence may be a peripheral feature of sCJD.  
7.8.2 The value of further work as a function of cost 
This experiment is underpowered and has yet to be validated, but preliminary 
results are encouraging. As granulocytes seem to be affected and (based on in 
silico estimates) elevated in sCJD, it may be worth prospectively comparing 
proportions of leukocyte populations between sCJD patients and controls. This will 
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both give a clearer picture as to what peripheral immunological processes are 
occurring in sCJD and may also prove useful in supporting diagnosis.  
However, such work is time-consuming, requires prospective blood sampling from 
patients of a rare disease, and although the leukocyte lineage is estimated to be 
increased in sCJD, populations in both sCJD and control bloods are within 
physiological ranges. It is also surprising that eFORGE indicated that observed 
changes would be most amplified in monocytes rather than granulocytes. These 
preliminary results are perhaps insufficient to justify expanding this work without 
validation of the efficiency of MACS enrichment, which could be done using control 
blood and validated by FACS rather than qPCR of cell surface markers. 
7.9 FKBP5 and AIM2: Peripheral inflammation in neurodegenerative 
disease 
Hypomethylation of FKBP5 and AIM2, and an enrichment of the latter in 
granulocytes, point towards inflammation in the periphery. Cortisol, a hormone with 
anti-inflammatory properties, was also found to be elevated in sCJD sera compared 
to control sera. The relationship between inflammation and neurodegeneration is 
well established, with chronic neuroinflammation observed in most 
neurodegenerative diseases (Frank-Cannon et al., 2009). Recently, peripheral 
inflammation in neurodegenerative disease has become a topic of interest. In 
Alzheimer’s Disease and Lewy Body Dementia (LBD) inflammatory cytokines such 
as IL-1β were found to be elevated in plasma from prodromal patients but not in 
those who were cognitively impaired, compared to controls (King et al., 2018). 
However, a meta-analysis of 175 AD studies found that cytokines were in fact 
elevated in clinically presenting patients, with IL-6 levels correlating inversely with 
Mini Mental State Examination scores (Lai et al., 2017). In Huntington’s Disease 
patients chemokine levels in plasma were found to increase linearly across disease 
progression and correlate with clinical scores (Wild et al., 2011). A meta-analysis of 
25 studies found elevated levels of cytokines were also elevated in ALS (Hu et al., 
2017), and treatment of peripheral blood mononuclear cells with α-synuclein 
significantly increased IL-6 and IL-1β production. 
It is therefore perhaps unsurprising that demethylation of AIM2 correlates with MRC 
Scale score, given the prior reports of similar associations between clinical scores 
and inflammatory markers in AD, HD and LBD. But how is peripheral inflammation 




7.9.1 Potential causes and roles of peripheral inflammation in sCJD 
The first is that immune cells infiltrate the brain, are affected by the disease 
microenvironment, and return to circulation. This hypothesis was strengthened by 
the eFORGE prediction of an enriched differential methylation signature in 
monocytes, a leukocyte class which are known to infiltrate tissues and in particular 
to be recruited into the brain early on in prion pathogenesis (Williams, Ryder and 
Blakemore, 1995). This hypothesis explains the relatively small effect sizes 
observed, as only a small fraction of cells would infiltrate the brain and a smaller 
fraction of them would return to the periphery. However, preliminary MACS results 
do not support this hypothesis. The lack of concordant blood/brain changes in 
methylation are also problematic, although it could be that leukocytes respond 
differently to the disease microenvironment than native neuronal, astrocyte or glial 
cells. 
The second is that neuroinflammatory factors leak into the periphery, perhaps due 
to impairment of the blood brain barrier (BBB), triggering epigenetic changes. As IL-
1β regulates BBB permeability, neuroinflammation should result in cytokines 
passing into the periphery, triggering systemic inflammation. Again, these molecules 
would be diluted across the total volume of the circulatory system which may also 
explain the relatively modest effect sizes observed. IL-1β is known to increase 
survival of neutrophils, so this hypothesis does explain both the estimated increase 
in granulocyte proportions in sCJD and the preliminary MACS results. 
Thirdly, it is possible that prions are present in the circulatory system. Prions have 
been detected in the blood of vCJD patients (Concha-Marambio et al., 2016; Nicot 
et al., 2016), but whether they are present in the blood of sCJD patients remains 
unclear. A bioassay where plasma from sCJD patients was injected intracerebrally 
into transgenic mice expressing human PRNP showed prion infectivity in 2 out of 4 
patient samples (Douet et al., 2014). Varying circulating prion titre between patients 
may also explain the relatively modest degree of separation between sCJD and 
control groups, and as cited above Aβ and α-synuclein (both prion-like proteins) are 
sufficient to trigger PRRs and thus activate inflammasomes.  This hypothesis is also 
supported by the estimated increase in granulocyte proportions in sCJD and the 
preliminary MACS results. Whether or not prions are present in the circulatory 
system of sporadic prion disease patients is an important question both in terms of 
pathophysiology and research biosafety. 
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At this stage, hypotheses two and three seem to be the most plausible and rely on 
fewer assumptions than hypothesis one. Profiling cytokine concentrations and 
leukocyte proportions in sCJD blood across the disease course would clarify 
whether there is indeed IL-1β driven inflammation and increased neutrophil survival, 
and whether these correlate with AIM2 demethylation. Comparison of IL-1β levels in 
human sCJD brain compared to control brains with no expected BBB impairment 
using immunohistochemistry would not only reveal whether cytokines and 
chemokines could leak from the brain into the periphery, but correlation of IL-1β 
presence in the brain with levels in blood could reveal a linear connection.   
Continuing and validating the MACS experiment is important to clarify which cells 
may be functionally affected by differential methylation. Enriched fractions of 
leukocytes can also be used, alongside plasma, in RT-QuIC or PMCA reactions – 
sensitive in vitro assays for PrPSc seeding – to establish whether prions are present 
in the periphery, and whether particular types of leukocyte are vulnerable to 
infection. 
7.10 Elevated cortisol in sCJD suggests dysregulation of the 
Hypothalamic-Pituitary-Adrenal Axis 
Hypomethylation of the promoter of FKBP5 and elevated levels of cortisol in sCJD 
patient sera both point towards potential dysregulation of the Hypothalamic-
Pituitary-Adrenal (HPA) axis. Briefly, this system coordinates signals generated by 
environmental or molecular stress stimuli – such as IL-1β – from various neural 
circuits to the hypothalamus, which releases corticotrophin-releasing hormone and 
arginine vasopressin. These stimulate the release of adrenocorticotrophic hormone 
(ACTH) by the pituitary gland, which travels through the circulatory system to the 
adrenal glands, which respond by producing and releasing glucocorticoids, such as 
cortisol (Bellavance and Rivest, 2014). It is highly likely that damage to the brain, 
such as occurs during sCJD, would through inflammation and IL-1β affect the 
function of the HPA axis. Because the HPA axis operates according to circadian 
and ultradian rhythms, many models of its function exist: a simplified model is 




Figure 64: Simplified model of the Hypothalamic-Pituitary-Adrenal axis. Here the hypothalamus 
receives stressor input (in this case inflammatory cytokines) and produces corticotrophin-releasing 
hormone (CRH). This stimulates the pituitary gland to secrete adrenocorticotrophic hormone (ACTH), 
which travels through the blood to the adrenal glands and promotes the secretion of glucocorticoids, 
such as cortisol. This has inhibitory effects (dashed lines) on CRH production, ACTH production, and 
leukocyte cytokine production. Figure is adapted from Malek et al., 2015. 
 
Glucocorticoids are potent anti-inflammatories, acting by silencing expression of 
chemokines and other factors required for infiltration of tissues by circulating 
leukocytes (Cronstein et al., 1992; Jahnsen et al., 1999), and by downregulating 
inflammatory and upregulating anti-inflammatory cytokines (Franchimont, 2004). 
This suppression of inflammation, provoked by inflammation, is in turn negatively 
regulated by FKBP5. It is therefore likely that sustained activation of the HPA axis 
leads to increased cortisol production in sCJD patients, which in turn results in 
demethylation of the FKBP5 promoter, upregulation of FKBP5 and a suppression of 
glucocorticoid receptor activity.  
 
Investigating this pathway in the context of sCJD is complicated by the breadth of 
inputs to the HPA axis and the levels at which it, and notably FKBP5 (Zannas et al., 
2016), is regulated. However, that the sizable change in methylation at FKBP5 does 
not associate with disease severity implies that dysregulation occurs in tandem with 
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pathogenesis. As such study of the axis’s effects on pathogenesis would best be 
done in mouse models, where the effects of corticosterone or adrenaline-enriched 
diets or Fkbp5 ablation on prion propagation and toxicity could reveal whether HPA 
axis activation is a protective response to, a downstream effect of or a contributing 
factor to prion pathology. Further investigation of HPA activity in patients, for 
example profiling of circulating ACTH or adrenaline levels, may clarify which 
elements of the pathway are being affected: do sCJD patients have decreased or 
increased levels of adrenaline? Systematic sampling of sCJD and control blood 
would also improve resolution, as while it is likely that blood from controls and 
patients was taken during “visiting hours” (10am-4pm), HPA axis activity and 
subsequent release of hormones fluctuate. Moreover, the circadian pattern of HPA 
axis activity is sensitive to disruption, with stress-induced HPA axis activation 
prompting dramatically greater elevations (602%) of circulating glucocorticoid levels 
during secretory phases of the ultradian cycle compared to nonsecretory phases in 
rats (Windle et al., 1998). The PPIase function of FKBP5 further complicates the 
picture. Does upregulation of this gene as a response to neuroinflammation 
increase the rate of PrP misfolding? Intriguingly, dysregulation of the HPA axis has 
also been consistently observed in Alzheimer’s Disease, suggesting that further 
research in the context of both diseases may provide new insight into pathogenesis 
and identify therapeutic targets, biomarkers or risk factors (De Leon et al., 1988; 
Breitner et al., 1994; Green et al., 2006). 
7.11 Machine learning classification of sCJD status has utility and sets 
precedence for future work 
Being able to train a classification model with an accuracy of 87.04% reinforces the 
validity of results from the 450K array analysis. However, the recursive feature 
elimination (RFE) identified probes overlap imperfectly with the Bonferroni-adjusted 
DMPs. This raises the question: as more useful predictive variables in sCJD/control 
classification, is DNA methylation at these probes rather than the DMPs a better 
molecular signature of sCJD status? Use of RFE to select targets for replication 
rather than manually selecting them as I did in the replication stage of the project 
may be a less biased approach and potentially result in the identification of 
biologically relevant candidates despite no prior association with 
neurodegeneration. It is also striking that the replicated DMPs in the promoter of 
AIM2 (cg10636246, cg17515347), the body of UHRF1 (cg17714703) and METTL9 
(cg02481950), and the three sites identified between the Houseman and EpiDISH 
algorithm in the promoter of FKBP5 (cg03546163, and cg00052684 and 
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cg25114611 respectively) were all included in the list of 33 RFE-identified probes, 
as was promising candidate MTRNR2L8 (cg05740793). It would be interesting to 
test RFE’s ability to identify replicable candidate probes in future work. 
The utility of this model in sCJD diagnosis is debatable. In clinical practice, it is not 
difficult to place an individual into the categories of “healthy” or “sCJD”. A better 
model would be one capable of classifying sCJD/non-prion dementia. That said, this 
model’s performance is a solid proof of concept and sets precedent for future work 
with the 850K EPIC array, perhaps considering classification discrimination between 
sCJD patient subgroups, sCJD and AD patients, or between sporadic, iatrogenic, 
inherited and variant prion diseases. An interesting phenomenon is the prevalence 
of PrPSc immunoreactivity in UK appendixes removed during routine 
appendectomies after exposure to the BSE epidemic (16 positive of 32441 studied), 
which can be extrapolated to estimate that 1 in 10,000 UK residents carries PrPSc in 
their gut (Noel Gill et al., 2013). Yet intriguingly, appendixes removed before 
exposure to the BSE epidemic (1970-1979) show immunoreactivity at roughly the 
same levels, i.e. 1 in 7000 (Advisory Committee on Dangerous Pathogens TSE 
Subgroup, 2016). Because of the rarity of these specimens and the rarity of vCJD 
samples, machine learning based on methylation of appendix-derived DNA between 
non-immunoreactive individuals, immunoreactive individuals and individuals who 
developed vCJD could potentially shed light on differences by which subclinical 
carriers of prions resist infection from the periphery compared to vCJD patients. 
Indeed, while sporadic CJD is near impossible to anticipate, identification of 
susceptibility factors using machine learning in combination with other risk factors 
such as exposure to prion epidemics, contaminated medical products, or inheritance 
of a disease-causing mutation could greatly aid in diagnosis, prognosis, and 









Over the course of this work I identified differential methylation at several genes in 
blood-derived DNA from sCJD patients. These differences are replicable and 
specific to the sporadic form of human prion disease. Three genes in particular 
(HOXA5, FKBP5, AIM2) have neurotrophic properties and/or play roles in mediating 
inflammation and the immune response, functions known to mediate 
neurodegeneration. They thus serve as biomarkers of sporadic CJD. 
Hypomethylation at cg10636246 in AIM2 correlates with MRC Scale score and can 
be considered a biomarker of disease severity. A preliminary attempt to use 450K 
array data for sCJD/control classification shows diagnostic potential, and further 
profiling of other patients from prion subgroups or other dementias may result in 
clinically useful models. While these experiments suggest that DNA methylation in 
sCJD may have translational potential, the most actionable outputs from this work 
are the hypotheses that emerge from the results discussed above. At a molecular 
level, the roles of AIM2 and FKBP5 in sporadic CJD and in the latter case prion 
pathogenesis specifically merit further explanation. At a physiological level, the 
melting of central pathology into the periphery shows promise not just for the 
discovery of biomarkers (be they cellular or molecular) but also suggests that 
dysregulation of the HPA axis, long suspected to predispose towards Alzheimer’s 
Disease, may be a component or consequence of prion disease pathogenesis. 
Prion disease bioassays, both in vitro and in vivo, are sufficiently established to 
allow measurement of the effects of manipulation of the HPA axis in terms of prion 
infectivity and toxicity. While this has been predominantly a study of blood, it is 
exciting to think that some of the changes observed may not simply be useful as 
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